Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

14
results for

"Insulin resistance"

Article category

Keywords

Publication year

"Insulin resistance"

Review

Steatotic liver disease

Epidemiology of metabolic dysfunction-associated steatotic liver disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clin Mol Hepatol 2025;31(Suppl):S32-S50.
Published online August 19, 2024
DOI: https://doi.org/10.3350/cmh.2024.0431
As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD). Currently, 38% of all adults and 7–14% of children and adolescents have MASLD. By 2040, the MASLD prevalence rate for adults is projected to increase to more than 55%. Although MASLD does not always develop into progressive liver disease, it has become the top indication for liver transplant in the United States for women and those with hepatocellular carcinoma (HCC). Nonetheless, the most common cause of mortality among patients with MASLD remains cardiovascular disease. In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers. Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden. Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients. Although several obesity and T2D drugs are available to treat co-morbid disease, resmetirom is the only MASH-targeted medication for patients with stage 2–3 fibrosis that has approved by the Food and Drug Administration for use in the United States. This review discusses MASLD epidemiology and its related risk factors and outcomes and demonstrates that without further global initiatives, MASLD incidence could continue to increase.

Citations

Citations to this article as recorded by  Crossref logo
  • Early burden, enduring risk: The alarming outcomes of pediatric MASLD
    Marialena Mouzaki
    Hepatology.2026; 83(3): 445.     CrossRef
  • Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
    Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
    Journal of Advanced Research.2026; 80: 893.     CrossRef
  • Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease
    Alina M. Allen, W. Ray Kim, Patrizia Carrieri, Rachel Canning, Fang-Shu Ou, Joanne Benson, Jessica L. Olson, Sudhakar K. Venkatesh, Jiahui Li, Meng Yin, Maysa Eslami, Richard L. Ehman, Jennifer Hunter Berg, Jeffrey V. Lazarus
    Hepatology.2026; 83(2): 362.     CrossRef
  • A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study
    Ho Soo Chun, Minjong Lee, Hye Ah Lee, Eun Seo Park, Jeong Yoon Choi, Hyo Song Baek, Tae Hun Kim, Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jé
    Clinical Gastroenterology and Hepatology.2026; 24(3): 688.     CrossRef
  • The OGT–TFF2 axis mediates intrahepatic crosstalk and MASH pathogenesis
    Lei Zhang, Cuijuan Han, Man Mohan Shrestha, Jiamei Le, Wilhelm K. Berger, Yiheng Huang, Reina Desrouleaux, Eric Wang, Laszlo Nagy, Xiaoyong Yang
    Hepatology.2026; 83(5): 1215.     CrossRef
  • Socioeconomic Factors Impact the Perception of Healthcare Experiences in Patients with Cirrhosis
    Nicole Ng, Subhanik Purkayastha, Xiaohan Ying, Arun Jesudian, Russell Rosenblatt
    Digestive Diseases and Sciences.2026; 71(2): 486.     CrossRef
  • Intersections of vitamin D deficiency, HIV and chronic liver diseases
    Francesca Farina, Aurgho Datta, Suzanne N. Morin, Sahar Saeed, Bertrand Lebouche, Giovanni Guaraldi, Salvatore Petta, Giada Sebastiani
    HIV Medicine.2026; 27(1): 4.     CrossRef
  • Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature
    Sami Akbulut, Tevfik Tolga Sahin
    European Journal of Gastroenterology & Hepatology.2026; 38(3): 243.     CrossRef
  • Pubertal exposure to glyphosate-based herbicide aggravates diet-induced steatosis and hormonal dysregulation in adult mice
    Jakeline Liara Teleken, Ana Paula Farina Rosolen, Joseane Morari, Sandra Lucinei Balbo, Rosane Aparecida Ribeiro, Maria Lúcia Bonfleur
    Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3589.     CrossRef
  • Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability
    Michael Ndaa, Prashant K. Pandya, Jordan Swensson, Niharika Samala, Saima Ajaz, Deepak Joshi, Walid S. Ayoub, Fatih Akisik
    Endocrine Practice.2026; 32(2): 258.     CrossRef
  • Semaglutide, the first approved GLP-1 receptor agonist for the management of metabolic dysfunction-associated steatohepatitis
    Chrysoula Boutari, Michael A. Hill, Christos S. Mantzoros
    Metabolism.2026; 174: 156397.     CrossRef
  • NSD2 exacerbates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway
    Yuan Qiao, Yijia Zhang, Cuiting Sun, Qi Jin, Peng Qu, Zecheng Li, Yang Qiu, Hua Meng, Dantao Peng, Liang Peng
    Metabolism.2026; 174: 156416.     CrossRef
  • The Bubble-Destruction Curve Obtained Using Contrast-Enhanced Ultrasound is Useful for Assessing Liver Fibrosis and Identifying At-risk MASH in Patients With MASLD
    Noritaka Wakui, Yu Ogino, Naohisa Kamiyama, Takuma Oguri, Tomoya Uchimura, Takahide Kudo, Kenichi Maruyama, Hideki Nagumo, Naoyuki Yoshimine, Kunihide Mouri, Kojiro Kobayashi, Takanori Mukozu, Teppei Matsui, Hidenari Nagai, Yoshinori Igarashi, Takahisa Ma
    Ultrasound in Medicine & Biology.2026; 52(1): 237.     CrossRef
  • Outcome-Specific Cardiovascular and Hypertensive Risk Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights From a Competing Risk Cohort Analysis
    Masashi Hirooka, Teruki Miyake, Ryo Yano, Yoshiko Nakamura, Yuki Okazaki, Toyoki Shimamoto, Atsushi Yukimoto, Yasunori Yamamoto, Takao Watanabe, Osamu Yoshida, Kana Hirooka, Yoshio Tokumoto, Masanori Abe, Takeru Iwata, Yoichi Hiasa
    Gastro Hep Advances.2026; 5(1): 100806.     CrossRef
  • Diabetes and the liver
    Ebo Dadey, Tiong Yeng Lim, Janine Makaronidis
    Clinical Medicine.2026; 26(1): 100528.     CrossRef
  • Association between longitudinal weight change and clinical outcome in individuals with MASLD
    Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Atsushi Nakajima, Hannes Hagström, Elisabetta Bugianesi, Wah-Kheong Chan, Jérôme Boursier, Boon-Bee George Goh, Arun J. Sanyal, Manuel Romero-Gomez, José Luis Ca
    Hepatology.2026; 84(2): 514.     CrossRef
  • Valproic Acid Exacerbates Lipid Accumulation in High‐Fat Hepatocytes Induced by Oleic Acid: Insights From Lipidomic Analysis
    Shansen Xu, Xianglei Ma, Lingli Huang, Tingting Yue, Ya'nan Chen
    Lipids.2026; 61(1): 163.     CrossRef
  • Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
    Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher
    JAMA.2026; 335(2): 163.     CrossRef
  • Recognizing the Burden of Metabolic Liver Disease in IBD
    Raseen Tariq, Richard K Sterling
    Inflammatory Bowel Diseases.2026; 32(3): 584.     CrossRef
  • Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD—Insights From a National Analysis
    Joyce Lui, Yesung Kweon, Mohamed I. Elsaid
    Alimentary Pharmacology & Therapeutics.2026; 63(5): 750.     CrossRef
  • Advances in Incretin‐Based Therapies for MAFLD: Mechanisms and Clinical Evidence
    Wenqi Dong, Haiming Zhang, Shaowei Mu, Shuyi Shi, Junli Zhang, Keshu Xu
    Clinical Pharmacology & Therapeutics.2026; 119(2): 336.     CrossRef
  • Protective effect of vitamin D on high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in mice
    Amal A. Mohamed, Wael Hafez, Said El-Feky, Mona G. Khalil, Amina S. Soliman, Karima Nasraldin, Ingy M. Ibrahim, Hanan A. Hegazy, Weam Shaheen, Abbas M. Abbas, Hager Shaheen, Marian FL. Abdelmalak, Hany N. Azzam, Omnia Ezzat, Noheir Ashraf Ibrahem Fathy Ha
    Steroids.2026; 225: 109718.     CrossRef
  • The adipokine Isthmin-1 in obesity and its complications: recent research advances
    Yuting Zhuang, Jialuo Liu, Yanling Sui, Jiamin Song, Guoyue Yuan, Li Zhao
    Life Sciences.2026; 384: 124092.     CrossRef
  • Integrated network toxicology, molecular docking and transcriptomics reveal the mechanistic role of phthalate esters in metabolic disease pathogenesis
    Yuancheng Shao, Qi Liu, Yicheng Jiang, Gang Zhou, Xihan Gu, Shufan Zhang, Shuai Chen, Jiaming Xue, Liming Tang
    Food and Chemical Toxicology.2026; 207: 115855.     CrossRef
  • Commercial glyphosate formulations exceed active ingredient toxicity via mitochondrial ROS and transcriptomic disruption
    Jakeline Liara Teleken, Leticia Prates Roma, Rosane Aparecida Ribeiro, Alex Rafacho, Maria Lúcia Bonfleur
    Toxicology in Vitro.2026; 111: 106178.     CrossRef
  • Effects of bariatric surgery on neurological disturbances and quality of life in patients with metabolic dysfunction-associated steatotic liver disease and obesity: a prospective longitudinal study
    Concepción Gómez, Juan José Gallego Roig, María Lapeña, Clara Alfaro-Cervelló, Alessandra Fiorillo, Adrià López-Gramaje, Raquel Alfonso Ballester, Norberto Casinello, María Capilla Lozano, María Desamparados Escudero-García, Cristina Montón, Amparo Urios
    Surgery for Obesity and Related Diseases.2026; 22(1): 113.     CrossRef
  • Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases
    Nicola Pugliese, Matteo Spertino, Miriana Mercurio, Stefano Ciardullo, Gianluca Perseghin, Cesare Hassan, Roberto Vettor, Salvatore Petta, Alessio Aghemo
    Clinical Gastroenterology and Hepatology.2026; 24(3): 583.     CrossRef
  • Novel dual AMPK/NRF2 activation by leucocyanidin from Hawthorn (Crataegus) for mitochondria repair-Targeted therapy of hepatic steatosis
    Yunheng Li, Minghua Ye, Qiaojun He, Bo Yang, Peihua Luo, Xiaochun Yang
    Phytomedicine.2026; 150: 157614.     CrossRef
  • The role of liver sinusoidal endothelial cells in liver diseases: Key players in health and pathology
    Eric Felli, Yeldos Nulan, Martí Ortega-Ribera, Anabel Fernández-Iglesias, Jordi Gracia-Sancho
    Journal of Hepatology.2026; 84(3): 655.     CrossRef
  • A comparative study between ultrasound-guided-attenuation-parameter (UGAP), controlled attenuation parameter (CAP), and proton density fat fraction (PDFF) for assessment of hepatic steatosis
    Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg
    Scandinavian Journal of Gastroenterology.2026; 61(1): 124.     CrossRef
  • Hepatic steatosis can accurately be measured during free breathing using ultrasound-guided attenuation parameter (UGAP) technology. Technical note
    Marie Byenfeldt, Patrik Nasr, Anna Lindam, Christer Grönlund, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg
    European Journal of Radiology.2026; 195: 112602.     CrossRef
  • Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
    Iulia Minciuna, Maria Iacobescu, Ioana Rusu, Oana Nicoara‐Farcau, Petra Fischer, Andreea Maria Soporan, Ioana Ecaterina Pralea, Horia Stefanescu, Cristina Adela Iuga, Bogdan Procopet
    Hepatology Research.2026; 56(4): 446.     CrossRef
  • The nexus of environmental endocrine-disrupting chemical exposure and metabolic dysfunction-associated steatotic liver disease: An emerging public health challenge
    Hongxia Chen, Hong Cui, Zhongji Meng
    Ecotoxicology and Environmental Safety.2026; 309: 119513.     CrossRef
  • Transient elastography during pregnancy: a glimpse into maternal liver health
    Seung Mi Lee, Won Kim
    The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(1): e2.     CrossRef
  • Elevated adipose inflammation, but reduced hepatic triacylglycerol storage in diet-induced obese Plin4−/− mice
    Atanaska Ivanova Doncheva, Ryoko Higa, Prabhat Khanal, Martine Villemo Øksenvåg Ingebrigtsen, Yuchuan Li, Shrikant Kolan, Pratibha Kolan, Ales Kvasnicka, Ingunn Jermstad, Shaista Khan, Bjørn Steen Skålhegg, Svein Olav Kolset, Hilde Nebb, Marit Hjorth, Fro
    Journal of Biological Chemistry.2026; 302(2): 111043.     CrossRef
  • Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities
    Akash Roy, Mithun Sharma, Anand V. Kulkarni, Sundeep Lakhtakia, Aniruddha Pratap Singh, Rakesh Kalapala, Gregory G. Ginsberg, D.Nageshwar Reddy, K. Rajender Reddy
    Gastro Hep Advances.2026; 5(2): 100838.     CrossRef
  • Effectiveness and safety of saroglitazar in managing dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease: A 12‐month observational study
    Gaurab Bhaduri, Shambo S. Samajdar, Sanjay Bandyopadhyay, Shatavisa Mukherjee, Shashank R. Joshi
    Diabetes, Obesity and Metabolism.2026; 28(3): 2449.     CrossRef
  • Association of Liver Fibrosis Fibrosis-4 Score with Perioperative Complications and Mortality: A Retrospective Multicenter Analysis
    Shira Zelber-Sagi, Vikas N. O’Reilly-Shah, Ashish K. Khanna, Peter Rock, Itay Bentov
    Anesthesiology.2026; 144(2): 365.     CrossRef
  • Distinct and complementary metabolic effects of GLP-1 and glucagon receptor agonism in diet-induced obese mice
    Marie Winther-Sørensen, Christine Rasmussen, Samuel A.J. Trammell, Caroline Hansen, Mogens Vyberg, Reza Serizawa, Erik A. Richter, Trisha J. Grevengoed, Lise Lotte Gluud, Rune E. Kuhre, Nicolai J. Wewer Albrechtsen
    Peptides.2026; 195: 171462.     CrossRef
  • Nutrition in MASLD: a patient focused, evidence-based clinician’s guide
    Katrina Pekarska, Paul N Brennan, Dana Ivancovsky Wajcman, Jennifer Towey, Leah Cox, Katie Weatherby, Stuart McPherson, Jonathan Stine, Jose Willemse, Wenhao Li, William Alazawi, Jeffrey V Lazarus, Richard Parker
    Frontline Gastroenterology.2026; 17(3): 262.     CrossRef
  • Noninvasive Assessment of Hepatic Steatosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Patients by Using Ultrasound Attenuation Imaging
    Kun Wang, Qun Liu, Jing Wang, Minghui Wang, Jinqiao Zhang, Yanjie Yu, Ling Liu, Hairong Liu
    Journal of Ultrasound in Medicine.2026; 45(6): 1209.     CrossRef
  • Hepatic adaptation to chronic metabolic stress primes tumorigenesis
    Constantine N. Tzouanas, Jessica E.S. Shay, Marc S. Sherman, Adam J. Rubin, Benjamin E. Mead, Tyler T. Dao, Junyan Tao, Brandon M. Lehrich, George Eng, Jeffrey Patterson-Fortin, Titus Butzlaff, Miyeko D. Mana, Kellie E. Kolb, Chad Walesky, Brian J. Pepe-M
    Cell.2026; 189(2): 435.     CrossRef
  • Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Zheng'ao Xu, Yongfen Zhu, Fengjuan Chen, Qiongyue Fan, Ruiqi Wang, Yilong Fu, Xunxun Wu, Li Zhu, Fushuang Ha, Qing Ye, Chunyan Ye, Xiaoming Chen, Meijie Chen, Jiale Niu, Yangyang Xie, Kaixin Chang, Jiakun Miao, Weili Liu, Junping Shi, Zhongjie Hu, Minghua
    Liver International.2026;[Epub]     CrossRef
  • Risk of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis: A Retrospective Cohort Study
    Semiu O. Gbadamosi, David Shi, Abdalla Aly, Caichen K. Zhong, Husam Albarmawi, Aidan McGovern, Anthony Hoovler, Carlos Campos
    Diabetes Therapy.2026; 17(2): 251.     CrossRef
  • Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
  • Linked Intronic Polymorphisms of the PNPLA3 Gene Are Associated with Serum Markers of Liver Injury in Patients with Spontaneous HCV Clearance
    Karina Gonzalez-Aldaco, Luis A. Torres-Reyes, Arturo Panduro, Sonia Roman
    International Journal of Molecular Sciences.2026; 27(1): 473.     CrossRef
  • Liver Stiffness Rises Early in MASLD and Drives Inflammation, Lipid Dysmetabolism, and Fibrosis via Piezo1–YAP Mechanotransduction
    Juan Ma, Ning Xie, Ziwei Wang, Xiru Liang, Yulong Han, Qiang Zhao, Ming Wang, Hongwei Lu, Wanyi Kou, William Alazawi, Jinhai Wang, Lu Li, Ning Liu, Na Liu, Haitao Shi, Feng Xu
    Advanced Science.2026;[Epub]     CrossRef
  • A sex-specific brake on liver oestrogen signalling
    Pamela Kakimoto, Natalie Krahmer
    Nature Metabolism.2026; 8(1): 8.     CrossRef
  • Mesenchymal Stromal/Stem Cell-Based Therapies for Liver Regeneration: Current Status and Future Directions
    Seohyun Choi, Jaemin Jeong
    International Journal of Molecular Sciences.2026; 27(2): 619.     CrossRef
  • The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity
    Siyuan Tan, Ting Huang, Zixi Zhang, Jiabao Zhou, Hao Chen, Tao Tu, Qiuzhen Lin, Yichao Xiao, Qiming Liu
    Diabetes Research and Clinical Practice.2026; 232: 113092.     CrossRef
  • Non-alcoholic fatty liver disease in Northeast India: a narrative review of rising metabolic syndrome
    Shiludi Longkumer, Maitrayee Dutta Swargiary
    Egyptian Liver Journal.2026;[Epub]     CrossRef
  • Dose‒response relationship between exercise and hepatic steatosis: A systematic review with Bayesian network meta-analysis of randomized controlled trials
    Xinyun Tan, Huihui Zou, Manjie Guo, Jiayu Liu, Xinjuan Huang, Ruoling Yu, Xuelian Liu, Chunxiang Qin
    Journal of Sport and Health Science.2026; 15: 101125.     CrossRef
  • Kefiran, a polysaccharide from kefir grain, modulates gut microbiota and hepatic metabolism to mitigate metabolic dysfunction-associated steatotic liver disease
    Yuanyuan Cui, Jiajia Zhu, Jun Xi, Changhe Ding, Jun Meng
    International Journal of Biological Macromolecules.2026; 341: 150147.     CrossRef
  • Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis
    Jiamei Song, Dan Liu, Jitong Li, Haoru Cong, Ruixue Deng, Yihan Lu, Jiayi Sun, Jingzhou Zhang
    Journal of Medical Internet Research.2026; 28: e78310.     CrossRef
  • Multi-Omics Evidence Linking Depression to MASLD Risk via Inflammatory Immune Signaling
    Keye Lin, Yiwei Liu, Xitong Liang, Yiming Zhang, Zijie Luo, Fei Chen, Runhua Zhang, Peiyu Ma, Xiang Chen
    Biomedicines.2026; 14(1): 174.     CrossRef
  • Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Dise
    Savvoula Savvidou, Elektra Augousti-Varela, Aikaterini Damianakou, Miltiadis Chalkias, Ioannis Stergiou
    Metabolic Syndrome and Related Disorders.2026; 24(3): 121.     CrossRef
  • Oxidative stress in metabolic dysfunction-associated steatohepatitis: Mechanisms and emerging therapeutic strategies
    Yidan Chen, Hui Yu, Xinyu Kai, Runting Yin, Zhen Ouyang, Yuan Wei, Cai Zhang
    Biochemical Pharmacology.2026; 246: 117702.     CrossRef
  • Diet intervention altered DNA methylation of potassium voltage-gated channel subfamily Q member 1 in metabolic dysfunction-associated steatohepatitis
    Xinyu Shi, Hualing Song, Xinying Xiong, Shuang Wei, Lei Zhang, Shengfu You, Wenjun Zhou, Guang Ji, Baocheng Liu, Na Wu
    Clinical Epigenetics.2026;[Epub]     CrossRef
  • Mechanisms of scramblases in regulating hepatic lipoprotein secretion and autophagy
    Allen Chen, Chen Zhang, Wen-Xing Ding, Hong-Min Ni
    Journal of Lipid Research.2026; 67(2): 100979.     CrossRef
  • Artificial Intelligence for Fibrosis Diagnosis in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review
    Neilson Silveira de Souza, Théo Cordeiro Veiga Vitório, Raphael Augusto de Souza, Marcos Antônio Dórea Machado, Helma Pinchemel Cotrim
    Diagnostics.2026; 16(2): 261.     CrossRef
  • Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort study
    Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai
    Hepatology International.2026; 20(2): 292.     CrossRef
  • Diagnostic Utility of Serum Activating Transcription Factor 4 and Toll-like Receptor 4 as Early Biomarkers of Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease
    Isa Yalcinkaya, Iskender Ekinci, Seyma Dumur, Eda Nur Duran, Hafize Uzun, Melda Yalcinkaya, Elif Kadioglu Yeniyurt, Omer Vehbi Alpaydin, Gulden Anataca, Omur Tabak
    Journal of Clinical Medicine.2026; 15(2): 559.     CrossRef
  • Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease
    Ke Yin, Yuyun Song, Ran Fei, Xu Cong, Baiyi Liu, Zilong Wang, Xin Ai, Minjun Liao, Yayun Ren, Kutbuddin Akbary, Wei Wang, Qiang Yang, Xiao Teng, Nan Wu, Huiying Rao, Xiaoxiao Wang, Feng Liu
    Diagnostics.2026; 16(2): 234.     CrossRef
  • Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs
    Lei Yang, Jiale Ruan, Yingying Fang, Anyi Xu
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation
    Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo
    Biology.2026; 15(2): 148.     CrossRef
  • Phosphatidylserine Supplementation Improves Metabolic Liver Disease and Glycemic Control in the Presence of Suppressed Oxidative Glucose Metabolism
    Li Dong, Sihan Lin, John Slavin, Satya Gunnam, Zhili Cheng, Shuai Nie, Michael G. Leeming, Nicholas A. Williamson, Magdalene K. Montgomery
    Diabetes.2026; 75(2): 273.     CrossRef
  • Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
    Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang, Jiao Xiao, Xiongjin Tan, Xun Chen, Peili Wu, Yukun Li
    npj Digital Medicine.2026;[Epub]     CrossRef
  • Morphological characterization of a novel model of steatohepatitis in the FAH -/- pig
    Silvana N. Wilken, Philipp Felgendreff, Anna Minshew, Boyukkhanim Ahmadzada, Seyed M. Hosseiniasl, Sara Kazeminia, Kachi Ezenekwe, Ameya Patil, Byoung U. Park, Ahmer Sultan, Lindsey Smith, Julio Cisneros Correa, Kamal Hussein, Harmeet Malhi, Roger K. More
    Veterinary Pathology.2026; 63(4): 746.     CrossRef
  • Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts
    Huangxin Zhu, Lihua Liu, Sicheng Yang, Yunfeng Fu, Yating Pan, Qingan Fu, Fan Du, Xiaodong Zhou
    Cardiovascular Diabetology.2026;[Epub]     CrossRef
  • Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism
    Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD
    Tianxiao Hu, Jiayu Qi, Yinuo Xu, Jia He, Qingying Tan, Jie Hao, Jing Wang, Jiewei Hong, Jianwei Wang, Lin Chen, Xiaobing Dou
    International Immunopharmacology.2026; 172: 116245.     CrossRef
  • Association of the Triglyceride-Glucose Index With Established Cardiovascular Disease in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study
    Soumayan Mondal, Sidharth S Pattnaik, Nihar Ranjan Mohanty, Sailendra Nayak, Ambika Mohanty, Shubhransu Patro
    Cureus.2026;[Epub]     CrossRef
  • Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk
    Qiqi Zhao, Shengwen Lu, Yu Guan, Zhiwen Sun, Shi Qiu, Aihua Zhang
    Lipids in Health and Disease.2026;[Epub]     CrossRef
  • Prognostic value of non-invasive fibrosis assessment scores in predicting mortality among individuals with metabolic dysfunction-associated steatotic liver disease
    Lingjie Wu, Shunling Cai, Zhongbin Lin, Ruilie Chen, Yuanfeng Zhang, Xiaobing Gong
    BMC Public Health.2026;[Epub]     CrossRef
  • Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
    Anna V. Naumova, Guilherme Moura Cunha, Nicole J. Kim, Jie Lu, Daniel Isquith, Baocheng Chu, Charles Maynard, Arash Mahdavi, Negar Firoozeh, Karen Ordovas, Xue‐Qiao Zhao, Francis Kim
    Obesity.2026; 34(3): 622.     CrossRef
  • Association Between Metabolically Associated Steatotic Liver Disease (MASLD) and Cardiovascular Risk Scores in Urban Adults
    FARIS HUSSAIN, KELVIN KANAYO NWABUEZE, FATIMA IJAZ, SONIA OUTALEB, MAHMUDUL HASAN NAHID, SYED ABID, MARIAM SALEEM, KHANT NYI ZAYA, SAIFULLAH SYED, HUMAIRA JANANTH, MANAHIL ZARIEF
    Juntendo Medical Journal.2026; 72(1): 54.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in Tanzania: prevalence and predictors
    Evangelista Malindisa, Illuminata Kafumu, Allen Rweyendera, Elisha Mkemangwa, David Majinge, Igembe Nkandala, Paulina Manyiri, Semvua Kilonzo
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • Body mass index and metabolic dysfunction associated steatotic liver disease remission among Chinese adults in a retrospective cohort study
    Jiwen Zhang, Yuyin Guo, Bi’e Li, Jiaqian Zhu, Chuang Gao, Qiongdan Zhang, Yong Han, Chuxuan Gu
    Scientific Reports.2026;[Epub]     CrossRef
  • 12,13-diHOME ameliorates MASLD by regulating Sestrin2-mediated AMPK/ULK1/Lipophagy in obese mice
    Kexin Zhang, Chengxia Kan, Hongyan Qiu, Junfeng Shi, Jian Chen, Tianpeng Zheng, Jingwen Zhang, Yujie Ma, Sufang Sheng, Ningning Hou, Fang Han, Xiaodong Sun
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(4): 168186.     CrossRef
  • Burden of MASLD and liver fibrosis: evidence from Phenome India cohort
    Meghana Arvind, Anshul Verma, Sreeshma Raj K, Satyartha Prakash, Vignesh S. Kumar, Mohammad Azhar Uddin, Ayushi Narayan, Mamta Rathore, Nancy Rawat, Ankita Sahu, Yogesh Kumar, Pulkit Hasmukhbhai Leuva, Monika Sharma, Rajesh S, Dwaipayan Saha, Ankita Mridh
    The Lancet Regional Health - Southeast Asia.2026; 45: 100723.     CrossRef
  • Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment
    Ina Bergheim, Jean Francois Cadranel, Jianguo Chen, Wenxing Ding, Robert Eferl, Carmen Garcia-Ruiz, Hartmut Jaeschke, Firouzeh Kazerouni, Amedeo Lonardo, Derek A. Mann, Nahum Méndez-Sánchez, Camelia Mokhtari, Han Moshage, Chiara Raggi, Pavel Strnad, Oren
    Exploration of Digestive Diseases.2026;[Epub]     CrossRef
  • Prevalence and risk factors for metabolic dysfunction–associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort
    Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P. Andersson, Hannes Hagström
    Journal of Internal Medicine.2026; 299(4): 481.     CrossRef
  • Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina
    Bárbara Suarez, Adriana Mabel Álvarez, María Florencia Mascardi, Ana Laura Manzano Ramos, Dong Hoon Woo, María Mercedes Gutiérrez, Guillermo Alzueta, María del Carmen Basbus, Santiago Bruzone, Patricia Cuart, Guillermo Dieuzeide, Teresita García, Olga Esc
    Life.2026; 16(2): 283.     CrossRef
  • Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review
    Abdulrahman Ismaiel, Vera Ciornolutchii, Stefan‐Lucian Popa, Dan L. Dumitrascu
    European Journal of Clinical Investigation.2026;[Epub]     CrossRef
  • Predictive factors of metabolic dysfunction associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors, multicenter cross-sectional study, North East Ethiopia
    Getachew Bizuneh Aydagnuhm, Aklile Semu Tefera, Gebru Tesfaw Getahun, Ermiyas Endewunet Melaku
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022
    Wenzhan Jing, Hang Pham, Samuel So
    JHEP Reports.2026; 8(4): 101754.     CrossRef
  • Pirfenidone as a Pleiotropic Antifibrotic Agent in Metabolic Steatohepatitis: From Mechanisms to Clinical Evidence
    Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Jorge L. Poo, Nahum Méndez-Sánchez
    Archives of Medical Research.2026; 57(4): 103387.     CrossRef
  • Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study
    Andreas Bartholdy, Kristine Frøsig Moseholm, Pernille Yde Nielsen, Nicolai J. Wewer Albrechtsen, Lise Lotte Gluud, Majken Karoline Jensen
    Metabolic Brain Disease.2026;[Epub]     CrossRef
  • Outils diagnostiques de la fibrose hépatique dans la stéatohépatite dysmétabolique
    Candice Gea, Guillaume Feugray, Valéry Brunel
    Revue Francophone des Laboratoires.2026; 2026(579): 36.     CrossRef
  • Mitochondrial dysfunction in MASH: Focusing on chronic inflammation and intercellular communication
    Wanyi Luo, Muxin Yu, Chuwei Zheng, Xiaowen Li, Xiaotian Ma, Guocheng Zeng, Jinming Zhang, Xia Ji, Liyan Sun
    Biochemical and Biophysical Research Communications.2026; 804: 153356.     CrossRef
  • Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
    Markos Kalligeros, Laurent Castera, Emmanuel A. Tsochatzis, Naim Alkhouri
    Clinics in Liver Disease.2026; 30(2): 323.     CrossRef
  • La ballonisation hépatocytaire : une nouvelle cible thérapeutique dans la Physiopathologie de la MASH
    Arthur Cens, Bart Staels, Réjane Paumelle
    Revue Francophone des Laboratoires.2026; 2026(579): 28.     CrossRef
  • Febuxostat Improves MASLD in Male Rats: Roles of XOR Inhibition and Associated JNK/NRF2/HO-1 Pathway Changes
    Zhiyu Pu, Yangyang Cen, Bowen Yang, Kaijun Xing, Linxi Lian, Xi Chi, Jianjun Yang, Yannan Zhang
    International Journal of Molecular Sciences.2026; 27(2): 1069.     CrossRef
  • Association between blood heavy metal levels and subtypes of steatotic liver disease: A nationally representative cross-sectional analysis in South Korea
    Ji Hye Choi, Juyeong Kim, Yesol Yim, Hyunjee Kim, Jiyoung Hwang, Ho Geol Woo, Sang Youl Rhee, Yerin Hwang, Dong Keon Yon
    Medicine.2026; 105(4): e47365.     CrossRef
  • Biological aging across the metabolic dysfunction–associated steatotic liver disease spectrum: A systematic review
    Chukwuemeka E. Ogbu, Stella C. Ogbu, Chidera P. Ogbu, Chinazor Umerah
    iLIVER.2026; 5(1): 100222.     CrossRef
  • Fermented Foods and the Gut–Liver Axis: Modulation of MASLD Through Gut Microbiota
    Agnieszka Wesołek-Leszczyńska, Dawid Rosiejka, Kalina Bogdańska, Paweł Bogdański
    Nutrients.2026; 18(3): 542.     CrossRef
  • Association of four insulin resistance indices with liver‐related adverse outcomes: A prospective cohort study
    Xiao‐Meng Wang, Hao Yan, Wen‐Fang Zhong, Jia‐Hao Xie, Huan Chen, Jun‐Jie Wang, Wei‐Qi Song, Dong Shen, Pei‐Dong Zhang, Xi‐Ru Zhang, Jiao‐Jiao Ren, Dan Liu, Zhi‐Hao Li, Chen Mao
    Diabetes, Obesity and Metabolism.2026; 28(5): 3598.     CrossRef
  • Efficacy of empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease with or without diabetes: a systematic review and meta-analysis of randomized controlled trials
    Khalid I. AlHussaini
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia
    Yusuf Yilmaz, Alina M. Allen, Jérôme Boursier, Juan P. Arab
    Clinics in Liver Disease.2026; 30(2): 289.     CrossRef
  • Associations of relative fat mass with metabolic dysfunction–associated steatotic liver disease and liver fibrosis: evidence from the U.S. NHANES 2017–2023
    Hai-Yuan Zhong, Ling-Dan Ma, Jin-Cheng Li, Dan Jiang, Yu-Mei Qin, Ming-Yu Lai, Guang Xiong
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Gut microbiota, liver disease, and perioperative anesthesia: interactions, risks, and therapeutic opportunities
    Lei Shi, Ye Yu, Zihan Ma, Weiyi Jiang
    Frontiers in Cellular and Infection Microbiology.2026;[Epub]     CrossRef
  • Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease
    Jeffrey V. Lazarus, Christopher J. Kopka, Aina Nicolàs, Safura Abdool Karim, Meena B. Bansal, Michael Betel, John F. Dillon, Pere Gines, Aleksander Krag, Veronica Miller, Cynthia A. Moylan, Alisa Pedrana, Paula Petrone, Jörn M. Schattenberg, Sunil S. Solo
    Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 355.     CrossRef
  • SIRT3 ameliorates hepatic inflammation, oxidative stress, and fibrosis in HFD- or MCD diet-fed mice
    Huifang Lv, Wenyue Sun, Cuixia Tian, Chunyong Bian, Zhongting Lu, Xin Guo
    The Journal of Nutritional Biochemistry.2026; 152: 110276.     CrossRef
  • Paulobutalipin, a Lipid Accumulation Inhibitor from a Streptomyces sp.
    Thanh-Hau Huynh, Hoseo Lee, Sangwook Kang, Jeong-Hyeon Kim, Huiyeong Ju, Ki-Bong Oh, Sang-Jip Nam, Ja Hyun Koo, Dong-Chan Oh
    Journal of Natural Products.2026; 89(2): 682.     CrossRef
  • MASLD, MASH, and the CKM Spectrum
    Faiez Zannad, Muhammad Shahzeb Khan, Nisha Bansal, Michael Böhm, Sven M. Francque, Nicolas Girerd, James L. Januzzi, Veronica Miller, Marie-Eve Piché, Vlad Ratziu, Bart Staels, Harriette G.C. Van Spall, Arun J. Sanyal, Javed Butler
    JACC.2026; 87(15): 2006.     CrossRef
  • Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction–associated steatotic liver disease and its progression to hepatocellular carcinoma
    Thomai Kouti, Panayiota Christodoulou, Stephanos Christodoulides, Foula Protopapa, Charalambos Michaeloudes, Paraskevi A. Farazi
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter
    Lanlan Chen, Paul Horn, Frank Tacke
    Diabetes, Obesity and Metabolism.2026; 28(S2): 46.     CrossRef
  • MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management—A Narrative Review
    Adela Gabriela Ştefan, Adina Mitrea, Diana Clenciu, Ionela Mihaela Vladu, Maria Magdalena Roşu, Diana Cristina Protasiewicz-Timofticiuc, Theodora Claudia Radu-Gheonea, Ion-Cristian Efrem, Anca Maria Amzolini, Beatrice Elena Vladu, Ana-Maria Efrem, Delia-V
    Medicina.2026; 62(2): 325.     CrossRef
  • The active components of the Danshen-Shanzha herb-pair exert a protective effect on MASLD by synergistically promoting fatty acid oxidation via the activation of PPARα, Plin-5 and Plin-2
    Ying Yang, Yaxing Li, Zirong Zhou, Hui Li, Yihan Ma, Wenjie Bi, Mengjiao Li, Xiaoli Liu, Qiang Jia, Liwen Han, Songsong Wang
    Journal of Ethnopharmacology.2026; 362: 121374.     CrossRef
  • Efficacy and Safety of Statins in MASLD and Other Chronic Liver Diseases
    I. Commins, D. Clayton-Chubb, N. Janko, A. Majeed, W. Kemp, S. K. Roberts
    Medical Sciences.2026; 14(1): 84.     CrossRef
  • Detection of hepatic steatosis with ultrasound-guided attenuation parameter (UGAP) in metabolic dysfunction-associated steatotic liver disease (MASLD) compared with proton density fat fraction (PDFF): Impact of measurement number and region of interest (R
    Marie Byenfeldt, Christer Grönlund, Patrik Nasr, Anna Lindam, Mattias Ekstedt, Peter Lundberg, Johan Kihlberg
    Ultrasound.2026;[Epub]     CrossRef
  • Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges
    Miguel Suarez, Raquel Martínez, Félix González-Martínez, Ana María Torres, Jorge Mateo
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Efficacy of ursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease: an umbrella review of meta-analyses on liver enzymes
    Alsu R. Khurmatullina, Dmitrii N. Andreev, Igor V. Maev, Andrey V. Zaborovsky, Yury A. Kucheryavyy, Petr A. Beliy, Philipp S. Sokolov
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Panax notoginseng Saponins Ameliorate High‐Fat Diet‐Induced Liver Injury via Mechanisms Involving TLR4‐Mediated Signaling and Lipid Metabolism
    Rong Li, Junyu Ma, Mengyao Li, Bangzhao Zeng, Xuexun Li, Xiaoyan Bi, Xin Zhao, Qin Gao, Yanling Yao, Yang Jiang, Chunmei Zhang, Fuli Ya
    Food Science & Nutrition.2026;[Epub]     CrossRef
  • MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5
    Morgan C. Nelson, Liam C. O’Malley, Soh-Hyun Lee, Kaylyn M. Bauer, Arevik Ghazaryan, William W. Tang, Chad VanSant-Webb, Van B. Tran, Colton Hernandez, Ben Battistone, Amber Thibeaux, June L. Round, Micah J. Drummond, H. Atakan Ekiz, Kimberley J. Evason,
    Cancer Research Communications.2026; 6(2): 359.     CrossRef
  • Imaging in MASLD
    Sudhakar K. Venkatesh
    Expert Review of Gastroenterology & Hepatology.2026; 20(3): 257.     CrossRef
  • Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
    Júlia Mayumi Tomaru, Iara Ribeiro Nunes, Caroline Fernandes de Souza Santiago, Alda Maria Machado Bueno Otoboni, Claudemir Gregorio Mendes, Adriana Maria Ragassi Fiorini, Elen Landgraf Guiguer, Claudia Cristina Teixeira Nicolau, Antonelly Cassio Alves Car
    Nutrients.2026; 18(4): 636.     CrossRef
  • Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis
    Siyu Duan, Yiyi Wei, Zhuoyu Ding, Chaomin Pan, Li Yang, Yan Gu, Xinke Wang
    PeerJ.2026; 14: e20616.     CrossRef
  • Liver involvement in dengue virus infection: a narrative review
    Madunil Anuk Niriella, Ravini Amila Premaratna, Shashini Hathurusinghe, Ranjan Premaratna, Anuradha Supun Dassanayake, Hithanadura Janaka de Silva
    Journal of Clinical Virology Plus.2026; 6(2): 100247.     CrossRef
  • Toll Like Receptor 4: A Potential Link Between Obesity and Metabolic Diseases
    Ghadeer Alhamar, Joanna Razafiarison, Fawaz Alzaid, Fahd Al‐Mulla, Rasheed Ahmad
    Obesity Reviews.2026;[Epub]     CrossRef
  • Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
    Xiao-Dong Zhou, Qin-Fen Chen, Qiong-Yue Fan, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Jérôme Boursier, Elisabetta Bugianesi, Hannes Hagström, Wah-Kheong Chan, Manuel Romero-Gomez, José Luis Calleja, Victo
    Hepatology.2026; 84(2): 529.     CrossRef
  • Editorial: Pharmacological and nutritional approaches to metabolic associated fatty liver disease: a step towards achieving SDG 3
    Mahmut Bodur, Bojana Vidović, Anastasios Nikolaou, Birsen Yilmaz
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Impact of newer antihyperglycemic agents on hepatic complications: A systematic review and meta-analysis of data from 5.3 million patients with type 2 diabetes mellitus
    Jiwon Yang, Yeongseok Hwang, Jin-Sung Ju, Seungbong Han, Jihyun An, Ju Hyun Shim
    Hepatology.2026;[Epub]     CrossRef
  • A novel C/EBPα–miR-335-5p–PRKAA2 regulatory axis drives hepatic lipid accumulation in MASLD
    Xiying Zeng, Yajing Xu, Sufang You, Honghong Duan, Qingyan Cai, Huibin Huang
    Scientific Reports.2026;[Epub]     CrossRef
  • Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling
    Kübranur Ünal, Leyla İbrahimkhanlı, Mehmet Emre Erol, Nemat İbrahimkhanlı, Sabri Engin Altıntop, Mahi Nur Cerit, Ethem Turgay Cerit, Halit Nahit Şendur
    International Journal of Tryptophan Research.2026;[Epub]     CrossRef
  • Modulation of metabolic, inflammatory, fibrotic, and cell death pathways by resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): a transcriptomic profiling study
    Chen-yang He, Zhi-hua Wang, Jian-ping Weng, Hans Strijdom, Suo-wen Xu
    Acta Pharmacologica Sinica.2026; 47(4): 1070.     CrossRef
  • From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
    Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang
    Portal Hypertension & Cirrhosis.2026; 5(2): 170.     CrossRef
  • Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017–2018
    Shaoguang Chen, Lixiao Zhu, Yulou Jiang
    Abdominal Radiology.2026;[Epub]     CrossRef
  • Deubiquitinase USP2 promotes hepatic stellate cell activation via p300 stabilization
    Seunghee Byun, Hyunsik Kim, Sun‐Ho Lee, Jae‐Hwan Kwon, Hyunseung Kim, Jung‐Yoon Yoo, Soo‐Yeon Park, Ho‐Geun Yoon
    FEBS Letters.2026; 600(9): 1318.     CrossRef
  • Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023
    Kexin Zhang, Wei Xu, Chengxia Kan, Sufang Sheng, Fang Han, Jian Chen, Xuan Li, Ningning Hou, Xiaodong Sun, Ying Xue
    Digestive Diseases and Sciences.2026;[Epub]     CrossRef
  • Impact of different subtypes of steatotic liver disease on immune checkpoint inhibitor-related drug-induced liver injury: a retrospective study
    Tianyi Ma, Zhanfang Guo, Haijia Bi, Huawei Yuan, Yu Li, Mei Sun
    European Journal of Gastroenterology & Hepatology.2026; 38(3): 351.     CrossRef
  • Triglyceride glucose index—a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging
    Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Peishu Li, Yifei Feng, Jiayuan Zhang, Bangde Xiang
    Cardiovascular Diabetology.2026;[Epub]     CrossRef
  • The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging
    Tugce Apaydin, Haluk Tarik Kani, Caglayan Keklikkiran, Yusuf Yilmaz, Dilek Gogas Yavuz
    Journal of Endocrinological Investigation.2026; 49(5): 1029.     CrossRef
  • From Childhood to Old Age: Current Knowledge and Practical Approaches to Metabolic Dysfunction-Associated Steatotic Liver Disease
    Iwona Gorczyca-Głowacka, Michał Tarnowski, Anna Zmelonek-Znamirowska, Przemysław Wolak
    Journal of Clinical Medicine.2026; 15(4): 1536.     CrossRef
  • Development of a Lipidomics-Based Cell Screening Platform for Indirect Antioxidants Targeting Oxidized Lipid Droplet Formation and Mitochondrial Membrane Abnormality
    Yuzu Shibata, Toshihiro Sakurai, Akiko Sakurai, Misuzu Sato, Shu-Ping Hui
    Nutrients.2026; 18(5): 719.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multisystemic Narrative Review of Cardiovascular and Oncological Implications
    Menatalla M. A. Mohamed, Maha M. M. I. Taha, Mohnd M. M. R. Ibrahim
    ASIDE Gastroenterology.2026; 2(2): 15.     CrossRef
  • Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography
    Hidenao Noritake, Takafumi Inoue, Takashi Yonekura, Hiroki Tamakoshi, Yuya Ida, Moe Matsumoto, Tomohiko Hanaoka, Maho Yamashita, Masahiro Umemura, Kazuyoshi Ohta, Takeshi Chida, Kazuhito Kawata
    Journal of Clinical Lipidology.2026; 20(5): 947.     CrossRef
  • Fecal microbiota transplantation alleviates steatosis and inflammation in high-fat and high-sugar diet-induced fatty liver in mice
    Fangxia Mi, Jinglu Guo, Wentao Zheng, Jianwei Shen, Hua Ye
    Frontiers in Cell and Developmental Biology.2026;[Epub]     CrossRef
  • Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4α
    Xinru Chen, Nga Nguyen, Susan E. Turner, Albert K. Tai, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos
    JHEP Reports.2026; 8(6): 101796.     CrossRef
  • Real-world comparison of GLP-1 agonists versus physical activity in metabolic dysfunction-associated steatotic liver disease
    Jason N. Chen, Bulent Tolga Delibasi, James Wang, Thomas Tran, Connie Hu, Charles W. Randall
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation
    Kelly O. Otakhor, Mohd Ali Abbas Zaidi, Rebecca E. Oberley-Deegan, Moorthy P. Ponnusamy, Kurt W. Fisher, Micah B. Schott
    Journal of Biological Chemistry.2026; 302(4): 111321.     CrossRef
  • Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis
    Gang Zhou, Xihan Gu, Xinyao Zhou, Shuai Chen, Hanyang Liu, Jing Wang
    BMJ Open Gastroenterology.2026; 13(1): e002123.     CrossRef
  • Epigenetic regulation in MASLD – insight for therapeutic target discovery
    Jan H. Britsemmer, Nuria Lopez Alcantara, Henriette Kirchner
    Epigenomics.2026; 18(3): 311.     CrossRef
  • Astaxanthin alleviates altered hepatic lipid metabolism and oxidative stress in animals fed a high-sucrose diet
    Matias Rodrigo Vargas, María del Rosario Ferreira, Paola Inés Ingaramo, Pablo Collins, María Eugenia D’Alessandro
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa
    Mohamed El-Kassas, C. Wendy Spearman, Manal El-Sayed, Zobair M. Younossi
    Clinics in Liver Disease.2026; 30(2): 513.     CrossRef
  • Patients’ Experience of Stigma as the Hidden Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Descriptive Qualitative Study with Thematic Analysis
    Johanne Lisa Jensen-LeBlanc, Pernille Andreassen, Mette Munk Lauridsen, Lea Ladegaard Grønkjær
    Healthcare.2026; 14(5): 579.     CrossRef
  • Targeting magnesium homeostasis: a novel therapeutic strategy for liver diseases
    Lili Ji, Hanhan Yu, Ruwen Wang, Hongmei Yan, Xiaofeng Yin, Shanshan Guo, Ru Wang
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review
    Alicia González-González, Virginia Soria-Utrilla, María Isabel Fontalba-Romero, María Ángeles Núñez-Sánchez, Antonio Adarve-Castro, María Isabel Queipo-Ortuño, Bruno Ramos-Molina, José Ignacio Martínez-Montoro, José Carlos Fernández-García
    Current Obesity Reports.2026;[Epub]     CrossRef
  • Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
    Xiaoning Sun, Xiaozhong Wang, Ayesha Younas, Shuanghu Wang, Muhammad Sohail, Jiaojian Lv, Zuxiu Huang, Yunxiao Liu
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Metabolic liver imaging: What you need to know
    Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T. Pierce, Jingwei Wei, Angelo Vanzulli
    Digestive and Liver Disease.2026; 58(4): 433.     CrossRef
  • Gut microbiota supportive dietary pattern associated with reduced MASLD risk mediated by metabolomic profiles: a prospective cohort study
    Dong-Run Li, Ke-Ru Li, Ying Wang, Jia-Qi Zheng, Wen-Rui Zheng, Bang-Quan Liu, Jia-Cheng Liu, Rui-Han Bao, Ting-Ting Gong, Qiu-Ju Sheng, Shan-Yan Gao, Qi-Jun Wu
    Nutrition Journal.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America
    Claudia P. Oliveira, Mario Guimarães Pessoa, Luis Antonio Diaz, Juan Pablo Arab, Adrian Gadano, Marco Arrese
    Clinics in Liver Disease.2026; 30(2): 529.     CrossRef
  • Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study
    Chao Yan, Xinxin Shen, Shaojie Han, Jinzheng He, Tongxu Wang, Xiaobing Gong, Jindong Ding Petersen
    Journal of Translational Medicine.2026;[Epub]     CrossRef
  • Retatrutide in type 2 diabetes mellitus and obesity: an overview
    Theodoros Panou, Evanthia Gouveri, Djordje S. Popovic, Nikolaos Papanas
    Expert Review of Clinical Pharmacology.2026; 19(4): 313.     CrossRef
  • Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha
    Liver International.2026;[Epub]     CrossRef
  • Optimal screening criteria for metabolic dysfunction-associated steatotic liver disease with fibrosis
    Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Annals of Hepatology.2026; 31(2): 102199.     CrossRef
  • The role and possible mechanism of intestinal fungi in the progression of chronic liver diseases
    Yirui Hu, Ye Yang, Shuyan Wang, Huikuan Chu
    npj Biofilms and Microbiomes.2026;[Epub]     CrossRef
  • Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD
    Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson
    Liver International.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study
    Min Jin Jeong, Yong Seok Lee, Youn Jin Choi, Kyung Do Han
    Cancers.2026; 18(6): 894.     CrossRef
  • Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
    Leonidas Diamantopoulos, Markos Kalligeros, Scott D. Isaacs, Didac Mauricio
    Clinics in Liver Disease.2026; 30(2): 271.     CrossRef
  • Hospitalization Trends Due to Chronic Liver Diseases: Vicious Circle of Co-Morbidities and Hospitalization Length
    Ivana Pantic, Nikola Grubor, Sofija Lugonja, Nina Rajovic, Svetlana Miltenovic, Marija Brankovic, Tijana Gmizic, Tamara Milovanovic
    Clinics and Practice.2026; 16(3): 57.     CrossRef
  • Integrated multi-omics analysis identifies and validates endoplasmic reticulum stress and mitophagy-related biomarkers in MASLD
    Quanrun Chen, Limin Liu, Jinqiu Feng, Chong Zhang, Zongming Zhang
    Scientific Reports.2026;[Epub]     CrossRef
  • Non-invasive risk stratification of metabolic dysfunction-associated steatotic liver disease and liver fibrosis in adults with type 1 diabetes
    Manuel Ramón García-Sáenz, Marilu Cervantes-Maldonado, Luis Angel López-Cruz, Eduardo Salif Luna-Avila, Paulo César Gete Palacios, Cristina Martínez-Berdeja, Omar Jaime-Leal, Aldo Ferreira-Hermosillo
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • MEANDERLINE BASED MICROSTRIP ANTENNA DESIGN FOR LIVER TUMOR DETECTION
    Volkan Akdoğan, Fatih Özkan Alkurt
    Kahramanmaraş Sütçü İmam Üniversitesi Mühendislik Bilimleri Dergisi.2026; 29(1): 401.     CrossRef
  • Metabolic-associated steatotic liver disease in children and adolescents: a scoping review and narrative synthesis of epidemiology, risk factors, and screening approaches with emerging implications for sub-Saharan Africa
    Bruno Basil, Peace Ngozi Okoro
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions
    Rashmee Patil, Winston Dunn, Mazen Noureddin, Naim Alkhouri
    Drugs.2026; 86(5): 627.     CrossRef
  • The Gut‐Liver Axis in Metabolic Dysfunction‐Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics
    Shaoliang Zhu, Mengjie Zou, Qijun Wu, Yan Zou, Tingting Tan, Zhangnan Huang, Zheng Gong, Honglin Luo, Xiaofeng Dong
    The FASEB Journal.2026;[Epub]     CrossRef
  • Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes
    Konstantinos Malandris, Konstantinos Charalampidis, Rohit Loomba, Emmanouil Sinakos
    Current Diabetes Reports.2026;[Epub]     CrossRef
  • Association between weekend catch-up sleep and Metabolic dysfunction-associated steatotic liver disease in US adults
    Jinlong Chen, Wei Wang, Jie He, Xinxin Fang
    Clinical and Experimental Medicine.2026;[Epub]     CrossRef
  • Ginsenoside Rg1 alleviates MASH by targeting GLS2 to enhance PINK1/Parkin-mediated mitophagy and improve mitochondrial function
    Zhijian Wang, Yinuo Wang, Peiyun Peng, Huating Luo, Liuling Xiao, Wenxiang Huang
    Biochemical Pharmacology.2026; 249: 117891.     CrossRef
  • Heterogeneous associations of regional adipose depots with liver fibrosis in U.S. adults
    Kuan-Yu Lai, Chun-Yi Wang, Hsian-Han Kao, Wen-Yuan Lin, Tsung-Po Chen
    Metabolism Open.2026; 30: 100461.     CrossRef
  • MASLD In Children - A Distinct Phenotype?
    Pervej Alom Barbhuiya, Manash Pratim Pathak
    Current Obesity Reports.2026;[Epub]     CrossRef
  • DNA hypermethylation of choline kinases drives blockage of choline-phosphatidylcholine biosynthesis: lipidomic biomarkers and epigenetic insights of hepatic steatosis induced by arsenic
    Qiwen Fu, Qi Wang, Dingyi Song, Xingcheng Zhou, Hualin Chen, Shaofeng Wei, Lu Ma
    BMC Medicine.2026;[Epub]     CrossRef
  • Comments on “Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection”
    Preeti Lamba
    Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
  • Association between triglyceride glucose-body mass index and metabolic dysfunction-associated steatotic liver disease in South Korean pregnant women
    Yuqin Shen, Dongqian Yang, Li Zhang, Rong Shuai
    Scientific Reports.2026;[Epub]     CrossRef
  • Combined effect of MASLD and low muscle strength on the risk of osteoporotic fractures: A UK Biobank cohort study
    Yongin Cho, Jong Hyun Jhee, Jong Ho Jhee, Hye-Sun Park
    European Journal of Endocrinology.2026; 194(3): 357.     CrossRef
  • Hepatoprotective Effects of Combined Inulin-Glucomannan Non-Starch Polysaccharide Against Western Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease
    I Gede Putu Adhi Wedharga, Made Cahyani Trisna Ananda, Nadilla Faiza Richadini, Bernadette Dian Novita, Herjunianto Herjunianto, Silvia Sutandhio, Adi Pramono Hendrata, Mulya Dinata, Yu Hirata, Suryo Kuncorojakti, Hendy Wijaya, Dawei Chen, Ester Natalia D
    Journal of Pharmaceutical Innovation.2026;[Epub]     CrossRef
  • Broccoli-Derived Exosome-like Nanoparticles Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulating the Gut–Liver Axis
    Feng Zhang, Ruolan Liu, Tongxiao Xu, Wentao Xu, Kunlun Huang, Xiaoyun He
    Nutrients.2026; 18(6): 953.     CrossRef
  • Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
    Mary E. Rinella, Silvia Sookoian
    Nature Reviews Gastroenterology & Hepatology.2026; 23(6): 460.     CrossRef
  • Association of Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Failure in the CKD Population
    Jin Kyung Kwon, Minsang Kim, Jinsun Lee, Jae-ik Oh, Jung Hun Koh, Min Woo Kang, Jeong Min Cho, Seong Geun Kim, Hyuk Huh, Sehyun Jung, Semin Cho, Soojin Lee, Eunjeong Kang, Yaerim Kim, Dong Ki Kim, Kyungdo Han, Sehoon Park
    Kidney International Reports.2026; 11(5): 106414.     CrossRef
  • Hepatic Outcomes in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease: Propensity‐Matched Cohort Study
    Rishi Chowdhary, Manjeet Kumar Goyal, Ashita Rukmini Vuthaluru, Megh Patel, Tanisha Sehgal, Kirti Arora, Rahul Chowdhary, Varun Mehta, Akash Batta, Omesh Goyal
    Hepatology Research.2026; 56(6): 1026.     CrossRef
  • Cytoglobin in Hepatic Stellate Cells Plays Anti-Fibrotic Role in Chronic Liver Injury
    Norifumi Kawada
    Antioxidants.2026; 15(3): 383.     CrossRef
  • Capabilities of magnetic resonance imaging in quantitative assessment hepatic steatosis in patients with different body mass index
    Yu. N. Savchenkov, G. E. Trufanov, V. A. Fokin, E. A. Ionova, T. A. Anosova, A. V. Anisonyan, E. S. Sbikina, O. V. Bodrova
    Medical alphabet.2026; (4): 40.     CrossRef
  • MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome
    Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Qin-Fen Chen, Michael D. Shapiro, Yuxing Dong, Ki-Chul Sung, Gregory Y. H. Lip, Jeffrey V. Lazarus, Ming-Hua Zheng
    Science China Life Sciences.2026; 69(6): 1950.     CrossRef
  • Frailty, cardiovascular health, and the risk of mortality and extrahepatic diseases in patients with metabolic dysfunction-associated steatotic liver disease
    Jie Li, Jiang Li, Xiaoqin Xu, Ningjian Wang, Bin Wang, Yingli Lu
    Maturitas.2026; 208: 108917.     CrossRef
  • Myeloid KIF13B suppresses the STT3A/CTSD/THBS1 axis to prevent MASH
    Kaikai Lu, Xianqin Shen, Ziyang Guo, Jingxuan Chen, Lei He, Aiden Xian, Si Mei, Yufei Han, Yinqi Zhao, Jinxuan Chen, Sijing Shi, Guolin Miao, Yitong Xu, Zihao Zhou, Lianxin Zhang, Chao Zhai, Ziwei Wang, Ling Zhang, Minghua Zheng, Lin Yao, Wei Huang, Yuhui
    Hepatology.2026;[Epub]     CrossRef
  • Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study
    Yue Li, Zixian Li, Siyu Wu, Ling Cao, Beibei Qian, Junxian Tao, Zhimin Qian, Li Xie, Xiaoli Cai, Xiaofang Sun, Ying Li, Zhenwen Zhang, Caifeng Yan, Dunmin She
    BMC Endocrine Disorders.2026;[Epub]     CrossRef
  • Niacin Derivatives in MASLD: Metabolic and Therapeutic Insights
    Marina Idalia Rojo-López, Julia Niño-Narvión, Maria Antentas, Berta Fernández-Camins, Elizabeth Martínez-Rojo, Maria Poca, María Antonia Martínez-Sánchez, Bruno Ramos-Molina, Joana Rossell, Didac Mauricio, Josep Julve
    Nutrients.2026; 18(6): 996.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease
    James M. Paik, Linda Henry, Khalid AlNaamani, Ariana Nader, Maria Stepanova, Mei-Hsuan Lee, Ming-Lung Yu, Zobair M. Younossi
    Clinics in Liver Disease.2026; 30(2): 241.     CrossRef
  • Assessing the Relationship Between Steatotic Liver Disease and Barrett’s Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants
    Nikolaus Götz, Andreas Völkerer, Hannah Hofer, Sarah Wernly, Franz Singhartinger, Ewald Wöll, Elmar Aigner, Maria Flamm, Christian Datz, Bernhard Wernly
    Zeitschrift für Gastroenterologie.2026; 64(05): 470.     CrossRef
  • Prevotella‐Derived Butyrate Inhibits CD8+ T‐Cell Glycolysis via AKT/mTOR Signalling to Alleviate MASH
    Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Yixin Hou
    Liver International.2026;[Epub]     CrossRef
  • CT-assessed abdominal visceral adiposity and MASLD: a sex-stratified cross-sectional analysis
    Linying Xu, Ting Chen, Yitian Xie, Xueyu Xiang, Yupeng Liu, Chongyong Xu, Shuran Wang
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • MetALD at the crossroads of metabolic and alcohol-related liver disease
    Gustavo Ayares, Luis Antonio Díaz, Juan Pablo Arab, Marco Arrese
    Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
  • Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design and translational endpoint interpretation
    Mengdi Lu, Hong Zhang, Xiaoxue Zhu, Jia Xu, Lin Xiang, Yue Hu, Jixuan Sun, Jiajia Mai, Yanhua Ding
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease
    Aryoung Kim, Danbee Kang, Sung Chul Choi, Dong Hyun Sinn, Hye Ryoun Jang, Geum-Youn Gwak
    The Journal of nutrition, health and aging.2026; 30(5): 100827.     CrossRef
  • Multi-omics integration reveals ANXA6-high γδ T cell–endothelial communication as a potential link between periodontitis and MASLD
    Zhongxuan Zhang, Zihan Ma, Ruidong Zhang, Min Ye, Zhongyu Shi, Miao Yu, Lingling Ou
    npj Systems Biology and Applications.2026;[Epub]     CrossRef
  • Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study
    Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and acute leukemias – a literature review and future directions
    Tareq Salah, Maximillian Stahl, Jan Philipp Bewersdorf
    Leukemia & Lymphoma.2026; 67(6): 1221.     CrossRef
  • Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
    Tina Reinson, Josh Bilson, Caroline Childs, Ryan M Buchanan, Giovanni Targher, Christopher D Byrne
    BMJ Medicine.2026; 5(1): e002038.     CrossRef
  • XBP1s-Regulated GFPT1 via Facilitating O-GlcNAcylation of FASN S509 Is Involved in Arsenic-Induced MASLD through Promoting Fatty Acid Synthesis in Hepatocytes
    Wenjie Li, Bowen Fan, Han Li, Qiong Du, Jiaheng Lin, Yi Yang, Xiaolin Ding, Haoran Zhang, Haibo Xia, Binafsha Manzoor Syed, Cheng Cheng, Qizhan Liu
    Journal of Agricultural and Food Chemistry.2026; 74(14): 11814.     CrossRef
  • Combination Training Improves Leptin Regulation, Reduces Body Fat, and Increases Skeletal Muscle Mass in Obese Females
    Dwi Cahyo Kartiko, Purwo Sri Rejeki, Dono Indarto, Irmantara Subagio, Sasminta Christina Yuli Hartati, Bekir Erhan Orhan, Yuni Nurwati, Adi Pranoto
    Physical Education Theory and Methodology.2026; 26(2): 380.     CrossRef
  • Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH)
    Mirjana Grocic, Madison Nguyen, Arun J. Sanyal
    Diabetes, Obesity and Metabolism.2026; 28(S2): 3.     CrossRef
  • Association of environmental chemical exposure with metabolic dysfunction-associated steatotic liver disease: a cross-sectional and network toxicology analysis
    Guodong Yang, Wenli He, Xin Qiu, Shuang Shen, Yifei Feng, Yi Peng, Taixin Yang, Zhaochan Wen, Peishu Li, Huili Luo, Xinyuan Wu, Ze Su, Bangde Xiang
    European Journal of Medical Research.2026;[Epub]     CrossRef
  • Burden of metabolic dysfunction-associated steatotic liver disease in the Asia-Pacific region from 1990 to 2023
    Xiao-Dong Zhou, Qin-Fen Chen, Giovanni Targher, Christopher D Byrne, Luca Valenti, Mark D Muthiah, Seung Up Kim, Daniel Q Huang, Masato Yoneda, Wenhao Li, Yusuf Yilmaz, Herbert Tilg, Vincent Wai-Sun Wong, Ming-Hua Zheng
    eGastroenterology.2026; 4(1): e100369.     CrossRef
  • Unraveling the Mechanisms of Wuling Powder Against MASLD by Integrated Metabolomics–Gut Microbiota–Serum Pharmacochemistry
    Huan Yang, Yan-Mei Tang, Shao-Cong Han, Peng-Quan Wang, Yu-Xuan Tao, Hui-Qiong Yang, Min Zhang, Min Li, Jie Yu, Xing-Xin Yang
    Pharmaceuticals.2026; 19(4): 557.     CrossRef
  • Crocin II alleviates metabolic dysfunction-associated steatotic liver disease by enhancing autophagic degradation of ANGPTL8
    Rongtian Zhang, Kongdong Li, Ziting Zhao, Xintong Jiang, Rumeng Zhang, Chang Liu, Wenxiang Zhang, Siyu Chen
    Targetome.2026;[Epub]     CrossRef
  • Endocrine disruptors reprogram hepatic metabolic and immune gene networks to promote hepatocellular carcinoma
    Yanggang Hong, Yi Wang, Qingyu Chen, Yirong Wang
    npj Gut and Liver.2026;[Epub]     CrossRef
  • Exercise-responsive skeletal muscle genes mechanistically linked to metabolic dysfunction-associated steatotic liver disease
    Jia-Hui Zhang, Kang Chen, Xiao-Min Zhu, Huan Zhou, Jia-Mi Jiang, Yu-Qing Zou, Ke-Rong Liu, Le Zhang, Yun Li
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Multimodal assessment of hepatic steatosis heterogeneity: segmental MRI-PDFF and ultrasound attenuation coefficient measurement
    M.M. Zhaivoronok, N.V. Deresh, I. Sporea, O.B. Dynnyk, S.V. Feysa, O.A. Pushkarenko, O.A. Fedusenko, O.V. Shcherbina, N.M. Kobyliak
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(2): 103.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease, biomarkers, and cardiovascular risk factors in children with excess weight
    Elisabeth A. Machado, Beatriz L.C. Themistocles, Jorge M.R. Teixeira, Fernanda M.G. Jannuzzi, Geísa Tomaz, Cecilia L. Oliveira, Isabel R. Madeira, Carlos Terra, Maria das Graças C. Souza, Alexandra Monteiro, Eliete Bouskela, Marise E. Marsillac, Paulo F.
    Jornal de Pediatria.2026; 102(3): 101534.     CrossRef
  • Ubiquitin-Specific Protease 2 (USP2) as a Modulator of Energy Metabolism: A Review of Studies Using Animal and Cellular Models
    Hiroshi Kitamura, Jun Okabe, Himeka Hayashi, Tomohito Iwasaki
    Biomedicines.2026; 14(4): 783.     CrossRef
  • Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm
    Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim
    Diabetes, Obesity and Metabolism.2026; 28(6): 5240.     CrossRef
  • Longitudinal performance of vibration controlled transient elastography in pediatric metabolic dysfunction associated steatotic liver disease
    Naima Diop‐West, Nicholas Denson, Ana Catalina Arce‐Clachar, Julie Bonn, Kristin Bramlage, Lisa Leesman, Rashmi D. Sahay, Emrah Gecili, Andrew T. Trout, Stavra Xanthakos, Marialena Mouzaki
    Journal of Pediatric Gastroenterology and Nutrition.2026; 82(6): 1366.     CrossRef
  • LPCAT3 deficiency Drives phospholipid remodeling and mitochondrial oxidative dysfunction to accelerate MASH-HCC development
    Gaoxuan Shao, Chenhao Ye, Chenceng Sun, Jiashu Pan, Lu Lu, Lei Wang, Tao Wu, Zemin Lin, Guang Ji, Hanchen Xu
    Journal of Advanced Research.2026;[Epub]     CrossRef
  • Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies
    Eleni A. Karavia, Andreas Pittaras, Ourania Andreopoulou, Aikaterini Hatziri, Amalia Makrydimitri, Dimitrios Anagnostopoulos, Patroklos Vareltzis, Kyriakos E. Kypreos
    Pharmaceuticals.2026; 19(4): 605.     CrossRef
  • Studying serum immunoglobulin levels in metabolic dysfunction-associated steatotic liver disease
    Hazem Abosheaishaa, Emad Ahmad Awad Hussein, Shereen Abou Bakr Saleh, Mahmoud Nassar, Abdulaziz Elmaradny, Mohammed Abdelwahed, Amr Ali, Khaled Elfert, Ahmed Mohamed ElGhandour
    Egyptian Liver Journal.2026;[Epub]     CrossRef
  • Association Between Periodontitis and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Cross‐Sectional Study
    Mizuki Saito, Yoshihiro Shimazaki, Saori Yoshii, Tetsuhito Kojima
    Clinical and Experimental Dental Research.2026;[Epub]     CrossRef
  • Endoscopy for Metabolic Diseases
    Maria Valeria Matteo, Jana Kefah Ibrahim Hussein, Giorgio Carlino, Vincenzo Bove, Valerio Pontecorvi, Loredana Gualtieri, Martina De Siena, Mariachiara Di Vincenzo, Lorenzo Zileri Dal Verme, Daniele Salvi, Clarissa Ferrari, Cristiano Spada, Ivo Boskoski
    Journal of Clinical Medicine.2026; 15(8): 2832.     CrossRef
  • Weekend warrior physical activity pattern and risk of all-cause and cardiovascular mortality among US adults with metabolic dysfunction-associated steatotic liver disease: A prospective cohort study of NHANES 2007–2018
    Mengbiao Cai, Kai Jin, YuLong Wang, Jian Zhu, Changnan Xu, Yi Yang, Zhenxiang Guo
    Science Progress.2026;[Epub]     CrossRef
  • Differential Impact of Metabolic Bariatric Surgery Versus Semaglutide on Adverse Hepatic and Extrahepatic Outcomes in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Type 2 Diabetes
    Weronika Stupalkowska, Alex E. Henney, David R. Riley, Eric G. Sheu, Uazman Alam, Daniel J. Cuthbertson
    Diabetes, Obesity and Metabolism.2026; 28(7): 5684.     CrossRef
  • Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities
    Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng
    Med.2026; 7(6): 101099.     CrossRef
  • Toxic lipid-induced epigenetic activation of ICAM1 in liver sinusoidal endothelium regulates myeloid-driven fibro-inflammatory response in MASH
    Qianqian Guo, Nantawat Satthawiwat, Akitoshi Sano, Chady Meroueh, Asma Hamdi, Xin Dai, Khaled Warasnhe, Alexander M. Washington, Patrick P. Starlinger, Alex Krivonos, Sheng Cao, Enis Kostallari, Johan W. Jonker, Bart van de Sluis, Feda H. Hamdan, Samar H.
    Hepatology.2026;[Epub]     CrossRef
  • Updates on paediatric MASLD: insights from an endocrine lens
    Natalie Segev, Marialena Mouzaki
    Diabetologia.2026;[Epub]     CrossRef
  • An Integrated Nanozyme‐Exosome Platform for Multi‐Targeted Therapy of Metabolic‐Associated Steatotic Liver Disease
    Kun Yu, Xinwei Li, Yingying Liu, Haonan Zhang, Guojie Liu, Tuo Ji, Yuzhi Gao, Lin Wang, Yuwei Bian, Guohua Chen, Zhiwen Zhao, Feng Wang, Xiaoming Yu, Jiachen He, Xuzhu Gao
    Advanced Healthcare Materials.2026;[Epub]     CrossRef
  • Safety and efficacy of pharmacological interventions for hepatic outcomes of metabolic dysfunction-associated steatotic liver disease: protocol for systematic review and network meta-analysis
    Kiavash Semnani, Farbod Semnani, Seyed Sahab Aarabi, Shirin Esmaeili, Ehsaneh Taheri, Armita Mahdavi-Gorabi, Mohsen Rajabnia, Shirin Djalalinia, Saba Goodarzi, Amir Kasaeian, Mohammad Shadab Siddiqui, Mostafa Qorbani
    BMJ Open.2026; 16(4): e111933.     CrossRef
  • Cholinesterase and the association between hepatic steatosis and liver fibrosis in patients with prior hepatitis E
    Ziteng Wang, Zhe Yu, Wen An, Herui Wei, Jing Luo, Mengqi Li, Lingling He, Jiali Ma, Fan Xiao, Lijuan Sun, Qi Gao, Hui Zhong, Hongshan Wei
    European Journal of Medical Research.2026;[Epub]     CrossRef
  • GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes
    Jonggi Choi, Gabby Mitchell, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung
    Hepatology Communications.2026;[Epub]     CrossRef
  • Analysis of B-Scan Ultrasonography Using Neural Networks to Predict Risk of Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Josefine Stansch, Kien Vu Trung, Valentin Blank, Jakob Nikolas Kather, Moritz Herzog, Tobias Seibel, Paul-Henry Koop, Robert Haase, Thomas Berg, Johannes Wiegand, Thomas Karlas
    Ultrasound in Medicine & Biology.2026; 52(7): 1346.     CrossRef
  • Sleeve Gastrectomy Alters Exosomal miR-497-5p Cargo to Ameliorate Metabolic Dysfunction–Associated Steatotic Liver by Targeting GABARAPL1
    Zenghui Li, Chenxu Tian, Mengqin Wang, Zhehong Li, Liang Wang, Zheng Wang, Chengyuan Yu, Dezhong Wang, Dongbo Lian, Nengwei Zhang
    Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
  • Hypertension in middle childhood
    Mirjam Močnik, Zala Hrovat, Sonja Golob Jančič, Martina Filipič, Mladen Crnobrnja, Nataša Marčun Varda
    BMC Pediatrics.2026;[Epub]     CrossRef
  • Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis
    Akash Roy, Surabhi Jajodia, Shardhya Chakraborty, Shruti Keyal, Awanish Tewari, Nikhil Sonthalia, Sourish Roy, Rajat Khandelwal, Anand Kulkarni, Uday Chand Ghoshal, Rajender Reddy, Mahesh Kumar Goenka
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities
    Veronika A. Prikhodko, Sergey V. Okovityi
    Biomedicines.2026; 14(4): 909.     CrossRef
  • Apple polyphenol extract mitigates high-fat diet induced cognitive impairment in C57BL/6 mice via a sex-dependent mechanism
    Jieyu Ma, Jiaxin Li, Le Wang, Jinlin Ma, Shilin Chen, Wenxue Luan, Xintong Tian, Siyuan Shang, Xinli Li
    Food Bioscience.2026; 80: 108892.     CrossRef
  • Current status of research on the risk factors and pathogenesis of metabolic dysfunction-associated steatotic liver disease
    Dan Chen, Lingling Yan, Tong Wu, Junpeng Zhao, Xuebing Xu, Weisong Xu, Hong Zhang, Mingbing Xiao
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Patatin-Like Phospholipase Domain-Containing Protein 3 rs2896019 and MASLD Susceptibility and Severity in Adults: A Systematic Review and Meta-Analysis of Case–Control Studies
    Wei-Yue Lim, Rosmawati Mohamed, Yuh-Fen Pung, Hak-Keith Leung, Rong-Xiang Ng, Shamsul Mohd Zain
    Metabolic Syndrome and Related Disorders.2026; 24(7): 285.     CrossRef
  • Heterogeneity of hepatic macrophages in MASLD/MASH: Lipid-associated programs, molecular mechanisms, spatial niches, and therapeutic implications
    Kaipeng Hu, Siyuan Liu, Shuyan Sheng, Shaobo Zhang, Binghua Li, Beicheng Sun, Anliang Xia
    iLIVER.2026; 5(2): 100234.     CrossRef
  • Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population
    Anh Gia Pham, An Vu-Khanh Le, Yen Thi-Hai Pham, Lanh Sy Nguyen, Huong Lan Nguyen, Nghia Chinh Quach, Thau Manh Cao, Hanh Thi Nguyen, Xuan Thanh Thai, Anh Tuan Luong, Thuy Thi Pham, Hai Duy Vu, Hai Thi-Thanh Tran, Lan Thi Le, Hai Vu, Giang Binh Tran, Hung
    Scientific Reports.2026;[Epub]     CrossRef
  • Lactational Western‐Style Fat Exposure in Mice Programs Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Male Offspring
    Amy Y. Zhao, Haijing Sun, Leyi Yan, Oyewale Shiyanbola, Dave Bridges, Brigid Gregg
    Molecular Nutrition & Food Research.2026;[Epub]     CrossRef
  • Monocyte reprogramming and trained immunity: Linking metabolism to inflammation in non-alcoholic fatty liver disease
    Stanislav Kotlyarov
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Exercise as a Metabolic Therapy for MASLD: Beyond Weight Loss Toward Sustainable Exercise Strategies
    Hee-Tae Roh, Ju-Yong Bae
    Medicina.2026; 62(4): 784.     CrossRef
  • Tissue-specific roles of IGFBP2 in glucose and lipid metabolism in obesity-related metabolic diseases
    Xiaoyu Song, Wentao Zhong, Hao Zheng, Xinyang Ou, Dongjin Zheng, Zhuo Li
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study
    Heejoon Jang, Yeonjin Kim, Yoo Kyoung Lim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Gi-Ae Kim, Woojoo Lee, Stefano Romeo, Won Kim
    Clinical and Molecular Hepatology.2026; 32(2): 737.     CrossRef
  • High-fat diet, gut dysbiosis, and oxidative stress: A synergistic triangle in metabolic dysfunction-associated steatotic liver disease pathogenesis
    Zi-Rui Zhang, Ling She, Yi-Rong Cao, Yuan-Wen Chen
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease
    Allen Anthony Laraño, Silvia Palmisano, Deborah Bonazza, Discipio Marina, Marica Meroni, Anna Ludovica Fracanzani, Lory S Crocè, Claudio Tiribelli, Paola Dongiovanni, Natalia Rosso, Pablo Giraudi
    Annals of Hepatology.2026; : 102206.     CrossRef
  • Alcohol-driven phenotypic transition in MASLD and risk of liver-related events
    Seohui Jang, Jihun Song, Eun Seok Kang, Sangwook Cheon, Taeho Kwak, Yihyun Kim, Seokjin Kong, Jinhyeok Choi, Minjeong Kang, Jaewon Khil, Hye Jun Kim, Jeongin Lee, Hwamin Lee, Seogsong Jeong
    JHEP Reports.2026; 8(7): 101866.     CrossRef
  • Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease: Editorial on “Hepatocytic ankyrin repeat and SOCS box protein 3 deficiency alleviates metabolic dysfunction-associated steatotic liver diseas
    Yueying Yang, Ying Yang, Yan Lu
    Clinical and Molecular Hepatology.2026; 32(2): 957.     CrossRef
  • Editorial on “Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease”
    Julia Kozlitina
    Clinical and Molecular Hepatology.2026; 32(2): 931.     CrossRef
  • Role of MicroRNAs in Precision Hepatology
    Youngwoo Lee, Eunho Choi, Young-Sun Lee
    Journal of Digestive Cancer Research.2026; 14(1): 102.     CrossRef
  • Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation
    Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan
    Clinica Chimica Acta.2026; 589: 121028.     CrossRef
  • Bupleuri Radix ameliorates MASLD induced by high-fat diet and circadian disruption in rats: Involvement of the NR1D1–SREBF1/CYP7A1 circadian–metabolic axis
    Shuheng Wang, Shuaidong Bai, Tianhui Zhou, Yukun Wang, Xue Bai, Yiming Wang, Junwen Ma, Xuemei Qin, Xiaoxia Gao
    Journal of Ethnopharmacology.2026; 367: 121770.     CrossRef
  • Comment on “High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C”
    Wen-Rui Li
    Journal of the Formosan Medical Association.2026;[Epub]     CrossRef
  • Calorie restriction mitigates steatotic liver disease in obese rats after bariatric surgery
    Yu-Ning Lin, Chin-Ying Wu, Yin-Ru Hsieh, Yi-Tung Lin, Weu Wang, Chun-Chao Chang, Shih-Yi Huang, Wei-Yu Kao
    Nutrition Research.2026; 151: 52.     CrossRef
  • Fucoxanthin Ameliorates MASLD by Directly Targeting GRP78 to Restore ER Homeostasis and Activate AMPK Signaling
    Lin Zhang, Ruifen Zhang, Yu Wu, Binbin Chen, Chao Wang, Cheng Wang, Zhengshun Wen, Jingui Zhang, Haibin Tong, Liang Hong
    Food Science & Nutrition.2026;[Epub]     CrossRef
  • Familial hypobetalipoproteinemia in pediatric patients with fatty liver: an under-recognized cause
    Nurit Loberman Nachum, Eyal Shteyer, Hofit Cohen, Odelia Chorin, Maya Granot, Batia Weiss
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • The effect of a two-week low glycaemic index, higher fibre diet versus high glycaemic index diet on body composition, ectopic lipids, inflammatory biomarkers, gastrointestinal hormones and gut microbiota in metabolic dysfunction-associated steatotic liver
    Amina A. Al-Awadi, Jane I. Grove, Stephen Bawden, Amrita Vijay, Ana M. Valdes, Penny Gowland, Moira A. Taylor, Guruprasad P. Aithal
    Clinical Nutrition ESPEN.2026; 73: 103306.     CrossRef
  • Di(2-ethylhexyl) phthalate exposure: Association with metabolic associated steatotic liver disease and underlying mechanisms
    Dapeng Yin, Yan Li, Wei Wu, Jiacheng Cheng, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li
    Ecotoxicology and Environmental Safety.2026; 317: 120210.     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach
    Beom Kyung Kim
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Evaluation of Factors Affecting Alpha Fetoprotein Levels in Patients With Hepatocellular Carcinoma in a Large Multicenter Cohort
    Nicole Shu Ying Tang, Ethan Kai Jun Tham, Nicholas Syn, Ken Liu, Gang Chen, Beom Kyung Kim, Mark Muthiah, Takumi Kawaguchi, Asahiro Morishita, Sung Won Lee, Karn Wijarnpreecha, Hirokazu Takahashi, Daniel Q. Huang
    Journal of Gastroenterology and Hepatology.2026; 41(6): 1883.     CrossRef
  • Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD
    Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu
    Frontiers in Molecular Biosciences.2026;[Epub]     CrossRef
  • The Role of MicroRNAs in the Progression of Metabolic Dysfunction-associated Steatotic Liver Disease
    Jang Hyun Choi
    Journal of Digestive Cancer Research.2026; 14(1): 82.     CrossRef
  • GCSH promotes MASH progression by regulating cuproptosis through the glycine–GSH metabolic pathway
    Xuan Fu, Yunmeng Li, Jing Chen, Baolong Yin, Mahbuba Nasrin, Rui Huo, Shuxin Tian
    Free Radical Biology and Medicine.2026; 252: 1.     CrossRef
  • A Descriptive Analysis of Mediterranean Diet Meal Plans Using the Dietary Inflammatory Index, Dietary Antioxidant Index, and Dietary Lipid Indices: Implications for Dietary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Melvin Bernardino, Claudio Tiribelli, Natalia Rosso
    Nutrients.2026; 18(8): 1281.     CrossRef
  • From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell‐free DNA in Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Wei‐Yue Lim, Rosmawati Mohamed, Yuh‐Fen Pung, Shamsul Mohd Zain
    Hepatology Research.2026; 56(6): 914.     CrossRef
  • Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review
    Brittany Bromfield, Jeremy Chimene-Weiss, Gregory Gheewalla, Theodore Feldman, Emilie K. Mitten, Piero Portincasa, Gyorgy Baffy
    eClinicalMedicine.2026; 95: 103921.     CrossRef
  • Concerns about the health effects of industrially produced seed oils are without scientific foundation: a scoping narrative review of the clinical and observational evidence
    Matthew Nagra, David M. Goldman, Martha A. Belury, Mark Messina
    Critical Reviews in Food Science and Nutrition.2026; : 1.     CrossRef
  • Neutrophils in Liver Diseases: Functions and Challenging Therapies
    Rui Ma, Haoran Meng, Xiutong Chen, Haiyuan Shen, Li Zuo, Hua Wang
    Seminars in Liver Disease.2026;[Epub]     CrossRef
  • The Degree of Liver Steatosis Is Associated with Abnormally High Serum Levels of Markers of Blood–Brain Barrier Dysfunction and Systemic Inflammation in Patients with Morbid Obesity
    Gabriela Hurtado-Alvarado, Karol Iliana Ávila-Soto, Marlene Monserrat Juárez, Lucía Angélica Méndez-García, Verónica Cevallos-López, Juan Antonio Peralta-Calcaneo, Marcela Esquivel-Velázquez, Antonio González-Chávez, Julio César Zavala-Castillo, Ana Alfar
    Medicina.2026; 62(5): 821.     CrossRef
  • Portal Vein Thrombosis in Cirrhotic Candidates for Liver Transplantation and Its Impact on the Transplant Accessibility
    Simona Parisse, Flaminia Ferri, Adriano De Santis, Fabio Melandro, Mario Corona, Quirino Lai, Pierleone Lucatelli, Gianluca Mennini, Massimo Rossi, Stefano Ginanni Corradini
    Journal of Clinical Medicine.2026; 15(9): 3358.     CrossRef
  • c-FLIP as a master regulator of immune homeostasis and disease mechanisms
    Eliana Urbini, Annalisa Adamo, Yushu Hu, Luca Giacobazzi, Silvia Dusi, Francesco De Sanctis, Carmine Carbone, Davide Gibellini, Sara Pilotto, Vincenzo Corbo, Vincenzo Bronte, Fulvia Vascotto, Stefano Ugel
    Cell Death & Disease.2026;[Epub]     CrossRef
  • Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective
    Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Bruno, Alessandro Cabrino, Emma Fogliati, Andrea Giusti, Marco Barbieri, Luigi Bottaro, Giorgio Colombo
    ClinicoEconomics and Outcomes Research.2026; Volume 18: 1.     CrossRef
  • Clinical differentiation between alcohol-associated and metabolic dysfunction-associated steatotic liver disease: a comparative case report
    Chang-Gue Son
    The Journal of Internal Korean Medicine.2026; 47(1): 70.     CrossRef
  • Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects
    Junfei Tan, Muhammad Zubair, Lin Zhang, Likang Liu, Kangrong Li, Yihua Wang, Yongmin Yan, Wenyan Xu
    International Journal of Nanomedicine.2026; Volume 21: 1.     CrossRef
  • Elevated liver fat content is independently associated with insulin resistance in people with type 1 diabetes
    Jonathan Mertens, Maarten Spinhoven, Rie Braspenning, Floris Vanhevel, Eveline Dirinck, Christophe De Block, Sven Francque
    JHEP Reports.2026; 8(8): 101887.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in cushing’s syndrome: a case controlled FibroScan study
    Tugce Apaydin, Caglayan Keklikkiran, Haluk Tarik Kani, Yusuf Yilmaz, Dilek Gogas Yavuz
    Journal of Endocrinological Investigation.2026;[Epub]     CrossRef
  • Non-Hispanic Black Persons With HIV Have a Lower Risk of Metabolic Dysfunction–Associated Steatotic Liver Disease and Clinically Significant Fibrosis Compared to Non-Hispanic White and Hispanic Individuals
    Tinsay A Woreta, Samer Gawrieh, Laura A Wilson, Yuchen Xin, Eduardo Vilar-Gomez, Kathleen E Corey, Richard K Sterling, Jordan E Lake, Susanna Naggie, Sonya Heath, Holly Crandall, Jennifer C Price, Rohit Loomba, Naga Chalasani, Mark S Sulkowski
    Open Forum Infectious Diseases.2026;[Epub]     CrossRef
  • Development and validation of the HABIT score: a practical and robust tool to predict hepatic steatosis using HbA1c, BMI, and triglycerides in patients with unexplained elevated liver enzymes
    Eike Humbert, Verena Wilkens, Semjon Bugaichuk, Karoline Horvatits, Ansgar W. Lohse, Samuel Huber, Sven Pischke, Thorben Fründt
    Annals of Hepatology.2026; 31(2): 102218.     CrossRef
  • Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Zobair M. Younossi, Markos Kalligeros, Vincent Wai-Sun Wong, Khalid M. Al-Naamani, Frank Tacke, Emmanouil Tsochatzis, Javier Crespo, Mohamed El-Kassas, Fernando Bril, Marco Arrese, Cyrielle Caussy, C. Wendy Spearman, Amalia Gastaldelli, Mário Guimarães Pe
    Clinical Gastroenterology and Hepatology.2026;[Epub]     CrossRef
  • Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH)
    Roberto Vettor, Maria Letizia Petroni, Idit Dotan, Gadi Lalazar, Martin Haluzík, C. Wendy Spearman, Joel A. Dave, Faisal Abaalkhail, Salah Abusnana, Ali Alshehri, Radan Bruha, Mariann Harangi, Ahmad Jazzar, Michał Kukla, Shiva Kumar, Vaia Lambadiari, Geor
    Reviews in Endocrine and Metabolic Disorders.2026; 27(2): 213.     CrossRef
  • Advances in Diagnostic and Therapeutic Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ryan Njeim, Omar Abureesh, Ali Sohail, Ryan Tam, Liliane Deeb
    Livers.2026; 6(3): 35.     CrossRef
  • The role of the resveratrol-sirtuin axis in the treatment of metabolic dysfunction-associated diseases
    Jiale Yang, Shuping Chen, Tiantian Zeng, Yuxuan Zhang, Zhaoxin Li, Haifang Li
    Exploration of Endocrine and Metabolic Diseases.2026;[Epub]     CrossRef
  • GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
    Xianhua Mao, Hong Fan, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H. Nguyen
    Hepatology.2026;[Epub]     CrossRef
  • Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
    Ralf Weiskirchen, Amedeo Lonardo
    Expert Opinion on Therapeutic Targets.2026; 30(5): 473.     CrossRef
  • Weight Loss-Induced Metabolic Remodeling in Metabolic dysfunction-associated steatotic liver disease: A Cohort Study Stratified by Genetic Risk
    J. Troisi, P. Torre, L. Schiavo, B.M. Motta, M. Lombardi, M. Festa, T. Sarcina, M. Masarone, M. Persico
    Clinical Nutrition.2026; 61: 106672.     CrossRef
  • Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model
    Jens Bjelke Kristensen, Jacob Nøhr-Meldgaard, Susanne E. Pors, Jenny Norlin, Sanne S. Veidal, Kristian Moss Bendtsen, Kristoffer Niss, Maja W. Andersen, Lea M. Harder, Mathilde Teilmann Dalhoff, Martin Rønn Madsen, Kristoffer Voldum-Clausen, Markus Latta,
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2026; 330(6): G659.     CrossRef
  • Effectiveness of therapeutic strategies based on dietary patterns on cardiovascular and hepatic markers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) ‒ A systematic review of clinical trials
    Valeria Antonia Rivera Marín, Camila Sanchez, Andrea Herrera-Santelices, Luisa Amanda Ramírez Araya, Edson Yáñez-Barros, Sebastian Cofré
    Nutrición Hospitalaria.2026;[Epub]     CrossRef
  • Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling
    Hinata Harada, Yusuke Ohsaki, Afifah Zahra Agista, Hsin-Jung Ho, Takuo Hirose, Kotaro Yamada, Mutsumi Furukawa, Tomonori Nochi, Wan-Chun Chiu, Ya-Ling Chen, Chiu-Li Yeh, Suh-Ching Yang, Takefumi Mori, Hitoshi Shirakawa
    International Journal of Molecular Sciences.2026; 27(9): 3735.     CrossRef
  • Nitric oxide pathway: Emerging therapeutic strategies for MASLD
    Yanling Zhang, Ying Zhang, Hongjin Chen, Fangfang Qi
    Pathology - Research and Practice.2026; 284: 156516.     CrossRef
  • Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Gang Li, Simone Staffer, Sabine Tuma‐Kellner, Uta Merle, Walee Chamulitrat
    Liver International.2026;[Epub]     CrossRef
  • MASLD Management in Spain: A Nationwide Survey of Gastroenterologists Highlighting Gaps in Risk Assessment and Primary Care Coordination
    Carolina Jiménez-González, Paula Argos Vélez, Lorena Cayón, Ana Belén García-Garrido, Noelia Fontanillas Garmilla, Antonio Cuadrado, Paula Iruzubieta, Javier Crespo
    Journal of Clinical Medicine.2026; 15(9): 3259.     CrossRef
  • Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study
    Jihad Slim, Murad Qirem, Paul Bellafiore, Bereket Tewoldemedhin, Tala B Shahin, Kevin Leyden, Ronald Poblete, Sandhya Nagarakanti, Hugo Vargas
    Open Forum Infectious Diseases.2026;[Epub]     CrossRef
  • Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia
    Soo Lim, Hui Zhou, Wataru Ogawa
    Journal of Obesity & Metabolic Syndrome.2026; 35(2): 130.     CrossRef
  • The gut-liver/bile axis: Gut microbiota and bacterial extracellular vesicles remodeling hepatobiliary pathogenesis
    Siyang Hu, Chunhui He, Kunqi Sun, Hongye Zhou, Xueyan Liu, Hao Wang, Sen Li, Haifeng Yu, Ke Xu, Wei Li
    iScience.2026; 29(5): 115623.     CrossRef
  • Effects of Animal-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities: A Systematic Review of Randomized Controlled Trials (2020–2026)
    Joanna Michalina Jurek, Katarzyna Zablocka-Slowinska, Joanna Pieczynska, Anna Lipert, Helena Clavero-Mestres, Teresa Auguet
    Nutrients.2026; 18(10): 1508.     CrossRef
  • Impact of probiotics and prebiotics on glucose/lipid metabolism in metabolic dysfunction-associated steatotic liver disease: mechanisms and implications
    Yinan Zhao, Ziyan Li, Guoying Yu
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes
    A.M. Urbanovych, N.Ya. Sidelnyk, O.Z. Lishchuk
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2026; 22(3): 340.     CrossRef
  • The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review
    Jeffrey V. Lazarus, Caroline Freeman, Hannes Hagström, Mazen Noureddin, Riku Ota, Mary E. Rinella, Giada Sebastiani, Fotis Tefos, Zobair M. Younossi
    Liver International Communications.2026;[Epub]     CrossRef
  • Evolving B-mode ultrasound-based techniques for assessing metabolic dysfunction-associated steatotic liver disease: Now and beyond
    Walaa Abdelhamed, Mohamed Elbadry, Mohamed El-Kassas
    Liver Research.2026; 10(2): 109.     CrossRef
  • Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study
    Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Chih-Cheng Lai
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Association between metabolic dysfunction-associated steatotic liver disease and overactive bladder: A cross-sectional study
    Shengqi Zheng, Xu Cui, Longyao Xu, Hong Chen, Liang Zheng, Chaoming Zhou
    Continence.2026; 18: 102466.     CrossRef
  • Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma
    Vanilla X. Zhang, Tiffany C.-Y. Yu, Yu M. Tsui, Irene O.-L. Ng
    Trends in Molecular Medicine.2026;[Epub]     CrossRef
  • Trends of metabolic dysfunction-associated steatotic liver disease in Mexico, 1990–2023: insights from the Global Burden of disease study
    Israel Rico-Alba, Alberto Retana-Guzmán, Marcela Agudelo-Botero, Claudio Alberto Dávila-Cervantes
    Annals of Hepatology.2026; 31(2): 102224.     CrossRef
  • Cross‐Vendor Validation of Proton Density Fat Fraction and T1 Mapping Using a Combined Proton Density Fat Fraction—T1 Phantom
    Jitka Starekova, Sebastian Weingärtner, David R. Rutkowski, Garrett C. Fullerton, Won C. Bae, Hung P. Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj D. Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando
    Journal of Magnetic Resonance Imaging.2026; 64(2): 482.     CrossRef
  • ПСИХОЛОГІЧНИЙ СТАН ПАЦІЄНТІВ ЗІ СТЕАТОТИЧНОЮ ХВОРОБОЮ ПЕЧІНКИ, АСОЦІЙОВАНОЮ З МЕТАБОЛІЧНОЮ ДИСФУНКЦІЄЮ, ЗА УМОВ ПОЄДНАННЯ З ГІПЕРУРИКЕМІЄЮ: ПІЛОТНЕ ОДНОЦЕНТРОВЕ КРОС-СЕКЦІЙНЕ ДОСЛІДЖЕННЯ
    Ігор Свінціцький , Валерія Каташинська
    Actual Problems of Nephrology.2026; (36-37): 26.     CrossRef
  • Natural Product Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Targeted Mitochondrial Quality Control
    Jing Liu, Fuxing Li, Qianru Zeng, Wenxiao Hu, Le Yang, Shengping Luo, Fang Lv, Dingxiang Li, Yihui Deng
    Drug Design, Development and Therapy.2026; Volume 20: 1.     CrossRef
  • The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?
    Shang-Chin Huang, Tai-Chung Tseng
    Gut and Liver.2026; 20(3): 350.     CrossRef
  • KCMF1 promotes MASLD progression via K48-linked ubiquitination and degradation of AMPKα
    Min Tang, Yunqin Ma, Jiaqi Wang, Han Cao, Shuangshuang Yao, Xiaohui Wei, Yijiong Tan, Hua Yang, Yi Lin, Bin Hu, Yang Yu, Jiaying Yang, Yufan Wang, Xingdong Zheng, Xiaofang Tang, Fang Liu, Yongde Peng, Nengguang Fan
    Metabolism.2026; 182: 156651.     CrossRef
  • Liver Disease Diagnosis: Fuzzy c-means and Scoring Ranking Approach
    Gabriel A. Leite, Beatriz Flamia Azevedo, Sofia Ribeiro Ferreira, Maria F. Pacheco, Florbela P. Fernandes, Ana I. Pereira
    SN Computer Science.2026;[Epub]     CrossRef
  • Mitochondrial Dysfunction in MASLD: Evidence in Dietary Models and Potential Therapeutic Interventions
    Elda Cristina Villaseñor-Tapia, Edgar Rubén Mendieta-Condado, David Alejandro Curiel-Pedraza, Edwin Estefan Reza-Zaldívar, Ana Laura Márquez-Aguirre, Venkata Ramireddy Narala
    Biochemistry Research International.2026;[Epub]     CrossRef
  • Protocol for volumetric quantification of intrahepatic triglyceride content in adults with obesity
    Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Alejandro López-Vázquez, Mara Concepción, José L. Martín-Rodríguez, Idoia Labayen, Jonatan R. Ruiz, Rafael Cabeza
    STAR Protocols.2026; 7(2): 104585.     CrossRef
  • Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis
    Jaclyn A. Rivas, Alexandria C. Murphy, Praveena Prasad, Mahmoud S. Yahia, Siem S. Goitom, Aaron S. Romero, Crystal Madera Enriquez, Brianna B. Maes, Prithvi R. Akepati, Marcus A. Garcia, Fredine T. Lauer, Rama R. Gullapalli, Kristen M. Gonzales, Jessica M
    Metabolism.2026; 181: 156652.     CrossRef
  • Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma
    Jie Chen, Lingling Li, Sufang Fang, Haitao Zhou
    Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
  • Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
    Elda Cristina Villaseñor-Tapia, Adriana Franco-Acevedo, Rebeca Rosas-Campos, Juan Armendariz-Borunda
    Pharmaceutics.2026; 18(5): 584.     CrossRef
  • Improving Care Quality for Metabolic Dysfunction-associated Steatotic Liver Disease Through a Structured Yogic Intervention: Protocol for a Randomised Controlled Trial
    Gautam Panwar, Garima Singh, Kanchan Joshi, Sanjay Gupta, Kuldeep Singh, Vikas Upadhyay
    Annals of Neurosciences.2026;[Epub]     CrossRef
  • The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies
    Karolina Kornatowska, Szymon Kopciał, Mateusz Wiekiera, Adrianna Wiekiera, Paweł Budzik, Mateusz Tyniec, Kamal Morshed
    Gastroenterology Insights.2026; 17(2): 33.     CrossRef
  • Metabolomics-Enhanced Liquid Biopsy Identifies Early Heptocellular Injury in Females with MetALD
    Anika Volkmar, Gregor Mattert, Florian Deisinger, Kornelius Schulze, Asmus Heumann, Werner Dammermann, Selina Strathmeyer, Steffen Heelemann, Thomas Kalinski, Stefan Lüth, Janine Kah
    International Journal of Molecular Sciences.2026; 27(11): 4695.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review
    Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y
    Journal of Biochemical Technology.2026; 17(2): 30.     CrossRef
  • X-chromosome gene dosage shapes MASLD beyond sex hormones
    Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo
    Trends in Endocrinology & Metabolism.2026;[Epub]     CrossRef
  • Mediating roles of insulin resistance and inflammatory markers between healthy sleep scores and metabolic dysfunction-associated steatotic liver disease
    Qing-Tao Yu, Yun-Ying Lin, Zi-Hao Gui, Hua-Lin Duan, Jun-Jie Yang, Yuan Meng, Xue-Tao Peng, Lan Liu, Heng Wan, Jie Shen
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease
    Jerome Lian, Mohan Patil, Ricky R. Lareu, Marco Falasca
    International Journal of Molecular Sciences.2026; 27(11): 4872.     CrossRef
  • Dantrolene attenuates steatohepatitis and liver fibrosis by suppressing Ca2+ dysregulation
    Juri Sakamoto, Takeshi Yamamoto, Minami Sato, Ayano Sasakura, Yoshihide Nakamura, Naoomi Tominaga, Masako Inamitsu, Naoki Yamamoto, Taro Takami, Motoaki Sano
    Biochemical and Biophysical Research Communications.2026; 827: 154042.     CrossRef
  • Epigenetic antifibrotic effect of expression of long noncoding RNAs lncR-p21, MEG3, H19 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease (systematic review and meta-analysis)
    A.E. Abaturov, A.O. Nikulina
    GASTROENTEROLOGY.2026; 60(2): 133.     CrossRef
  • Metabolic dysfunction–associated steatotic liver disease and heart failure with preserved ejection fraction: mechanisms and clinical implications from a heart–liver metabolic axis perspective
    Xuebi Wu, Yongxin Ma, Xueshi Yin, Jianping Liu, Yongheng Zhang
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography
    Steffen P. Häseli, Jakob Schattenfroh, Tom Meyer, Paul Spiesecke, Tobias Puengel, Florian Roßner, Bernhard Gebauer, Raphael Mohr, Münevver Demir, Frank Tacke, Ingolf Sack, Rolf Reiter
    Journal of the Mechanical Behavior of Biomedical Materials.2026; 180: 107480.     CrossRef
  • Determination of ultrasound diagnostic thresholds for detecting early hepatic steatosis in children: a comparative evaluation of different ultrasound systems using MRI-PDFF as the reference standard
    O.A. Pushkarenko, M.M. Zhaivoronok, O.B. Dynnyk, O.T. Yemets, N.V. Deresh, V.V. Kaliy
    GASTROENTEROLOGY.2026; 60(2): 90.     CrossRef
  • Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
    Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2026; 17(7): e01042.     CrossRef
  • Four new amide alkaloids from the fruits of Piper longum and their anti-adipogenic activities
    Xue-Ting Cui, Ling-Yu Li, Jia Liu, Hui-Hui Wang, Tao Zhang, Zhong-Mei Zou
    Journal of Asian Natural Products Research.2026; : 1.     CrossRef
  • Upcycling Agricultural By‐Products: RNA‐Seq‐Based Elucidation of Body Weight‐Independent Hepatoprotective Mechanisms of Cucumis melo var. makuwa Leaf Extract in Diet‐Induced Obese Mice
    Ji Young Hwang, Ji Yun Van, Hyeon Hak Jeong, Yerin Seong, Seokmin Lee, Jaeseong Seo, Bo‐Mi Ryu, Seungjun Lee, Suhyeon Baek, Sanggil Lee, Won‐Kyo Jung, Jae‐Il Kim, Bonggi Lee
    eFood.2026;[Epub]     CrossRef
  • Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study
    Log Young Kim, Ji Soo Lee, Jeong-Ju Yoo, Eun Ju Cho, Sang Gyune Kim, Young Seok Kim, Tyng-Yuan Jang
    PLOS One.2026; 21(5): e0349593.     CrossRef
  • Rendimiento del puntaje MAFLD-S para el tamizaje no invasivo de esteatosis hepática metabólica en el primer nivel de atención
    J.A. Torres-Díaz, A. Olivas-Martinez, J.A. Ruiz-Manriquez, A. Kammar-García, L.C. Chávez-García, L.F. Uscanga-Domínguez, S.E. Martínez-Vázquez
    Revista de Gastroenterología de México.2026;[Epub]     CrossRef
  • Impact of liver and pancreatic steatosis on behavioral responses in rats under experimental conditions and after cessation of combined exposure to steatogenic factors
    A.M. Halinska, O.A. Maltseva, O.O. Halinskyi
    GASTROENTEROLOGY.2026; 60(2): 82.     CrossRef
  • Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease
    Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata
    Biomolecules.2026; 16(6): 797.     CrossRef
  • EASL position paper on preclinical models of steatotic liver disease
    Suchira Gallage, Rui E. Castro, Jennifer Estall, Ira Tabas, Quentin M. Anstee, Dina G. Tiniakos, Gyongyi Szabo, Jun Yu, Chantal Desdouets, Frank Tacke, Fiona Oakley, Mathias Heikenwalder
    Journal of Hepatology.2026; 85(2): 345.     CrossRef
  • Liver Endothelial Heg1 Signal Limits Hepatic Steatosis via Wnt-Mediated Fatty Acid Oxidation in Hepatocytes
    Xiyun Rao, Qianqian Zhao, Jinbiao Chen, Min Zheng, Mingyue Xing, Yu Feng, Jiayuan Chen, Shichao Zhu, Zhiming Han, Geoffrey W. McCaughan, Xiangjian Zheng
    Cellular and Molecular Gastroenterology and Hepatology.2026; 20(9): 101807.     CrossRef
  • Risk factors for atherosclerotic plaque formation in MASLD patients: insights from cross-sectional and Mendelian randomization analyses
    Wei-hao Peng, Jing Zhang, Yu-hua Ruan, Yan Li, Ye Liu, Ming-jia Dai, Jing-kun Jin, Xue-bin Yan, Fang Ji
    Nutrition, Metabolism and Cardiovascular Diseases.2026; : 104815.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
    Ruizhe Ren, Xiao Liang, Xiyang Wei
    Molecular Biomedicine.2026;[Epub]     CrossRef
  • Structural characterization of the pectic polysaccharide from corn silk and its protective mechanism against MASLD via regulation of the gut-liver axis
    Haichao Wang, Jiajing Yan, Haolin Jia, Xiaoyan Li, Bingxuan Li, Xuefang Zhang, Shujun Wang, Zheng Li, Yuhong Liu, Yifei Bian
    Carbohydrate Polymers.2026; 388: 125510.     CrossRef
  • Association of Hepatic Steatosis Burden With Microalbuminuria in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study
    Komal S Jog, Harini Bopaiah, Guru Yogendra Muthyal, Sai Deepika R
    Cureus.2026;[Epub]     CrossRef
  • Renal Dysfunction Across Etiologies of Chronic Liver Disease: A Cross-Sectional Study From a Tertiary Care Center
    Asha Saranya Rapeti, Rakesh Pilla, Gayathri Chouthai, Abhinav Maharaj Thota, Mrinal Shashidhar, Chaithanya Shanthi Vanamada
    Cureus.2026;[Epub]     CrossRef
  • Steatotic liver disease in Latin America: current views and perspectives
    Francisco Idalsoaga, Luis Antonio Díaz, Francisco Barrera, Adrian Gadano, Claudia P. Oliveira, Juan Pablo Arab, Marco Arrese
    Nature Reviews Gastroenterology & Hepatology.2026;[Epub]     CrossRef
  • Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies
    Ioannis Katsaros, Dimitrios Schizas
    Life.2026; 16(6): 915.     CrossRef
  • Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
    Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim
    Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603.     CrossRef
  • Post-transplant MASLD: a risk-stratified approach to assessment and personalized management
    He-Yu Huang, Zhong-Qi Fan, Guo-Yue Lv
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • The efficacy of carbohydrate-restricted diets on reducing visceral and liver fat in individuals with overweight and obesity: a systematic review and pairwise and network meta-analyses
    Mousa Khalafi, Aref Habibi Maleki, Mahsa Ehsanifar, Maryam Aghaeinejad, Mohammad Hossein Sakhaei, Sara K. Rosenkranz, Michael E. Symonds, Fatemeh Ramezani
    Critical Reviews in Food Science and Nutrition.2026; : 1.     CrossRef
  • Synbiotics and antioxidants synergistically attenuate disease progression in metabolic dysfunction-associated steatotic liver disease
    Zhilu Xu, Wenyi Zhu, Qiyun Xia, Wenli Huang, Yuanyuan Chi, Haoyu Qi, Oi Yee Pessy Chan, Jessica YL Ching, Francis KL Chan, Nor Norman Chan, Siew C. Ng
    Biomedicine & Pharmacotherapy.2026; 201: 119656.     CrossRef
  • Integrative Multi‐Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance
    Kejun Liu, Bozhi Zhang, Yezhen Tang, Zhenyao Tan, Yang Bu, Yongxue Lv
    The FASEB Journal.2026;[Epub]     CrossRef
  • A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning
    Binghui Li, Yiru Zhang, Ziyang Li, Zhiyang Chen, Zhe Guo, Weimin Wu, Li Tan, Lini Dong, Xiangyu Zhang, Xing Lyu, Min Hu, Qichen Long
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
    Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal, Ant
    Nature Medicine.2026;[Epub]     CrossRef
  • Bisphenol S induces hepatic steatosis and insulin resistance through AMPK inhibition and endoplasmic reticulum stress
    Vinicius Sepúlveda-Fragoso, Emanuelle Barreto-Reis, Thais de Souza Carvalho-Laureano, Milena Barcza Stockler-Pinto, Eliete Dalla Corte Frantz, Denise Pires de Carvalho, Xavier Palomer, Emma Barroso, Manuel Vázquez-Carrera, Leandro Miranda-Alves, D'Angelo
    Food and Chemical Toxicology.2026; 215: 116222.     CrossRef
  • The association between six heavy metal levels and the risk of liver fibrosis in women without gestational diabetes mellitus
    Juan Yu, Li Wang, Shu-lan Zhu, Min Xiao, Hai-xing Huang, Yan-hong Shao, Qi-chen Bao, Miao-miao Ma, Ying-ying Chen
    The American Journal of the Medical Sciences.2026;[Epub]     CrossRef
  • Strengthening Dietary Antioxidant Capacity in Primary Care: A Low-Cost Strategy to Prevent Metabolic Syndrome and MASLD in Iran
    M Sepehrinia, A Nikparast, J Mirzay Razzaz, Reza Homayounfar
    Iranian Journal of Nutrition Sciences and Food Technology.2026; 20(5): 83.     CrossRef
  • Diversity in metabolic dysfunction-associated steatotic liver disease: a framework for precision medicine
    Donghyun Ko, Jordan Low, Peter Low, Damien Chua, Yock Young Dan, Vincent Chen, Jonathan A. Fallowfield, Timothy J. Kendall, Hirokazu Takahashi, Cheng Han Ng, Nicholas Syn, Mark Muthiah
    npj Gut and Liver.2026;[Epub]     CrossRef
  • Shall You Get an Invasive Examination? An AI-Driven Risk Stratification Model for Individuals with Suboptimal Health Status
    Chia-Yu Lai, Jen Yu, Chieh Lee, Guan-Yu Wang, Shania Andea Perdana, Tsung-Hsing Chen, Ta-Sen Yeh
    Service Science.2026;[Epub]     CrossRef
  • Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction–Associated Steatotic Liver Disease
    Jingyuan Nie, Jing Zhou, Yuanjia Hu, Changhong Zhang, Pingping Yu, Xun Lei
    Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
  • Exposure to Per- and Polyfluoroalkyl Substances and the Risk of Sarcopenia: The Mediating Role of Serum Albumin
    Mingkun Sun, Chu Chu, Kun Zhao, Zhengmin Qian, Mario Schootman, Stephen McMillin, Jiaxiang Dong, Wenwen Bao, Muhammad Amjad, Haseeb Moryani, Yang Zhou, Yan Yang, Peipei Wang
    Toxics.2026; 14(6): 478.     CrossRef
  • Non-alcoholic fatty liver disease and Helicobacter pylori infection: problems and solutions. A review
    Elena V. Onuchina
    Consilium Medicum.2026; 28(5): 387.     CrossRef
  • Impact of Volatile Organic Compound Mixtures on Cardiovascular Health in Adults With Metabolic Dysfunction–Associated Fatty Liver Disease: A US Population Study
    Qingping Wu, Meiling Jin, Shan Liu, Yue Wu, Tarek Alshaal
    Indoor Air.2026;[Epub]     CrossRef
  • A Single-Food Substitution Strategy (SFSS) Improves Fat Mass and Metabolic Parameters in MASLD: A Prospective Pilot Study
    Nicole Cerabino, Caterina Bonfiglio, Leonilde Bonfrate, Rosanna Donvito, Pasqua Letizia Pesole, Dolores Stabile, Endrit Shahini, Gianluigi Giannelli
    Nutrients.2026; 18(12): 1873.     CrossRef
  • Limited Agreement of Different Elastography Techniques in Assessing Liver Stiffness in Postmenopausal Women with Early-Stage Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ilias D. Vachliotis, Vasileios Rafailidis, Athanasios D. Anastasilakis, Nikoletta Pyrrou, Stergios A. Polyzos
    Livers.2026; 6(3): 53.     CrossRef
  • Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease
    Kuo Fang, Ji Miao, Guobin Song
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Edible extracellular vesicle-like particles from Exocarpium Citri Grandis: A natural nanoplatform for oral treatment of metabolic dysfunction-associated steatotic liver disease
    Jingxiu Zhao, Tao Huang, Chengshi Fu, Yingjie Xiong, Anran Gao, Kui Wang, Yujia Song, Zanxiang Luo, Xiangyun Teng, Wei Zhao, Jianhua Xu
    International Journal of Biological Macromolecules.2026; 372: 152952.     CrossRef
  • Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease
    Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru
    Frontiers in Epidemiology.2026;[Epub]     CrossRef
  • Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review
    Karol P. Sagan, Zuzanna Lipiec-Rzepecka, Martyna Patalong-Wójcik, Michał P. Wasilewicz, Elżbieta Andrysiak-Mamos, Anhelli Syrenicz
    Journal of Endocrinological Investigation.2026;[Epub]     CrossRef
  • Cardiovascular Risk Factors in Greece: Looking Beyond the Classics. A narrative review.
    George Michas, Grigorios Trikas, Athanasios Trikas
    Hellenic Journal of Cardiology.2026;[Epub]     CrossRef
  • Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus
    Ying Zhao, Zhaoyue Li, Tian Yu, Yan Yang, Tingting Du
    BMJ Open Diabetes Research & Care.2026; 14(3): e005841.     CrossRef
  • Prevalence and Predictors of MASLD and Fibrosis in an Urban Outpatient Setting: A Cross-Sectional Study
    Nicolás Ortiz-López, Daniela Simian, Máximo Cattaneo, Katherine Rojas, Daniel Durán, Martina Contreras, Diego Lizama, María Fernanda Eyssautier, Camila Meza, Catalina Molina, Gerardo Jara, Jaime Poniachik
    Journal of Clinical Medicine.2026; 15(12): 4533.     CrossRef
  • Mortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999–2023
    Hongzhou Liu, Ru Wang, Liqin Cui, Linlin Wang, Jia Liu, Yangfan Du, Song Dong, Kaide Xia
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Nanoformulations for obesity-driven MASLD and MASH: Cell-specific hepatic drug delivery, comorbidity outcomes, and translational perspectives
    Polu Picheswara Rao
    Obesity Medicine.2026; 62: 100720.     CrossRef
  • Fatty acid‑activated proton transporter SR4 prevents hepatic steatosis and metabolic alterations in diabetic mice by improving mitochondria function, energy balance and oxidative stress
    James Figarola, Jyotsana Singhal, Sharad Singhal
    Experimental and Therapeutic Medicine.2026; 32(1): 1.     CrossRef
  • Non-Invasive Tests in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Diagnosis to Treatment Monitoring
    Han Ah Lee, Young Youn Cho, Hyung Joon Kim
    Clinical Ultrasound.2026; 11(1): 1.     CrossRef
  • Selenoprotein P deficiency in MASLD: association with insulin resistance and liver fibrosis: a prospective case-control study
    Mona A Hegazy, Samar Saad Mohamed, Eman H Saad, Ahmed Abdelghani, Dalia Abd el Fattah, Mohamed Ahmed Elsayed Mekki, Mona Fathy, Nora Hassan, Omar Ashoush
    BMC Gastroenterology.2026;[Epub]     CrossRef
  • MASLD and sarcopenia research (2012–2025): a multi-database bibliometric analysis
    Keyan Gao, Liwen Xun, Shalei Hao, Min An, Lingfeng Zuo, Jiayu Wang, Ying Wang, Junhua He
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Integrating UHPLC-Q-TOF/MS and multi-omics to elucidate the regulatory mechanisms of Xiong's Shiwei Wendan decoction in MASLD
    Miao Jiang, Qiu Wu, Rong Yu, Zehua Zhang, Ge Wen, Yuan Zhong, Zhoujin Tan, Zhijian Li, Xuejiao Xie
    Journal of Chromatography B.2026; 1281: 125181.     CrossRef
  • Korean red ginseng saponins ameliorate metabolic dysfunction-associated steatohepatitis in mice by inhibiting caspase-11 and NLRP3 inflammasomes
    Eojin Kim, Hee Ryeong Lim, Deok-Hyeong Choi, Young-Su Yi
    Journal of Ginseng Research.2026; : 101075.     CrossRef
  • Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System
    Naim Alkhouri, Raj Vuppalanchi, Mazen Noureddin, Eric Lawitz, Edward Mena, Nadege T. Gunn, Khurram Jamil, Seth Zuckerman, Stephen A. Harrison, Naga Chalasani
    Gastro Hep Advances.2026; 5(8): 101004.     CrossRef
  • Integrating the Fatty Liver Index into Primary Care: A Low-Cost Strategy for Early Identification of Chronic Kidney Disease Risk in Iran
    S Bazmi, M Farjam, J Mirzay Razzaz, matin Sepehrinia, R Homayounfar
    Iranian Journal of Nutrition Sciences and Food Technology.2026; 20(5): 117.     CrossRef
  • Obesity Management in Primary Care: Clinical Approaches and Policy Implications in the Era of Incretin-Based Therapies
    Chung-woo Lee
    Korean Journal of Family Practice.2026; 16(2): 81.     CrossRef
  • A celastrol derivative–based multifunctional nanozyme for oxidative stress scavenging and lipid metabolism regulation in metabolic dysfunction-associated steatotic liver disease
    Haoran Yang, Xue Cui, Kun Yu, Zhiwen Zhao, Longlong Jin, Qing Wang, Huiying Yang, Xinwei Li, Xuzhu Gao, Xianfu Wu
    Biomaterials Advances.2026; 188: 215027.     CrossRef
  • Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity
    Sara Rico-Chazarra, Carmen García-Melgares, Inmaculada Ros-Madrid, María A. Martínez-Sánchez, Lidia Sánchez-Alcoholado, Alba Oliva-Bolarín, Virginia E. Fernández-Ruiz, Mercedes Ferrer-Gómez, Antonio J. Ruiz-Alcaraz, Carlos M. Martínez, Adriana Mika, María
    Biomedicine & Pharmacotherapy.2026; 201: 119687.     CrossRef
  • Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons
    Dimitrios Patoulias, Manfredi Rizzo
    Current Pharmaceutical Design.2026; 32(20): 1537.     CrossRef
  • Steatotic Shadows: The Dark Link Between Metabolic Dysfunction-associated Steatotic Liver Disease and Cancer Risk
    Shakta Mani Satyam, Mohamed El-Tanani, Syed Arman Rabbani, Alaa A. Aljabali, Yahia El-Tanani, Dimitrios Patoulias, Manfredi Rizzo
    Current Pharmaceutical Design.2026; 32(20): 1539.     CrossRef
  • Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort
    Hyo Jung Cho, Seong Hee Kang, Hye Yeon Chon, SungA Bae, Eunju Kim, Seong Kyun Na, Su Jin Kim, Dooyeon Kim, Hye Ri Ahn, Huigyeong Kim, Jae Youn Cheong, Soon Koo Baik, Young Kul Jung, Soon Sun Kim, Hyung Joon Yim
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • LY6D promotes hepatic steatosis via the GRB2–AMPK–SREBP1 signaling axis
    Qiurong Zhao, Linxin Chen, Sha Xie, Juanjuan Meng, Wei Cui, Yao Wu, Ting Zeng, Huaming Mou, Xiaohe Luo
    International Journal of Obesity.2026; 50(7): 1588.     CrossRef
  • The Hepato-Exposome Axis: How Endocrine Disruptors Hijack Liver Receptors to Drive MASLD
    M. Martín-Grau, J.H. Kamstra, T. Hyötyläinen, M. Orešič, Y. Song, N. Veličković, A. Djordjevic, D. Vojnović Milutinović, R.F. Jackson, R. van Vorstenbosch, J. Massart, A. Vidal-Puig, S. Carobbio
    Journal of Hepatology.2026;[Epub]     CrossRef
  • Association of metabolic dysfunction-associated steatotic liver disease trajectories with incident liver cancer: a UK Biobank cohort study
    Ryuk Jun Kwon, Yohwan Lim
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review
    Naiyu Wang, Minmin Li, Mingjing Lu, Zheng Wang, Hualin Wang, Meiyue Yao, Hailing Ding, Muhammad Shahbaz, Muhammad Ijaz
    Medicine.2026; 105(25): e49379.     CrossRef
  • Dysregulated Lipid Metabolism in Hepatocellular Carcinoma: Mechanisms and Therapeutic Strategies
    Yi Yi, Xi Liu, Xi Zhang, Yongsheng Li, Huakan Zhao
    MedComm – Oncology.2026;[Epub]     CrossRef
  • Fibroblast- and Macrophage-Derived Thrombospondin-1 Orchestrates the Fibroinflammatory Niche in Metabolic Dysfunction-Associated Steatohepatitis-Induced Fibrosis
    Sung Woo Cho, Jung Hoon Cha, Deok Wha Seo, Mi Hyun Kwon, Kwon Yong Tak, Hee Sun Cho, Keungmo Yang, Seo Young Jung, SuHyun Hwangbo, Jae Yong Ryu, Si Hyun Bae, Pil Soo Sung
    Diabetes & Metabolism Journal.2026;[Epub]     CrossRef
  • Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease
    Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer
    Clinical Pharmacology & Therapeutics.2026;[Epub]     CrossRef
  • Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study
    Hyuk Kim, Jeong-Ju Yoo, Young Chang, Jae Young Jang, Tom Ryu, Soung Won Jeong, Sang Gyune Kim, Young Seok Kim, Suyeon Park
    Frontiers in Medicine.2026;[Epub]     CrossRef
  • Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review
    Dina Mahoon, Fares Kellany, Imad Khan, Somieya Khan, Alexandra E. Butler
    International Journal of Molecular Sciences.2026; 27(12): 5618.     CrossRef
  • Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD
    Eva Katharina Messer, Janett Fischer, Toni Herta, Albrecht Boehlig, Madlen Matz-Soja, Adrienn Tuennemann-Tarr, Susanne Gaul, Ulrich Laufs, Thomas Berg, Pavel Strnad
    PLOS One.2026; 21(6): e0349666.     CrossRef
  • Aging and Western Diet Synergistically Impair Hepatic Thyroid Hormone Signaling to Promote Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) in Mice
    Xinru Zhang, Madhulika Tripathi, Chun Ting Goh, Chee Seng Chan, Anita Boelen, Paul M. Yen, Brijesh Kumar Singh, Eveline Bruinstroop
    Aging Cell.2026;[Epub]     CrossRef
  • Cost‐Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in the United States
    Ali A. Abdeen, Turgay Ayer, Aanan Biswas, Chase J. Wehrle, Sobia N. Laique, Ali Aminian
    Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
  • Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010–2023
    Jialin Wu, Bonan Chen, Fuda Xie, Jiahui Hu, Mingyu Liang, Yang Lyu, Peiyao Yu, Tiejun Feng, Muyang Huang, Canbin Fang, Ka Fai To, Terry Cheuk-Fung Yip, Xingxin Wang, Wei Kang
    Hepatology International.2026;[Epub]     CrossRef
  • Letter to the Editor: Steatotic liver disease in chronic hepatitis C - a marker of systemic risk, not direct-acting antiviral treatment failure
    Abdo Imad El Tawil, Claudia Alexandra Pontes Ivantes
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease in Inflammatory Bowel Disease: A Cross-Sectional Study of Prevalence and Associated Factors
    Hüseyin Aykut, Nermin Mutlu Bilgiç, Duygu Demirtaş, Süleyman Sayar, Kamil Özdil
    Metabolites.2026; 16(7): 450.     CrossRef
  • Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review
    Jeong-Hwan Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Journal of the Korean Medical Association.2026; 69(6): 492.     CrossRef
  • Decoding the Gut–Fat–Heart Axis: From Molecular Communication Networks to Clinical Translation Strategies
    Zijin Sun, Wei Shao, Haojia Zhang, Kai Wang, Yongchao Liu, Rui Zhou
    International Journal of Molecular Sciences.2026; 27(12): 5596.     CrossRef
  • Macrophage–neutrophil crosstalk via the Selplg–Sell–YAP axis drives NETosis and MASH-associated liver fibrosis
    Fulin Nian, Chen Wu, Dejun Wu, Yifan Ma, Yueying Chen, Lin Xu, Yuqin Li, Ling Dong, Wujun Xiong
    Hepatology.2026;[Epub]     CrossRef
  • Diagnostic Performance of Ultrasound-Guided Attenuation Parameter (UGAP) for Hepatic Steatosis Assessment: Comparison with MRI-PDFF and Evaluation of Cohort-Derived Thresholds
    Dimitrios Kavvadas, Natalia-Valeria Pentara, Dimitrios Kourdakis, Aris Liakos, Emmanouil Sinakos, Panos Prassopoulos, Vasileios Rafailidis
    Diagnostics.2026; 16(13): 2006.     CrossRef
  • Metabolic dysfunction associated fatty liver disease (MAFLD), metabolic dysfunction associated steatotic liver disease (MASLD), metabolic associated steatohepatitis (MASH) and obesity
    Davor Štimac
    Best Practice & Research Clinical Gastroenterology.2026; : 102116.     CrossRef
  • Ammonia in the crosshairs: microbial targets for metabolic dysfunction–associated steatohepatitis prevention
    Vanessa A. Leone, Arion Kennedy
    Journal of Clinical Investigation.2026;[Epub]     CrossRef
  • Fibrosis and Perinatal Features Correlated with Telomere Shortening in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease
    Maria Rita Braghini, Salvatore Daniele Bianco, Marzia Bianchi, Giulia Andolina, Antonella Mosca, Cristiano De Stefanis, Michela Piccione, Paola Francalanci, Clara Balsano, Luca Miele, Tommaso Mazza, Anna Alisi
    Life.2026; 16(7): 1068.     CrossRef
  • The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH
    Caichen Zhong, Nana Boame, Semiu O. Gbadamosi, Maximilian Jara, Rakesh Luthra, Alex Salamun, Yu Hong, Abdalla Aly, Fernando Bril, Mary E. Rinella
    Expert Review of Pharmacoeconomics & Outcomes Research.2026; : 1.     CrossRef
  • Editorial: Advancing immune research in chronic liver diseases through new approach methodologies
    Sara Massironi, Ana C. Maretti-Mira
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Association of Sleep Characteristics With Suspected Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Risk Among Adults Attending a Community Health Center
    Tushar Prabhakar, Gahan S Jois, Satya V Singh, Bronica Saini, Adarsh Mohan
    Cureus.2026;[Epub]     CrossRef
  • Vitamin E dosing study (VEDS) in patients with metabolic dysfunction–associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial
    Srinivasan Dasarathy, Emily P. Mitchell, Laura A. Wilson, Brent A. Neuschwander-Tetri, Naga Chalasani, Jeanne M. Clark, Anna Mae Diehl, Bilal Hameed, Rohit Loomba, Liyun Yuan, Kris V. Kowdley, Arun J. Sanyal
    Hepatology.2026;[Epub]     CrossRef
  • MASH‐Related Liver Cancer Estimates Need Aetiology‐Specific Validation in the Asia‐Pacific Region
    Haoyang Hu
    Liver International.2026;[Epub]     CrossRef
  • Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics
    Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen
    BMJ Open Gastroenterology.2026; 13(1): e002343.     CrossRef
  • Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications
    Kenneth Tachi, Adwoa Agyei-Nkansah, Yacoba Atiase, Bright Forkuo, Victoria Akosua Agyen-Frimpong
    BMJ Open Gastroenterology.2026; 13(1): e002294.     CrossRef
  • Artificial intelligence predicts sex-specific risk of metabolic dysfunction-associated steatotic liver disease
    Mohamad Jamalinia, Giovanni Targher, Amedeo Lonardo, Seyed Taghi Heydari, Kamran Bagheri Lankarani
    Biology of Sex Differences.2026;[Epub]     CrossRef
  • A carotenoid-rich functional tomato sauce (OsteoCol®) reduces liver fat content in adults with metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial
    Rosario Mare, Yvelise Ferro, Samantha Maurotti, Elisa Mazza, Alberto Castagna, Carmelo Pujia, Francesca Rita Noto, Angelo Galluccio, Angela Mirarchi, Giuseppe Andrea Giampà, Marta Moraca, Tiziana Montalcini, Arturo Pujia
    European Journal of Nutrition.2026;[Epub]     CrossRef
  • Association of the cholesterol-HDL-glucose index with prevalent metabolic dysfunction-associated steatotic liver disease and its incremental metabolic-hepatic assessment value: a hospital-based cross-sectional study
    Ziqian Song, Hao Sun, Cai Wang, Yuantao Qi, Yuan Liu
    Frontiers in Nutrition.2026;[Epub]     CrossRef
  • Apigenin attenuates hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease by targeting the TGF-β signaling pathway
    Lijun Cao, Yongna Zhao
    Cytotechnology.2026;[Epub]     CrossRef
  • A TyG–UHR-based machine learning model for screening lean MAFLD: development and external validation
    Yansong Ji, Hui Zhang, Jingjing Xia, Guilian Chen, Hong Li
    BioMedical Engineering OnLine.2026;[Epub]     CrossRef
  • Intermittent fasting strategies for metabolic dysfunction-associated steatotic liver disease: A systematic review and frequentist network meta-analysis of randomized controlled trials
    Husam Abu Suilik, Ahmed Farid Gadelmawla, Mohamed Rifai, Moayad Alhawi, Abdellrahman Ashour, Hassan Abdalshafy, Omar Abdullah Bataineh, Hazem Rezq, Anas Bani Hani, Ismail Elkhattib, Mohamed Abuelazm
    Clinical Nutrition ESPEN.2026; 75: 103415.     CrossRef
  • Non-alcoholic fatty liver disease: Modern approaches to therapy and possibilities of using tirzepatide
    V. V. Gorban, E. V. Gorban, P. E. Kocherga
    Meditsinskiy sovet = Medical Council.2026; (8): 126.     CrossRef
  • Progression of Metabolic Dysfunction–Associated Steatohepatitis in US Adults Using Linked Records and Claims
    Yestle Kim, Romina Fakhraei, John C. O’Donnell, Karissa Johnston, Melissa Bather, Reem Mustafa, Andrew R. Kennedy, Amreen Dinani
    Gastro Hep Advances.2026; 5(9): 101031.     CrossRef
  • Interactive Roles of Metabolic Dysfunction‐Associated Steatotic Liver Disease and Nutritional Status in the Prognosis of Patients With Hepatocellular Carcinoma After Surgical Resection
    Chun‐Ting Ho, Chien‐An Liu, Chia‐Jung Ho, Yi‐Chen Lin, Shin‐Yu Tsai, Hao‐Jan Lei, Shu‐Cheng Chou, Yi‐Hsiang Huang, Ming‐Chih Hou, Jaw‐Ching Wu, Chien‐Wei Su
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study
    Yanqiu Huang, Yadan Xu, Chenghao Zhang, Wen Gu, Yue Li, Haojia Zhang, Tian Wang, Tangyi Su, Yangchen Lhamu, Yichen Chen, Liang Zhou, Lipeng Hao, Yang Yang, Hui Wang
    Cardiovascular Diabetology.2026;[Epub]     CrossRef
  • Piezo1 as a novel therapeutic target of salvianolic acid B for metabolic dysfunction-associated steatotic liver disease
    Yuxue Zhang, Chang Liu, Weiyi He, Wenhui Li, Wentao Duan, Chaofeng Wu, Hui Jia, Jieying Lan, Zeyu Tong, Qiaohui Du, Haiyan Lin, Zhuowei Gao, Wenxia Zhao, Piao Luo, Lei Gao
    Phytomedicine.2026; 159: 158546.     CrossRef
  • Phellinus igniarius Polysaccharides Ameliorate Nonalcoholic Fatty Liver Disease Through Suppressing SREBP1
    Ying‐Jun Zhang, Kai‐Yue He, Wei‐Tao Yin, Qing‐Chun Zhao, Xiong‐Yan Xiang, Jun‐Qi Li, Zhi‐Feng Zhang, Yong‐Ping Jian, Zhi‐Xiang Xu
    Food Frontiers.2026;[Epub]     CrossRef
  • Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies
    Jialin Wu, Wenting Wei, Terry Cheuk-Fung Yip, Xinyi Deng, Bonan Chen, Yang Lyu, Peiyao Yu, Tiejun Feng, Fuda Xie, Ge Zhang, Kangmin Zhuang, Aimin Li, Wei Kang
    Clinical and Experimental Medicine.2026;[Epub]     CrossRef
  • Weight loss and alcohol reduction synergize for hepatic steatosis remission in elderly patients with metabolic alcohol-associated liver disease (MetALD): a retrospective cohort study
    Tianxiang Lin, Xiaoxue Yuan, Yanrong Zhao, Wei Wang, Chen Wu, Song Yang, Yinwei Qiu
    International Journal of Obesity.2026;[Epub]     CrossRef
  • Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic‐Dysfunction Associated Steatotic Liver Disease
    Jarell Jie‐Rae Tan, Joo Wei Ethan Quek, Sean Shao Wei Lam, Ming‐Hua Zheng, Christophe Corpechot, Aldo J. Montano‐Loza, Yu Jun Wong
    Liver International.2026;[Epub]     CrossRef
  • A Simple Clinical Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Obesity
    Yang Liao, Fei Wang, Ting-Ting Tian, Xiu-Fen Li
    Indian Journal of Pediatrics.2026;[Epub]     CrossRef
  • Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
    Javier Crespo, Paula Iruzubieta, Tomas de Vega, Jose Luis Calleja
    Medicina Clínica.2026; 166(9): 107536.     CrossRef
  • Clinically Inferred Metabolic Dysfunction-Associated Steatotic Liver Disease and Its Association with Atrial Fibrillation Subtypes: A Prospective Clinical and Cardiometabolic Analysis
    Monika Różycka-Kosmalska, Boguslawa Luzak, Marcin Kosmalski
    Life.2026; 16(7): 1101.     CrossRef
  • Association between oxidative balance score and metabolic dysfunction-associated steatotic liver disease in US adolescents: A cross-sectional NHANES analysis
    Zhen Liu, Fei Wang, Liting He, Xiaoqing Huang, Fengfeng Liu, Lan Zhang
    Medicine.2026; 105(28): e49723.     CrossRef
  • Fucoxanthin Suppresses Lipid Accumulation and Inflammatory Responses in FFA-Induced Hepatocyte Models via the EGR2-CD36 Axis
    Xiangyu Li, Chen Yang, Qionghui Chen, Xianchuan Xu, Lian Wang, Peng Zhang, Qiang Hu, Danxiang Han, Aiqun Yu, Jing Jiang, Qizhou Lian
    Molecules.2026; 31(14): 2423.     CrossRef
  • Indole-3-carbaldehyde mitigates fibrosis progression in MASH with T2DM via the SIRT1/TGF-β/SMAD signaling pathway
    Lu Li, Zeyu Wang, Yinglan Ji, Raorao Wang, Xiangjuan Qi, Yana Zhu, Yaping Wang, Xiaoyang Zhang, Man Li, Yong Jiang
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2026; 1872(8): 168363.     CrossRef
  • Preliminary In Silico Evaluation of Extra Virgin Olive Oil-Derived Bioactive Compounds as Multi-Target-Directed Ligands in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ludovico Abenavoli, Maja Milanović, Giuseppe Guido Maria Scarlata, Nataša Milošević, Maria Luisa Gambardella, Nataša Milić
    Life.2026; 16(7): 1146.     CrossRef
  • Association between the skeletal muscle-to-visceral fat area ratio and liver fibrosis risk in patients with non-alcoholic fatty liver disease: a cross-sectional study
    Jingru Liu, Xitong Jiao, Lu Liu, Anqi Chen, Qixue Kang, Jiayue Guo, Yuxing Wang, Yanmeng Qi, Lili You
    Frontiers in Public Health.2026;[Epub]     CrossRef
  • Drug Development for MASH‐Related Compensated Cirrhosis: Past, Present and Future
    Ren‐Qiang Zeng, Yi‐Xuan Shao, Ru‐Tao Lin, Xu‐Ting Shen, Qin‐Mei Sun, Xin Xin, Ping Liu, Jian‐Gao Fan, Yi‐Yang Hu, Qin Feng
    Liver International.2026;[Epub]     CrossRef
  • Mediterranean diet adherence and non-alcoholic fatty liver disease risk in Turkish adults: a case–control study
    Reza Khoshbakht Farshad, Elif Akbaş, Yasemin Ertaş Öztürk
    British Journal of Nutrition.2026; : 1.     CrossRef
  • Childhood Underweight and Adulthood Obesity Associated With Increased Risk of MASLD and Cirrhosis: A Prospective Cohort Study of 375,125 Adults
    Jiadong Zeng, Jian Liang, Hao Zhang, Hanming Wang, zheyang Lin, Wenzhe Zhang, Haobin Zhang, Xudong Deng, Jiahui Lin, Minqi Liu, Minwen Chen, Yue Qiu, Zhen Zhang, Zhaohua Zhu, Yi Zeng
    Hepatology Research.2026;[Epub]     CrossRef
  • Dietary folate intake and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
    Qingchun Li, Xinyu Zhang, Fengyuan Zhao, Dongfeng Zhang, Weijing Wang, Zhongyang Zhang, Feng Yang
    Nutrition & Metabolism.2026;[Epub]     CrossRef
  • Comorbid type 2 diabetes and cardiovascular disease drive higher healthcare costs in MASLD/MASH: a retrospective Swedish cohort study
    Helena Skröder, Mattias Ekstedt, Stergios Kechagias, Riku Ota, Ying Shang, Fotis Tefos, Emilie Toresson Grip, Johan Vessby, Hannes Hagström
    Scandinavian Journal of Gastroenterology.2026; : 1.     CrossRef
  • Development of a machine learning-based noninvasive diagnostic model for liver fibrosis in metabolic-associated steatotic liver disease
    Yixin Hui, Yuping Zeng, Mei Zhang
    European Journal of Gastroenterology & Hepatology.2026;[Epub]     CrossRef
  • Body Mass Index and Mucosal Healing in Japanese Patients with Ulcerative Colitis: A Cross-Sectional Study
    Masakazu Hanayama, Shinya Furukawa, Teruki Miyake, Osamu Yoshida, Hironubu Nakaguchi, Ayumi Kanamoto, Masumi Miyazaki, Yoshimasa Murakami, Keiichiro Horiuchi, Kazuhiro Tange, Shogo Kitahata, Tomoyuki Ninomiya, Seiyuu Suzuki, Katsuhisa Ohashi, Hideomi Tomi
    Digestion.2026; : 1.     CrossRef
  • Metabolite-driven remodeling of hepatic lipid metabolism by the plasticizer di-isononyl phthalate
    Sini Pitkänen, Henriikka Hakomäki, Olli Kärkkäinen, Marko Lehtonen, Sreejita Das, Jaana Rysä, Jenni Küblbeck, Anna-Liisa Levonen
    Molecular Metabolism.2026; 110: 102412.     CrossRef
  • Longitudinal association of dietary spermidine with hepatic function indexes and cardiometabolic traits in older adults with metabolic syndrome
    Andrés López-González, Esther Cuadrado-Soto, José M. Ordovás, Miguel Ángel Martínez-González, Dolores Corella, Jordi Salas-Salvadó, Montserrat Fitó, J. Alfredo Martínez, Ángel M. Alonso-Gómez, Julia Wärnberg, Jesús Vioque, Dora Romaguera, José López-Miran
    European Journal of Nutrition.2026;[Epub]     CrossRef
  • Composite dietary antioxidant index and risk of metabolic dysfunction – associated steatotic liver disease: evidence from a prospective cohort study
    Matin Sepehrinia, Sina Bazmi, Ali Nikparast, Elahe Etesami, Farhad Vahid, Gholamali Javdan, Hananeh Rozbahani, Jalaledin Mirzay Razaz, Mohammad Shafi Kuchay, Reza Homayounfar
    Nutrition & Metabolism.2026;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Steatosis to Systemic Metabolic Failure: Classical Pathophysiology, Emerging Systemic Mechanisms and Modifiable Lifestyle Determinants
    Stefania Capuccio, Caterina Cocuzza, Grazia Letizia Di Marco, Alessandra Scamporrino, Salvatore Piro, Maurizio Russello
    Nutrients.2026; 18(14): 2316.     CrossRef
  • Human stem cell-derived hepatic cells recapitulate polygenic risk in MASLD development and highlight CD36 as a key mediator
    Alexandra Gatzios, Marth Stinckens, Anouk Verhoeven, Matthias Rombaut, Dinja De Win, Anja Heymans, Arne Loosen, Freddy Van Goethem, Joery De Kock, Robim M. Rodrigues, Joost Boeckmans, Tamara Vanhaecke
    Life Sciences.2026; 402: 124587.     CrossRef
  • Racial and gender disparities in access to living donor liver transplantation between 1999–2021
    Nicole Ng, Alexander Zhao, Nathaly Llore, Benjamin Samstein, Abhishek Mathur, Jennica Kim, Pamela Cobbs, Alyson Fox, Jason Hawksworth, Russell Rosenblatt
    Journal of Liver Transplantation.2026; 23: 100364.     CrossRef
  • Epitranscriptomic Remodeling: m6A Methylation as a Master Regulator of de novo Lipogenesis in MASLD
    Pervej Alom Barbhuiya, Pompy Patowary, Manash Pratim Pathak
    Current Hepatology Reports.2026;[Epub]     CrossRef
  • Lipidomics and proteomics in MASLD: reading the molecular script toward precision therapeutics
    Anna Sofia Germanidou, Theocharis Koufakis
    Hormones.2026;[Epub]     CrossRef
  • High Cardiometabolic Risk Burden Predicts Adverse Outcomes in Patients with MASLD-Related Hepatocellular Carcinoma
    Yeonhong Do, Young Hyeon Ahn, Young Chang, Jeong-Ju Yoo, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Hong Soo Kim, Keungmo Yang, Tom Ryu
    Gut and Liver.2026; 20(4): 655.     CrossRef
  • Relationship between metabolic dysfunction-associated steatotic liver disease and cardiovascular mortality risk in individuals with CKM stages 0–2: Mediating roles of inflammation and insulin resistance
    Zhuoxing Li, Qianyu Yang, Li Zang, Hongwei Leng, Panpan Qin, Simeng Li, Buyuan Tian, Xumao Deng, Yun Sun, Xiang Xiao
    Diabetes Research and Clinical Practice.2026; 239: 113411.     CrossRef
  • High salt supplementation of a MASH-inducing diet causes lean MASH phenotype with increased hepatic urea cycle activity and EIF5A hypusination
    Shaopeiwen Luo, Norihiko Morisawa, Anissa Anindya Widjaja, Brijesh Kumar Singh, Derek John Hausenloy, Paul Michael Yen, Jin Zhou
    Molecular Metabolism.2026; 111: 102417.     CrossRef
  • Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study
    Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, Dakshata Padhye, Lakshmi Nalini Kopalle, Ashok Kumar Das, Om Lakhani, Jothydev Kesavadev,
    Frontiers in Clinical Diabetes and Healthcare.2026;[Epub]     CrossRef
  • Metabolic and Lifestyle Profiles of Metabolic Dysfunction-Associated Steatotic Liver Disease in Romanian and Italian Adults
    Naomi-Adina Ciurea, Harshitha Shanmugam, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Simona Bataga, Agostino Di Ciaula, Piero Portincasa
    Medicina.2026; 62(7): 1403.     CrossRef
  • Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives
    Mario Romeo, Claudio Basile, Andrea Imperatore, Giambattista Mozzi, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Luigi Di Puorto, Mattia Indipendente, Marcello Dallio, Alessandro Federico
    Cells.2026; 15(14): 1292.     CrossRef
  • Deep behavioral phenotyping reveals novel features in a mouse model of metabolic dysfunction-associated steatohepatitis
    Naoaki Sakamoto, Takamasa Numano, Yui Kobayashi, Masahiro Fukuda, Maria Osaki, Keisuke Omori, Taichi Yamamoto, Takahisa Murata
    Scientific Reports.2026;[Epub]     CrossRef
  • MYH11 upregulation attenuates autophagy dysfunction through modulation of ATG4A in metabolic dysfunction-associated steatotic liver disease
    Guang-Peng Liu, Xiao-Han Ma, Hong-Qian Wang, Cheng-Cheng Tong, Xi Chen
    Biochemical Pharmacology.2026; 253: 118279.     CrossRef
  • Clinical applications and advances in noninvasive prognostic assessment of metabolic dysfunction-associated steatotic liver disease
    Xin-Long He, Rui-Xu Yang, Jian-Gao Fan
    Hepatoma Research.2026;[Epub]     CrossRef
  • Association between chrononutrition patterns and metabolic dysfunction-associated steatotic liver disease in adolescents: a population-based study
    Yueju Wang, Mingxin Wang, Jingya He, Congwei You, Cai Tang, Lihong Zhu, Le Zhang, Xiaodie Yao
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2026;[Epub]     CrossRef
  • Outcome after liver transplantation: Predicting the unpredictable
    Ylenia Capraro, Leonard Lamfu, Martina Milana, Ilaria Lenci, Leonardo Baiocchi
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Letter to the Editor: Xietu Hemu prescription: A novel therapeutic strategy for obesity and metabolic dysfunction-associated steatotic liver disease?
    Alessia Provera, Anteneh Nigussie Sheferaw, Emmanuel Kivumbi, Salvatore Sutti
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Integrated computational analysis identifies FABP4, PTGS2, and HPGD as Key molecular targets linking PET microplastic exposure to metabolic dysfunction-associated steatotic liver disease
    Yi Zhang, Yao Yu, Bin Ge, Dacai Gong, Lan Zheng, Yuanyi Wang, Peng Chen, Seth Agyei Domfeh
    PLOS One.2026; 21(7): e0354607.     CrossRef
  • LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial
    A. N. Saidi, B. Burggraaf, A. J. van der Lelij, E. van der Zwan-van Beek, M. Castro Cabezas
    Rheumatology International.2026;[Epub]     CrossRef
  • Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease
    Kyla Z. Gelev, Seung Hyuk T. Lee, Marcus Alvarez, Rosellina M. Mancina, Federica Tavaglione, Oveis Jamialahmadi, Umberto Vespasiani-Gentilucci, Asha Kar, Zitian Wang, Dorota Kaminska, Minna U. Kaikkonen, Ville Männistö, Sini Heinonen, Tuure Saarinen, Anne
    Nature Communications.2026;[Epub]     CrossRef
  • Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases
    Ana Flávia Pontes Sodré, Lucca Gonsales Rodrigues, Kátia P. Sloan, Lance A. Sloan, Masaru Tanaka, Rui Curi, Larissa Naomi Takeda, Ricardo de Alvares Goulart, Ana Luiza Decanini Miranda de Souza, Claudia Rucco Penteado Detregiachi, Antonelly Cassio Alves C
    International Journal of Molecular Sciences.2026; 27(15): 6554.     CrossRef
  • MASLD In PBC: A Shift From Liver‐Centred to Cardiometabolic Risk Assessment?
    Francesca Colapietro, Mauro Viganò
    Liver International.2026;[Epub]     CrossRef
  • Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies
    Lashin S. Ali, Mohamed O. Mostafa, Dana Alsharayiah, Mohamed A. Elkholy, Khaled A. Ahmed, Ahmed A. El-Mansy, Abd El Rahman M. Sharfeldeen, Gehan El Wakeel, Abdelnaser A. Badawy, Ahmed H. Sulaiman, Elryah I. Ali, Shabram Mariam Alenazi, Mohammed M. Alruwai
    Frontiers in Pharmacology.2026;[Epub]     CrossRef
  • Time-dependent predictive accuracy of noninvasive liver scores for chronic kidney disease onset in metabolic dysfunction-associated steatotic liver disease
    Huttakan Navadurong, Padoemwut Teerawongsakul, Thananda Trakarnvanich, Witchakorn Ruamtawee, Nutachat Treerasoradaj, Supatsri Sethasine
    World Journal of Hepatology.2026;[Epub]     CrossRef
  • Reframing MASLD: A Hepatic Condition with Systemic Clinical Impact
    Patricia S. Castillo-Flores, Itzayana Rodríguez-Antonio, Misael Uribe, Norberto C. Chávez-Tapia, Eduardo E. Montalvo-Javé, Natalia Nuño-Lámbarri
    Journal of Clinical and Experimental Hepatology.2026; : 103631.     CrossRef
  • Hepatic inflammation after exposure to a mixture of low-dose arsenic and cadmium in a murine model of fatty liver disease
    Nivetha K Subramaniam, Natascha Gagnon, Cynthia Guilbert, Rushmi Perinpanathan, Madelyn Abraham, Christophe Goncalves, Jaymie R Meliker, Sonia Del Rincon, Koren K Mann
    Toxicological Sciences.2026;[Epub]     CrossRef
  • Human placenta extract declines fat deposition in an in vitro novel 3D MASLD model
    Parisa Taheri, Fatemeh Majidi, Kosar Nouri, Masoumeh Nouri, Morteza Zarrabi, Elham Rismani, Abbas Piryaei, Massoud Vosough
    In vitro models.2026;[Epub]     CrossRef
  • DNMT1 facilitates the progression of metabolic dysfunction-associated steatotic liver disease by impeding transcription mediated by HNF4α and PPARα
    Hyun Ahm Sohn, Hanyong Go, Tae Hyeon An, Jun Min Lee, Hee-Jin Kim, Keeok Haam, Amal Magdy, Hyo-Jung Jung, Yang-Ji Shin, Hyun Jung Lim, Yujin Jeong, Yejin Bae, Youngae Jung, Seong-Hwan Park, Kyung Chan Park, Myeong Jun Song, Eun-Wie Cho, Eun-Soo Kwon, Jeon
    Clinical and Molecular Hepatology.2026; 32(3): 1201.     CrossRef
  • Hepatic fibro-inflammation measured by magnetic resonance imaging iron-corrected T1 predicts extrahepatic cancer risk: a UK Biobank study
    Hye Yeon Chon, Seok-Jae Heo, SungA Bae, Tae Seop Lim, Ja Kyung Kim
    Clinical and Molecular Hepatology.2026; 32(3): 1349.     CrossRef
  • Andrias davidianus Liver-Derived Peptides Ameliorate MASH Accompanied by Attenuation of PPARγ Signaling and Selective Modulation of Gut Microbiota
    Xing Shen, Ya-Na Qu, Yi-Xiao Huang, Chen-Yu Liang, Si-Jia Liu, Na Liu, Zi-Jie He, Shuai-Kun Su, Qing-Zhu Sun, Tai An, Hua Han
    Metabolites.2026; 16(8): 532.     CrossRef
  • Blood Urea Nitrogen to Serum Albumin Ratio Is Associated with MASH and Significant Fibrosis: Report from a Turkish Biopsy-Proven MASLD Cohort
    Ali Kirik, Eda Kaya, Caglayan Keklikkiran, Yusuf Yilmaz
    Journal of Clinical Medicine.2026; 15(15): 5892.     CrossRef
  • The natural history and individualized prediction of liver stiffness-based fibrosis risk in metabolic dysfunction-associated steatotic liver disease
    Yu Shi, Ruoqi Zhou, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Manuel Romero-Gomez, Emmanuel Tsochatzis, Philip Newsome, Hannes Hagström, George Boon-Bee Goh, Wah-Kheong Chan, José-Luis Calleja, Jerome Boursi
    Clinical and Molecular Hepatology.2026; 32(3): 1333.     CrossRef
  • Capturing systemic disease burden in MASLD: Toward integrated liver–kidney–cardiovascular economic models: Reply to correspondence on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic live
    Anna Di Sessa, Gianmario Forcina, Emanuele Miraglia del Giudice
    Clinical and Molecular Hepatology.2026; 32(3): e447.     CrossRef
  • Selective SGLT2 inhibitors in MASLD/MASH: an outcome-specific systematic review and meta-analysis of hepatic and cardiometabolic outcomes
    Danilo Caponio, Giuseppina Alessia Acucella, Michele Acucella
    Acta Diabetologica.2026;[Epub]     CrossRef
  • Therapeutic Targets for Hepatic Fibrosis Driven by Hypoxia-Mediated Hepatic Stellate Cell Activation
    Wenteng Li, Tong Li, Jingwei Mao
    Biomolecules.2026; 16(8): 1089.     CrossRef
  • Dapagliflozin in Metabolic Dysfunction–Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential
    Rajesh Upadhyay, Mangesh Tiwaskar, Bharat Saboo, L Sreenivasamurthy, Kirti Sonawale, Charmy Prajapati, Parthasarathy Muralidharan
    Euroasian journal of hepato-gastroenterology.2026; 16(1): 98.     CrossRef
  • Understanding regional differences in MASLD: the Indian perspective
    Karthik Shree Harini, Devaraj Ezhilarasan
    npj Metabolic Health and Disease.2026;[Epub]     CrossRef
  • MASLD and Pancreatic Diseases: From Shared Mechanisms to Clinical Implications and Future Directions
    Jesús Rivera-Esteban, Belén Agudo, Beatrice Patrizi, Alejandra Manzur, Daniel de la Iglesia, Víctor Valverde, Neus García Ferris, Carlos Esteban, Elena Santos, Fernando Pons, Marta Hernández-Conde, Javier Abad, Mariano González-Haba, José Luis Calleja
    Nutrients.2026; 18(15): 2480.     CrossRef
  • Liver muscle bone axis in metabolic dysfunction-associated steatotic liver disease
    Binhua Li, Yimeng Zhang, Can Zhou, Haixia Cao, Jing Zeng
    Metabolism and Target Organ Damage.2026;[Epub]     CrossRef
  • Cardiometabolic Factor-Specific Metabolic Signatures in Metabolic Dysfunction-Associated Steatotic Liver Disease: Insights from Non-Targeted Metabolomics
    Keigo Misawa, Kouichi Miura, Kenichi Aizawa, Eri Noguchi, Eiko Ueki, Masako Watanabe, Hitoshi Osaka, Tomonori Yano
    Antioxidants.2026; 15(8): 950.     CrossRef
  • Screening for Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence, Challenges, and the Role of Imaging—From the AJR Special Series on Screening
    Shin Mei Chan, Cheng William Hong, Lael Ceriani, Manish Dhyani, Kathryn J. Fowler, Michael S. Middleton, Theodore T. Pierce, Perry J. Pickhardt, Scott B. Reeder, Anthony E. Samir, Adam Searleman, Dorathy Tamayo-Murillo, Claude B. Sirlin
    American Journal of Roentgenology.2026;[Epub]     CrossRef
  • Characterization of Post-translational Modification in Metabolic Dysfunction-Associated Steatohepatitis: Acetylation, Lactylation, and Phosphorylation
    Kuan Li, Yundong Li, Yuqing Zhang, Shuxian Song, Chengzhou Pa, Chen Du, Lianjun Yang, Guoyou Xue, Hongqiang Gao
    Journal of Lipid Research.2026; : 101116.     CrossRef
  • Fibroblast growth factor 21 in metabolic dysfunction-associated steatotic liver disease and beyond: from bench to bedside
    Hak-Keith Leung, Guo-Jeng Tan, Wei-Kei Wong, Farahani Khamis, Shamsul Mohd Zain, Wah-Kheong Chan
    Hepatoma Research.2026;[Epub]     CrossRef
  • Strategy to Improve Diagnostic Performance of Hepatic Steatosis Grading Using Ultrasound: Combination of Qualitative and Quantitative Approaches
    Abdusattorov Shavkat Shokirjon ugli, Sunyoung Lee, Ja Kyung Yoon, Jae Seung Lee, Seung-seob Kim
    Medicina.2026; 62(8): 1467.     CrossRef
  • A WHA resolution on Steatotic liver diseases -A Global Call to Action
    Khaled Abdel Ghaffar, El Amira Rashwan, Mohamed Hassany
    Journal of Hepatology.2026;[Epub]     CrossRef
  • A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper
    Tao Chen, Ashok Choudhury, Wei Liu, Meng Zhang, Wenhui Wu, Huiling Xiang, Xiaojing Wang, Zaigham Abbas, Tatsuo Kanda, Ramazan Idilman, Kemal Fariz Kalista, Hai Li, Rosmawati Binti Mohamed, Paolo Angeli, Mohamed Elbasiony, Hasitha S. Wijewantha, Charles Pa
    Hepatology International.2026;[Epub]     CrossRef
  • Adipose Tissue Browning in MASLD and Its Molecular Mechanisms and Metabolic Crosstalk
    Jonathan Jaime G. Guerrero, Mark Angelo S. del Rosario, Paolo C. Encarnacion, Chen-Sung Lin, Lu-Te Chuang, Kin Israel Notarte, Jiayan Zhou, Chih-Hao Wang, Ching-Wen Chang, Wan-Chun Li
    Current Obesity Reports.2026;[Epub]     CrossRef
  • Association of sleep patterns and disorders with metabolic dysfunction-associated steatotic liver disease and liver fibrosis in contemporary American adults
    Guannan Zong, Wangjia Mao, Ming Wen, Xiaoyun Cheng, Guanghui Liu
    Annals of Hepatology.2025; 30(2): 101583.     CrossRef
  • Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease
    Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang
    Diabetes & Metabolism.2025; 51(1): 101602.     CrossRef
  • High-Intensity Interval Training Reduces Liver Enzyme Levels and Improves MASLD-Related Biomarkers in Overweight/Obese Girls
    Wissal Abassi, Nejmeddine Ouerghi, Mohamed Bessem Hammami, Nidhal Jebabli, Moncef Feki, Anissa Bouassida, Katja Weiss, Beat Knechtle
    Nutrients.2025; 17(1): 164.     CrossRef
  • Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD
    Ester S. Alves, Jessica D. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Carlos H. Z. Talarico, Anne R. M. Santos, Carlos A. A. Silva, Henrique J. N. Morgan, Sandro L. Matos, Layanne C. C. Araujo, João Paulo Camporez
    Pathophysiology.2025; 32(1): 1.     CrossRef
  • Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
    Fan Zhang, Longgen Liu, Wenjian Li
    Nutrition Journal.2025;[Epub]     CrossRef
  • The association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014
    Ruli Wang, Ningxi Wu, Huan Qu, Xiaowei Zheng, Haoyang Zhang, Lihong Zhu, Xiaolei Wang, Xiaodie Yao, Le Zhang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort
    Xin Zhang, Haili Wang, Chengnan Guo, Shuzhen Zhao, Yi Li, Zhenqiu Liu, Tiejun Zhang
    Digestive and Liver Disease.2025;[Epub]     CrossRef
  • Tetrahydrocurcumin Alleviates Metabolic Dysfunction-Associated Steatohepatitis in Mice by Regulating Serum Lipids, Bile Acids, and Gut Microbiota
    Shang Peng, Moran Meng, Ping Luo, Jiao Liu, Junjun Wang, Yong Chen
    International Journal of Molecular Sciences.2025; 26(3): 895.     CrossRef
  • Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
    Katharina L. Hupa-Breier, Heiko Schenk, Alejandro Campos-Murguia, Freya Wellhöner, Benjamin Heidrich, Janine Dywicki, Björn Hartleben, Clara Böker, Julian Mall, Christoph Terkamp, Ludwig Wilkens, Friedrich Becker, Karl Lenhard Rudolph, Michael Peter Manns
    Molecular Metabolism.2025; 93: 102104.     CrossRef
  • Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
    Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
    Cells.2025; 14(3): 221.     CrossRef
  • Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
    Yunfei Wu, Guojun Zheng, Fan Zhang, Wenjian Li
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Liver fibrosis progression analyzed with AI predicts renal decline
    Dan-Qin Sun, Jia-Qi Shen, Xiao-Fei Tong, Ya-Yun Ren, Hai-Yang Yuan, Yang-Yang Li, Xin-Lei Wang, Sui-Dan Chen, Pei-Wu Zhu, Xiao-Dong Wang, Christopher D. Byrne, Giovanni Targher, Lai Wei, Vincent W.S. Wong, Dean Tai, Arun J. Sanyal, Hong You, Ming-Hua Zhen
    JHEP Reports.2025; 7(5): 101358.     CrossRef
  • Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis
    Adrian Rotaru, Remus Stafie, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Horia Minea, Laura Huiban, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Catalin Sfarti, Carol Stanciu, Anca Trifan
    Life.2025; 15(2): 288.     CrossRef
  • Sex differences in diet-induced MASLD – are female mice naturally protected?
    Jana Meyer, Ana Mendes Teixeira, Sandy Richter, Dean P. Larner, Asifuddin Syed, Nora Klöting, Madlen Matz-Soja, Susanne Gaul, Anja Barnikol-Oettler, Wieland Kiess, Diana Le Duc, Melanie Penke, Antje Garten
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis
    Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nak
    Journal of Gastroenterology.2025; 60(7): 891.     CrossRef
  • Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785.     CrossRef
  • A Narrative Review on the Risk Factors and Healthcare Disparities of Type 2 Diabetes
    Elvira Meni Maria Gkrinia, Andrej Belančić
    Diabetology.2025; 6(4): 25.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur
    Stergios A. Polyzos, Christos S. Mantzoros
    Metabolism.2025; 168: 156253.     CrossRef
  • Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives
    Yilong Chen, Shuixiu Bian, Jiamei Le
    Genes.2025; 16(4): 399.     CrossRef
  • Significance of FXR agonists in MASLD treatment: a deep dive into lipid alteration by analytical techniques
    Pirangi Srikanth, Khaja Moinuddin Shaik, Vijay Patibandla, Deepak Kumar, Sukhendu Nandi
    Exploration of Endocrine and Metabolic Diseases.2025;[Epub]     CrossRef
  • Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
    Hannah Mohr, Jonathan G. Stine
    Alimentary Pharmacology & Therapeutics.2025; 61(9): 1565.     CrossRef
  • The socioeconomic and environmental determinants of metabolic dysfunction-associated steatotic liver disease: understanding inequalities in prevalence and outcomes
    Dominika Lorek, Krzysztof Łupina, Wiktoria Bisaga, Dominik Malicki, Weronika Stępień, Laura Kumor, Jakub Janczura
    Korean Journal of Family Medicine.2025; 46(2): 61.     CrossRef
  • Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
    Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho
    Trends in Endocrinology & Metabolism.2025; 36(11): 1000.     CrossRef
  • Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting
    Edgar A. Villavicencio, Cindy Serdjebi, Adriana Maldonado, Estefania Ochoa Mora, Adrien Besson, Naim Alkhouri, David O. Garcia
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(5): 102581.     CrossRef
  • Potential bidirectional communication between the liver and the central circadian clock in MASLD
    Frédéric Gachon, Elisabetta Bugianesi, Gabriele Castelnuovo, Henrik Oster, Julie S. Pendergast, Sara Montagnese
    npj Metabolic Health and Disease.2025;[Epub]     CrossRef
  • Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy
    云飞 曲
    Journal of Clinical Personalized Medicine.2025; 04(02): 826.     CrossRef
  • GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”
    Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen
    Clinical and Molecular Hepatology.2025; 31(2): e189.     CrossRef
  • Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
    Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
    Clinical and Molecular Hepatology.2025; 31(2): e145.     CrossRef
  • Prognostic impact of body composition in hepatocellular carcinoma patients undergoing interventional and systemic therapy
    Yun Feng, Bingran Yu, Anxiao Liu, Chongpeng Cai, Changming Zhou, Tong Tong, Lu Wang, Qi Pan
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • The Unequal Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease in 204 Countries and Territories From 1990 to 2021
    Junqiao Feng, Yudan Fan
    Liver International.2025;[Epub]     CrossRef
  • Chronic Hepatitis B and MASLD: Growing Awareness and Unmet Clinical Needs
    Nicola Pugliese, Davide Polverini, Stefano Ciardullo
    Liver International.2025;[Epub]     CrossRef
  • Multi‐Center, Multi‐Vendor Validation of Simultaneous MRI‐Based Proton Density Fat Fraction and R2* Mapping Using a Combined Proton Density Fat Fraction‐R2* Phantom
    Jitka Starekova, David Rutkowski, Won C. Bae, Hung Do, Ananth J. Madhuranthakam, Vadim Malis, Sheng Qing Lin, Suraj Serai, Takeshi Yokoo, Scott B. Reeder, Jean H. Brittain, Diego Hernando
    Journal of Magnetic Resonance Imaging.2025; 62(3): 800.     CrossRef
  • Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease
    Murali Krishna Moka, Deepalaxmi Rathakrishnan, D.K. Sriram, Melvin George
    Clinical Nutrition.2025; 49: 52.     CrossRef
  • Targeting Metabolism: Innovative Therapies for MASLD Unveiled
    Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He
    International Journal of Molecular Sciences.2025; 26(9): 4077.     CrossRef
  • Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?
    Luciana Agoglia, Maria Chiara Chindamo, Cristiane Villela-Nogueira
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease
    Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus
    Chun-Hua Wang, Xuan-Yao Ji, Nian Ji, Qing-Feng Yan, Hong-Qing Xu, Xue-Qin Wang, Xiang-Fan Chen, Chun-Feng Lu
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease
    Lissette Duarte, Fabien Magne, Martin Gotteland
    Current Opinion in Clinical Nutrition & Metabolic Care.2025; 28(4): 307.     CrossRef
  • Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease
    Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies
    Claudia Reytor-González, Daniel Simancas-Racines, Martín Campuzano-Donoso, Janeth Castano Jimenez, Náthaly Mercedes Román-Galeano, Gerardo Sarno, Evelyn Frias-Toral
    Food and Agricultural Immunology.2025;[Epub]     CrossRef
  • Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 2001–2018
    Zhengjin Wang, Zhangxin Chen, Hanxu Zhuang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
    Yee Hui Yeo, Yixuan Zhu, Jingli Gao, Shanghao Liu, Wenjing Ni, Fajuan Rui, Xue Bai, Nan Geng, Rui Jin, Elizabeth K. Speliotes, Chao Wu, Junping Shi, Xiaolong Qi, Vincent L. Chen, Philip N. Newsome, Jie Li
    Alimentary Pharmacology & Therapeutics.2025; 62(2): 168.     CrossRef
  • Association of gut microbiota dietary index with metabolic dysfunction-associated steatotic liver disease: the mediating roles of inflammation and body mass index
    Yu Pu, Zongbiao Tan, Yanrui Wu, Suqi Zeng, Haodong He, Jixiang Zhang, Weiguo Dong
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018
    Xiaodie Wei, Xiaohui Liu, Jinhan Zhao, Yang Zhang, Lixia Qiu, Jing Zhang
    Frontiers in Aging.2025;[Epub]     CrossRef
  • Low carbohydrate and low-calorie diets reduce liver fat and lower brain glutamate and myo-inositol levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Andreana P. Haley, Jack Knight-Scott, Marie Caillaud, Isabelle Gallagher, Jessica Park, Yanrong Li, Tianyu Wang, Hirofumi Tanaka, Jeffrey D. Browning
    Metabolic Brain Disease.2025;[Epub]     CrossRef
  • FGF21 reverses MASH through coordinated actions on the CNS and liver
    Jesse P. Rose, Donald A. Morgan, Andrew I. Sullivan, Xiaorong Fu, Melissa Inigo-Vollmer, Shawn C. Burgess, David K. Meyerholz, Kamal Rahmouni, Matthew J. Potthoff
    Cell Metabolism.2025; 37(7): 1515.     CrossRef
  • Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
    Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah
    Gastroenterology Report.2025;[Epub]     CrossRef
  • From liver to limb: Exploring the association between fatty liver disease and peripheral artery disease—A systematic review
    Vera Ciornolutchii, Abdulrahman Ismaiel, Jennifer Bogdan, Stefan‐Lucian Popa, Teodora Surdea‐Blaga, Dan L. Dumitrascu
    European Journal of Clinical Investigation.2025;[Epub]     CrossRef
  • Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease
    Fan Zhang, Longgen Liu, Wenjian Li
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis
    Zhifa Ge, Qingwei Wu, Chengyu Lv, Qifeng He
    Immunology.2025; 176(2): 145.     CrossRef
  • Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
    Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
    Biomedicines.2025; 13(5): 1260.     CrossRef
  • Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
    Yusuf Yilmaz, Caglayan Keklikkiran, Andrei Racila, Maria Stepanova, Zobair M. Younossi
    Clinical and Translational Gastroenterology.2025; 16(6): e00844.     CrossRef
  • Impact of Metabolic Dysfunction–associated Steatotic Liver Disease on Cardiovascular Structure, Function, and the Risk of Heart Failure
    Bhavik Bansal, Fannie Lajeunesse-Trempe, Neil Keshvani, Carl J. Lavie, Ambarish Pandey
    Canadian Journal of Cardiology.2025; 41(9): 1777.     CrossRef
  • Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis
    舒惟 梁
    Advances in Clinical Medicine.2025; 15(05): 2063.     CrossRef
  • Prevalence of MASLD, Met-ALD, and ALD and Associated Fibrosis Among US Adults
    James M. Paik, Kathryn Hobbs, Amolika Gupta, Rand Jamal Alkalbani, Manuel Alexander Reyes, Zobair M. Younossi
    Journal of Clinical Gastroenterology.2025;[Epub]     CrossRef
  • Association between weight fluctuation and the risk of metabolic dysfunction-associated steatotic liver disease
    Jin-Ping Wang, Jia-Yang Wang, Pei-Qi Sun, Xue-Wei Wang, Ze-Ting Yuan, Qin Cao, Shu-Ming Pan, Yuan-Ye Jiang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Increased prevalence and risk of atherosclerotic cardiovascular disease in individuals with Type 1 diabetes and metabolic dysfunction-associated steatotic liver disease
    Jonathan Mertens, Jonas Weyler, Eveline Dirinck, Luisa Vonghia, Wilhelmus J. Kwanten, Luc F. Van Gaal, Benedicte Y. De Winter, Sven Francque, Christophe De Block
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study
    Arjuna P De Silva, Krishanni Prabagar, Anuradha S Wickramasinghage, Aruni A Wanniarachchi, Dileepa S Ediriweera, Madunil A Niriella, Hithanadura J De Silva
    Cureus.2025;[Epub]     CrossRef
  • GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)
    Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion
    Nina Rodriguez, Cecilia Katzenstein, Marcia Lange, Jeanette Rios, Tatyana Kushner, Rachel Meislin, Emma Rosenbluth, Carin Carroll, Theresa Worthington, Shaelyn O’Hara, Joanne Stone, Sonam Rosberger, Keith Sigel, Rhoda Sperling, Norah A. Terrault
    Journal of Hepatology.2025; 83(5): e236.     CrossRef
  • Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
    Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke
    Cellular & Molecular Immunology.2025; 22(10): 1159.     CrossRef
  • Association between trans-palmitoleic acid and metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma: NHANES 1999–2018
    Qirui Li, Luqi Zhan, Qian Li, Shuai Zhu, Shuaihui Liu, He Jiang, Jinlin Cheng, Lanjuan Li
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • To sleeve or not to sleeve: Validation of liver transplantation with sleeve gastrectomy
    Linda W. Moore, Elizabeth W. Brombosz, R. Mark Ghobrial
    Journal of Hepatology.2025; 83(3): 625.     CrossRef
  • Redefining Diagnosis and Management in Hepatology with Multiparametric Ultrasound
    Yolande Chalmers
    EMJ Hepatology.2025; : 66.     CrossRef
  • Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
    Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual
    Current Obesity Reports.2025;[Epub]     CrossRef
  • Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
    Daniel Clayton-Chubb, William W. Kemp, Ammar Majeed, Peter W. Lange, Jessica A. Fitzpatrick, Karl Vaz, John S. Lubel, Alexander D. Hodge, Joanne Ryan, John J. McNeil, Alice J. Owen, Robyn L. Woods, Stuart K. Roberts
    Nutrients.2025; 17(13): 2189.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease is associated with the risk of severe liver fibrosis in pediatric population
    Wei Li, Lina Jiang, Meiling Li, Chen Lin, Li Zhu, Bokang Zhao, Yisi Liu, Yan Li, Yiyun Jiang, Shuhong Liu, Ping Liang, Junqi Niu, Jingmin Zhao
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Extracellular Vesicles as Biomarkers in Chronic Hepatobiliary Diseases: An Overview of Their Interplay
    Eleni Myrto Trifylli, Sotirios P. Fortis, Anastasios G. Kriebardis, Nikolaos Papadopoulos, Evangelos Koustas, Panagiotis Sarantis, Spilios Manolakopoulos, Melanie Deutsch
    International Journal of Molecular Sciences.2025; 26(13): 6333.     CrossRef
  • Relationship between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analyses
    Ninglin Xia, Jiwei Wang, Qian Lu, Xue Fan, Zhenzhou Jiang, Qinwei Yu
    Clinical Nutrition ESPEN.2025; 68: 679.     CrossRef
  • Time trends and health inequalities of cirrhosis caused by metabolic Dysfunction-associated steatotic liver disease from 1990 to 2021: A global burden of disease study
    Min Wu, Yifeng Li, Dong Liu, Weinong Wen, Yan Min, Qiang Su, Zhenxiang An, Xiaofang Yang
    Journal of Endocrinological Investigation.2025; 48(11): 2599.     CrossRef
  • Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
    Philip N. Newsome, Rohit Loomba
    Journal of Clinical Investigation.2025;[Epub]     CrossRef
  • High Prevalence of Fatty Liver in Bangladeshi Adolescents and Young Adults with Type 2 Diabetes: Key Predictors and Screening Recommendations
    Kishore Shil, Mashfiqul Hasan, Nusrat Sultana, Sayad Salam, Syeda Mostafa, Muhammad Hasanat
    Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 2019.     CrossRef
  • Adipose Tissue Dysfunction and Hepatic Steatosis in New-Onset Diabetes
    Emilia Rusu, Mariana Jinga, Raluca Cursaru, Georgiana Enache, Adrian Costache, Ioana Verde, Andra Nica, Anca Alionescu, Florin Rusu, Gabriela Radulian
    Diabetology.2025; 6(7): 70.     CrossRef
  • Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review
    Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi
    Nutrients.2025; 17(13): 2211.     CrossRef
  • Altered HDL Phospholipid and Fatty Acid Profile in MASLD: A Possible Explanation for the Increased CVD Risk
    Sofia Kartsoli, Christina E. Kostara, Athanasios Papathanasiou, Vasilis Tsimihodimos, Eleni T. Bairaktari, Dimitrios K. Christodoulou
    International Journal of Molecular Sciences.2025; 26(13): 6148.     CrossRef
  • Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis
    Qing Zhou, Jisu Xue, Lu Hao
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018
    Yanshan Yi, Li Yang
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights
    Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population
    Ayesha Sualeheen, Sze-Yen Tan, Robin M. Daly, Ekavi Georgousopoulou, Gavin Abbott, Stuart K. Roberts, Jacob George, Elena S. George
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102649.     CrossRef
  • Quantitative US in Metabolic Dysfunction–Associated Steatotic Liver Disease
    Manjiri Dighe, Manish Dhyani
    Radiology.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and gastrointestinal cancer risk in youth: is it time to unveil a hidden link?
    Gianmario Forcina, Vittoria Frattolillo, Maria Grazia Fusco, Emanuele Miraglia Del Giudice, Anna Di Sessa
    Expert Review of Gastroenterology & Hepatology.2025; : 1.     CrossRef
  • Metals in the human liver: An underappreciated risk factor of hepatic insulin resistance and associated pathophysiology
    Rahul Kumar, Ashwin Chinala, Dhruv Grandhe, S. Joseph Endicott, Marcus A. Garcia, Matthew J. Campen, Rama R. Gullapalli
    Environmental Pollution.2025; 383: 126844.     CrossRef
  • La alimentación es pieza clave en la patogénesis de la enfermedad hepática esteatósica asociada a disfunción metabólica en la población pediátrica
    R. Vázquez-Frias
    Revista de Gastroenterología de México.2025; 90(3): 347.     CrossRef
  • Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring
    Gong Feng, Vincent Wai-Sun Wong, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng
    Gut.2025; 74(10): 1741.     CrossRef
  • Intestinal TM6SF2 and the gut-liver axis in MASLD: new insights
    Markos Kalligeros, Linda L. Henry, Zobair M. Younossi
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice
    Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Ichimura-Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsu
    Antioxidants.2025; 14(7): 891.     CrossRef
  • The role of Bergamot Polyphenolic Fraction (BPF) in MASLD-Induced HFpEF: Mitigate diastolic dysfunction by targeting chronic low-grade inflammation
    Cristina Carresi, Antonio Cardamone, Vincenzo Musolino, Rocco Mollace, Annamaria Tavernese, Anna Rita Coppoletta, Micaela Gliozzi, Vincenzo Mollace
    Biomedicine & Pharmacotherapy.2025; 190: 118375.     CrossRef
  • Nonlinear Association Between BMI and Depression Among Nonalcoholic Fatty Liver Disease: NHANES (2017–2018)
    Hui Peng, Dan Zhou, Yuan Dai, Weifeng Chen, Tauheed Ishrat
    Behavioural Neurology.2025;[Epub]     CrossRef
  • Analysis of gastric electrical rhythm in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
    Xi-Xi Wang, Chun Yan, Su-Juan Wang, Hong Zhu, Chang-Chun Cao, Li Wu, Shuang Wang, Ji Hu, Hong-Hong Zhang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration
    Evelien Van Dijck, Steven Van Laere, Emilie Logie, Steven Timmermans, Erik Fransen, Joe Ibrahim, Timothy J. Kendall, Jonathan A. Fallowfield, Ligia M. Mateiu, Claude Libert, Guy Van Camp, An Verrijken, Luc Van Gaal, Sven Francque, Wim Van Hul, Wim Vanden
    Clinical Epigenetics.2025;[Epub]     CrossRef
  • Physical Activity and Metabolic Disorders—What Does Gut Microbiota Have to Do with It?
    Aneta Sokal-Dembowska, Ewelina Polak-Szczybyło, Kacper Helma, Patrycja Musz, Maciej Setlik, Weronika Fic, Dawid Wachowiak, Sara Jarmakiewicz-Czaja
    Current Issues in Molecular Biology.2025; 47(8): 630.     CrossRef
  • Geniposidic acid alleviated metabolic dysfunction-associated steatotic liver disease by exciting SIRT6 signaling
    Yingya Zhou, Meng Feng, Hongyan Hai, Xinmeng Teng, Xinxin Zhou, Yong Gao, Yanhua Zhong, Changhui Liu
    Phytomedicine.2025; 146: 157140.     CrossRef
  • Optimal Vegetable Intake for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Prevention: Insights from a South Italian Cohort
    Maria Noemy Pastore, Caterina Bonfiglio, Rossella Tatoli, Rossella Donghia, Pasqua Letizia Pesole, Gianluigi Giannelli
    Nutrients.2025; 17(15): 2477.     CrossRef
  • Glucagon‐Like Peptide‐1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta‐Analysis of Randomised Controlled Trials
    Alessandro Mantovani, Riccardo Morandin, Veronica Fiorio, Maria Giovanna Lando, Norbert Stefan, Herbert Tilg, Christopher D. Byrne, Giovanni Targher
    Liver International.2025;[Epub]     CrossRef
  • Discovery of Highly Potent, Selective, and Liver-Targeted THR-β Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
    Ju Liang, Yipei Gu, Liuyu Hu, Hui Qu, Nana Li, Chaoyue Xia, Lei Feng, Li Qin, Li Hai, Yaxi Yang, Ying Leng, Bing Zhou
    Journal of Medicinal Chemistry.2025; 68(16): 17457.     CrossRef
  • Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends
    Salvatore Pezzino, Stefano Puleo, Tonia Luca, Mariacarla Castorina, Sergio Castorina
    Biomedicines.2025; 13(8): 1854.     CrossRef
  • Dietary Strategies in the Prevention of MASLD: A Comprehensive Review of Dietary Patterns Against Fatty Liver
    Barbara Janota, Karolina Janion, Aneta Buzek, Ewa Janczewska
    Metabolites.2025; 15(8): 528.     CrossRef
  • Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: a cross-sectional study based on NHANES 2017–2020
    Ting Xu, Weifang Zhu
    Diabetes Research and Clinical Practice.2025; 227: 112418.     CrossRef
  • Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
    Shikha Patel, Sarfaraz K. Niazi
    Pharmaceutics.2025; 17(8): 1036.     CrossRef
  • CircDock6 drives metabolic dysfunction–associated steatotic liver disease progression in mice and mouse hepatocytes via mmu-let-7g-5p/insulin-like growth factor 1 receptor regulation
    Hongpeng Lu, Xiaoyun Ding, Peifei Li
    Journal of International Medical Research.2025;[Epub]     CrossRef
  • Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease
    Zixuan Wang, Ge Chen, Xutong Sun, Jia Xiao, Lingling Kong, Shunshun Jiang, Tingting Xu, Meijiao Wang, Hong Zhao
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Amaranthus graecizans L. Mitigates Hyperlipidemia-Induced Nonalcoholic Fatty Liver Disease in Experimental Rats: Future Pharmaceuticals
    Nadiah S. Alzahrani, Bayan Aljahdali, Aeshah Alhosain, Abeer Abdullah Alasmari, Touseef Amna, Soha Mohamed Yousef
    Pharmaceuticals.2025; 18(8): 1196.     CrossRef
  • Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD)
    Shreya C. Pal, Mariana M. Ramírez-Mejía, Andrew P. Keaveny, Nahum Méndez-Sánchez
    Expert Review of Gastroenterology & Hepatology.2025; 19(9): 1021.     CrossRef
  • Controlled Red Blood Cell Apheresis as a Pretreatment of Hepatic Peliosis Resection Surgery for Severe Polycythemia Secondary to Hepatic Peliosis in a Child
    Chun‐Xi Wu, Rong Fu, Jie Yan, Bin Zhang, Zhong‐Mei Yi, Qiang Zhang
    Pediatric Blood & Cancer.2025;[Epub]     CrossRef
  • SGLT2 inhibitors and the risk of hepatocellular carcinoma in patients with MASLD and Type 2 diabetes
    Ruey-Shyang Soong, Wan-Ming Chen, An-Tzu Jao, Ming-Che Lee, Szu-Yuan Wu, Chih-Lang Lin
    Diabetes & Metabolism.2025; 51(6): 101698.     CrossRef
  • MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study
    Shengbo Yang, Litao Zhang, Mingli Hu, Weina He
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Early Insights from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients: An Observational Study on Polygenic Risk and Liver Biomarkers
    Pietro Torre, Benedetta Maria Motta, Tommaso Sarcina, Mariano Festa, Mario Masarone, Marcello Persico
    International Journal of Molecular Sciences.2025; 26(17): 8426.     CrossRef
  • Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross‐Sectional Study Based on the NHANES (1999–2020)
    Qingwan Yang, Xin Cai, Zhenghua Xiao
    Food Science & Nutrition.2025;[Epub]     CrossRef
  • Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications
    Mariana M. Ramírez‐Mejía, Sandra M. Barbalho, Guadalupe Ponciano‐Rodríguez, Mohammed Eslam, Jacob George, Ming‐Hua Zheng, Nahum Méndez‐Sánchez
    Liver International.2025;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review
    Marcelo do Rego Maciel Souto Maior, Nathália de Lacerda Interaminense Ribeiro, Hannah Vicentini Vitoriano Silva, Edmundo Pessoa Lopes, Emilia Chagas Costa
    Biomedicines.2025; 13(9): 2162.     CrossRef
  • Mediation analysis of the molecular phenotypes in a severe MASH-like liver injury mouse model
    Zhuolin Song, Volodymyr P Tryndyak, Rose A Willett, Igor P Pogribny, Ivan Rusyn, Fred A Wright
    Toxicological Sciences.2025; 208(1): 155.     CrossRef
  • Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights
    Ha Nguyen, Duong Hoang Huy Le, Thinh Nguyen, Hung Cao Dinh, Tuan Nguyen
    Clinical and Experimental Gastroenterology.2025; Volume 18: 191.     CrossRef
  • Narrative review of metabolic syndrome and its relationships with non-alcoholic fatty liver disease, gonadal dysfunction and obstructive sleep apnea
    Doha Reda
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease in patients with prediabetes and type 2 diabetes mellitus
    Armida N. Sasunova, Alexey A. Goncharov, Sergey V. Morozov, Vladimir I. Pilipenko, Vasily A. Isakov
    Terapevticheskii arkhiv.2025; 97(8): 689.     CrossRef
  • Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?
    Amedeo Lonardo, Ralf Weiskirchen
    Exploration of Drug Science.2025;[Epub]     CrossRef
  • Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study
    Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Simona Bataga
    Medicina.2025; 61(9): 1527.     CrossRef
  • Steatotic liver disease and cancer: from pathogenesis to therapeutic targets
    Zhihong Yang, Zhenjie Liu, Wanqing Liu, Xiaocheng Charlie Dong
    eGastroenterology.2025; 3(3): e100218.     CrossRef
  • Increasing Acute Coronary Syndrome Mortality in Cirrhosis After a Period of Decline: A National Analysis of Temporal and Demographic Disparities
    Abdalhakim Shubietah, Ameer Awashra, Fathi Milhem, Mohammed AbuBaha, Maisam Tobeh, Abubakar Nazir, Mohamed S. Elgendy, Mohammad Bdair, Jehad Zeidalkilani, Hosam I. Taha, Anwar Zahran, Ahmed Emara, Suleiman Khreshi, Islam Rajab
    Catheterization and Cardiovascular Interventions.2025; 106(6): 3136.     CrossRef
  • Prenatal Choline Attenuates the Elevated Adiposity and Glucose Intolerance Caused by Prenatal Alcohol Exposure
    Susan M. Smith, Carolyn A. Munson, George R. Flentke, Sandra M. Mooney
    Cells.2025; 14(18): 1429.     CrossRef
  • THE CHANGING LANDSCAPE OF TRANSPLANT ONCOLOGY: OPPORTUNITIES AND CHALLENGES
    Emanuele Federico Kauffmann, Michael Ginesini, Allegra Ripolli, Paolo De Simone
    European Journal of Transplantation.2025; 3(1): 3.     CrossRef
  • Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals
    Karina Sato‐Espinoza, Robert A. Vierkant, Perapa Chotiprasidhi, Filippo Pinto e Vairo, Shulan Tian, Jun Ma, Daniel O'Brien, Konstantinos N. Lazaridis, Carola Dlugosch, Carolin Scheider, Alina M. Allen, Kirk J. Wangensteen
    Liver International.2025;[Epub]     CrossRef
  • MASLD Under the Microscope: How microRNAs and Microbiota Shape Hepatic Metabolic Disease Progression
    Clelia Asero, Maria Stella Franzè, Irene Cacciola, Sebastiano Gangemi
    International Journal of Molecular Sciences.2025; 26(17): 8633.     CrossRef
  • Diet is a key factor in the pathogenesis of metabolic dysfunction-associated steatotic liver disease in the pediatric population
    R. Vázquez-Frias
    Revista de Gastroenterología de México (English Edition).2025; 90(3): 347.     CrossRef
  • Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption
    Melvin Bernardino, Claudio Tiribelli, Natalia Rosso
    Nutrients.2025; 17(18): 2932.     CrossRef
  • Refining the Classification of Steatotic Liver Disease: Beyond Self-Reported Alcohol Intake
    Won-Mook Choi
    Gut and Liver.2025; 19(5): 639.     CrossRef
  • Immunonutrition: Another Player on the MASLD Field
    Iván López-Méndez, Misael Uribe, Eva Juárez-Hernández
    International Journal of Molecular Sciences.2025; 26(18): 8928.     CrossRef
  • Extracellular RNAs in Liquid Biopsy: Applications in MASLD and MASH Diagnosis and Monitoring
    Dimitrios Raptis, Shiny Teja Kolli, Sonal Agarwal, Praveen Kumar Komminni, Prashamsha Bhattarai, Prinka Hablani, Rahul Kumar, Petras Das, Martin McIntosh, Michail Kladas, Priyanka Gokulnath, Michail Spanos
    Diagnostics.2025; 15(18): 2346.     CrossRef
  • Diagnostic Performance of Fibrosis‐4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, AST‐To‐Platelet Ratio Index, and BARD Score Among Young and Older Adults for the Diagnosis of Advanced MASLD Fibrosis: A Retrospective Cohort Study
    Frank Lin, Ayah Obeid, Mehak Sharma, Parampreet Kaur, Kimberly Chaput, Hammad Liaquat
    JGH Open.2025;[Epub]     CrossRef
  • The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model
    Oscar René Zambrano-Vásquez, Fernando Cortes-Camacho, Juan Carlos Cabrera-Angeles, Ana Lilia Hernández-Alba, Fernando Enrique García-Arroyo, Jorge Ismael Castañeda-Sánchez, Elena Aréchaga-Ocampo, Omar Emiliano Aparicio-Trejo, Leonardo Del Valle-Mondragón,
    International Journal of Molecular Sciences.2025; 26(18): 9010.     CrossRef
  • Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
    Metha Yaikwawong, Khanittha Kamdee, Somlak Chuengsamarn
    International Journal of Molecular Sciences.2025; 26(19): 9286.     CrossRef
  • A Systematic Review and Meta-Analysis of Cannabis Use Frequency and Metabolic Dysfunction-Associated Steatotic Liver Disease: Scapegoat or Healer?
    Néstor Israel Quinapanta Castro, Abdel Bermúdez-del Sol
    Cureus.2025;[Epub]     CrossRef
  • Cumulative Effect of Metabolic Factors on Hepatic Steatosis
    Anna Egresi, Brigitta Kozma, Márton Karácsony, Aladár Rónaszéki, Klára Werling, Barbara Csongrády, Pál Kaposi Novák, Anikó Folhoffer, Attila Szijártó, Krisztina Hagymási
    Diagnostics.2025; 15(18): 2406.     CrossRef
  • A non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis
    Xiaobo Wang, Mary P. Moore, Hongxue Shi, Yang Xiao, Jiayu Zhang, Lanuza A. P. Faccioli, Zhiping Hu, Shareef Khalid, Danish Saleheen, Dwayne G. Stupack, Tatiana Kisseleva, Alejandro Soto Gutierrez, Mitchell A. Lazar, Ira Tabas
    Nature Metabolism.2025; 7(10): 2067.     CrossRef
  • The impact of aging on liver health and the development of liver diseases
    Sha Neisha Williams, Wen-Xing Ding
    Hepatology Communications.2025;[Epub]     CrossRef
  • Timosaponin AIII from Anemarrhena asphodeloides binds and inhibits S100A8-mediated neutrophil infiltration and NET formation ameliorates MASH
    Yunfan Bai, Jingxin Ju, Ruishi Xie, Jing Li, Xinyi Zhao, Xiaoxue Fang, Ming Zhu, Xintian Lan, Haoming Luo
    International Immunopharmacology.2025; 166: 115539.     CrossRef
  • Clinacanthus nutans leaf extract prevents metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) progression in western diet-fed C57BL/6 mice
    Nurina Hasanatuludhhiyah, Arifa Mustika, Viskasari Pintoko Kalanjati, Muhammad Miftahussurur, Hirokazu Wakuda, Naoto Uemura
    Pharmacia.2025; 72: 1.     CrossRef
  • The role of hypothalamus in the pathophysiological process of MASLD and advances in drug discovery
    Shizhang Wei, Yuan Dong, Yanping Wang, Guohui Li, Yanling Zhao, Ruimao Zheng
    Pharmacological Research.2025; 221: 107972.     CrossRef
  • BMI mediates the association of CALLY index with liver steatosis and fibrosis
    Si-Hua Wen, Tao Tang, Zheng-Rong Ye
    Scientific Reports.2025;[Epub]     CrossRef
  • Era of metabolic dysfunction-associated steatotic liver disease and impact on the liver donor pool
    Juanita Pérez-Escobar, Aline Huerta-Álvarez, Graciela Elia Castro-Narro, María Isabel Astudillo-Delgado, Paulina Carpinteyro-Espin
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) - pathogenesis, prevention and treatment
    Stanisław Surma, Łukasz Bułdak
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply
    Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Advances in understanding the mechanism of noncoding RNA (ncRNA)-mediated regulation of macrophage polarization in NAFLD
    Chang Ge, Yi Yuan, Xiaoning Li, Jianmin Zhang, Jitao Ling, Xuehong Zheng, Yuting Wu, Xin Huang, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Jing Zhang, Peng Yu
    Biochemical Pharmacology.2025; 242: 117372.     CrossRef
  • Association of serum trace elements with non-invasive fibrosis scores in metabolic dysfunction-associated steatotic liver disease
    Erfan Banisefid, Sahand Karkon Zonouzi, Sina Hamzehzadeh, Zeinab Nikniaz, Seyedehyasmin Moghaddamziabari, Leila Alizadeh
    Scientific Reports.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: epidemiological trends, risk factors, and the role of gut microbiota in disease progression (a literature review)
    А.А. Antoniv, L.V. Kanovska, O.V. Kaushanska, Yu.M. Yarinich
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2025; 21(6): 656.     CrossRef
  • Preventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies
    Ijin Joo
    Journal of Liver Cancer.2025; 25(2): 217.     CrossRef
  • Real-World Lifestyle Interventions are a Practical Model to Improve Liver Stiffness
    Christopher Kasia, Mary Rinella
    Journal of Clinical and Experimental Hepatology.2025; 15(6): 103201.     CrossRef
  • The effects of different exercise intensities on body composition and cardiovascular risk indicators in children with metabolic syndrome: a RCT network meta-analysis
    Yimin Hu, Juan Ouyang, Yi Xia, Yi Sheng
    BMC Sports Science, Medicine and Rehabilitation.2025;[Epub]     CrossRef
  • Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies
    Sana Raza, Rukshana Mahamood, Pratik Medhe, Ambuj Shahi, Abhishek Yadav, Archana Tewari, Rohit A. Sinha
    npj Metabolic Health and Disease.2025;[Epub]     CrossRef
  • Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction
    Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon
    International Journal of Molecular Sciences.2025; 26(19): 9715.     CrossRef
  • Spatial Transcriptomics and snRNA‐seq Expose CAF Niches Orchestrating Dual Stromal‐Immune Barriers in Hepatocellular Carcinoma
    Yingxue Li, Changxiang Huan, Haoting Sun, Wei Zhang, Zhen Guo, Chuanyu Li, Jia Yao, Zhiqi Zhang, Shizhe Yu, Qiongzhu Dong, Lunxiu Qin, Jinze Li, Lianqun Zhou
    Advanced Science.2025;[Epub]     CrossRef
  • Immunosenescence and metabolic reprogramming in MASLD: an age-dependent immunometabolic vicious cycle and therapeutic opportunities
    Yuxin Xu, Qiuxiang Li, Xuehua Jiao
    Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
  • Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ralf Weiskirchen, Amedeo Lonardo
    International Journal of Molecular Sciences.2025; 26(19): 9594.     CrossRef
  • Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis
    Meng Li, Jianli Hu, Yip Han Chin, Han Shi Jocelyn Chew, Wenru Wang
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Investigation of the Effect of Isotonic Drinks on Quantitative MRI Markers of the Liver and Spleen
    Natassa N. Pittas, Michael Pavlides, Ferenc E. Mózes
    NMR in Biomedicine.2025;[Epub]     CrossRef
  • Physiological roles of phosphoinositides and inositol phosphates: Implications for metabolic dysfunction-associated steatotic liver disease
    Zhili Cheng, Magdalene K Montgomery
    Clinical Science.2025; 139(19): 1095.     CrossRef
  • Naringin mitigates liver damage in a tissue-engineered liver of metabolic dysfunction-associated steatotic liver disease model by promoting autophagy via the mTOR-ULK1 pathway
    Jihui Jia, Yizhi Zhang, Jing Lin, Zhongping Duan, Yu Chen, Xiaohui Zhang
    Molecular Biology Reports.2025;[Epub]     CrossRef
  • Dietary supplementation with a designer metabolic modulator improves MASLD and associated anxiety in mice
    Agnese Segala, Gaia Favero, Emanuela Bottani, Alice Vetturi, Emirena Garrafa, Edoardo Parrella, Chiara Ruocco, Maurizio Ragni, Rita Rezzani, Enzo Nisoli, Alessandra Valerio
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • From Steatosis to Immunosenescence: The Impact of Metabolic Dysfunction on Immune Aging in HIV and Non-HIV Populations
    Carlo Acierno, Maria Frontuto, Giulio Francesco De Stefano, Ana Erezanu, Andrea Limone, Simona Morella, Francesco Picaro, Donatella Palazzo, Michele Gilio
    Biomedicines.2025; 13(10): 2513.     CrossRef
  • Constructing biomimetic microenvironments for liver regeneration
    Yawen Zhu, Wanqi Yang, Zhongxia Wang, Dayu Chen, Jinglin Wang, Haozhen Ren
    Journal of Nanobiotechnology.2025;[Epub]     CrossRef
  • Linear association between the composite dietary antioxidant index and the prevalence of sarcopenia in metabolic dysfunction-associated steatotic liver disease
    Jue Zhang, Huan Shi
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study
    Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • 2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Jaehyun Bae
    The Journal of Korean Diabetes.2025; 26(3): 172.     CrossRef
  • Pharmacotherapy of the metabolically associated fatty liver disease
    E.E. Mulyukova, E.L. Novikova, I.A. Skirdov, K.S. Usmanova, N.V. Yusifzade
    Russian Journal of Preventive Medicine.2025; 28(10): 103.     CrossRef
  • Proton Density Fat Fraction and Its Role in Prediction of Metabolic Dysfunction
    Scott B. Reeder, Jitka Starekova
    Radiology.2025;[Epub]     CrossRef
  • Coffee and Tea Intake Is Inversely Associated With Hepatic Fat Deposition, Iron Deposition, and Fibroinflammation in the General Population
    Zhuoshuai Liang, Xiaoyue Sun, Huizhen Jin, Wenhui Gao, Xinmeng Hu, Yi Cheng, Jikang Shi, Yawen Liu
    Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
  • Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota
    Yuji Xiao, Xue Zhang, Bing Shao, Ziyi Wu, Xiao Li, Dongxin Yi, Tao Li, Tao Yang, Jiaxin Zhu, Tiecheng Huang, Yixue Deng, Tianming Qiu, Guang Yang, Xiance Sun, Ningning Wang
    Journal of Agricultural and Food Chemistry.2025; 73(43): 27450.     CrossRef
  • Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis
    Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
    GASTROENTEROLOGY.2025; 59(3): 206.     CrossRef
  • CT-Based Radiomic Models in Biopsy-Proven Liver Fibrosis Staging: Direct Comparison of Segmentation Types and Organ Inclusion
    Andreea Mihaela Morariu-Barb, Tudor Drugan, Mihai Adrian Socaciu, Horia Stefanescu, Andrei Demirel Morariu, Monica Lupsor-Platon
    Diagnostics.2025; 15(21): 2671.     CrossRef
  • Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years
    Ieva Vanaga, Oksana Kolesova, Aleksandrs Kolesovs, Maija Radzina, Davis Simanis Putrins, Jelena Egle, Sniedze Laivacuma, Jelena Storozenko, Ludmila Viksna
    Journal of Clinical Medicine.2025; 14(21): 7604.     CrossRef
  • Metabolic dysfunction–associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy
    Teresa Cardoso Delgado, Celia Martín-Cuevas, Ana C. Sánchez Hidalgo, Antonio Gil Gómez, Claudia M. Rejano Gordillo, Jon Landa, Rocío Gallego Durán, Naroa Goikoetxea-Usandizaga, Irene González-Recio, Clàudia Gil-Pitarch, L. Estefanía Zapata-Pavas, Jon Ande
    Science Advances.2025;[Epub]     CrossRef
  • Association of Diet Quality, Dietary Acid Load, and Dietary Antioxidant Index With Cardiometabolic and NAFLD Risk Factors Among Patients With Metabolic Syndrome: A Cross‐Sectional Study
    Bijan Ghobadian, Seyedeh Atiye Shahrokhi, Saman Rezaei Talabon, Vahid Notash, Fatemeh Maleki Sedgi, Mehran Rahimlou
    Food Science & Nutrition.2025;[Epub]     CrossRef
  • Quantitative Approaches to Accelerate MASH Drug Discovery and Development
    Yasmeen Abouelhassan, Shailendra Tallapaka, Ramin Mehrani, Scott Q. Siler, Li Qin, Zeyuan Wang, Maria E. Trujillo
    Clinical Pharmacology & Therapeutics.2025; 118(6): 1378.     CrossRef
  • Mitochondrial transplantation and platelet rich plasma for the treatment of non-alcoholic fatty liver disease
    Manuel Alejandro Vargas-Vargas, Marcela González-Montoya, Olin Torres-Isidro, Omar Ortiz-Avila, Elizabeth Calderón-Cortés, Christian Cortés-Rojo
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease
    Leonidas H. Duntas, Stergios A. Polyzos, Ulrike Gottwald-Hostalek, Bogumila Urgatz, Paul M. Yen
    Endocrine.2025; 90(3): 1043.     CrossRef
  • Genetic polymorphisms associated with metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk susceptibility in the Chinese Han population
    Mingjia Dai, Yan Li, Jing Zhang, Yuhua Ruan, Ye Liu, Jungui Hao, Fang Ji, Xuebing Yan
    Human Genomics.2025;[Epub]     CrossRef
  • Lipid-lowering mechanism of Swietenia macrophylla king leaves through SREBP-1c/FASN axis and RNA sequencing validation
    Yingwei Liu, Yunpeng Sun, Ting Zhou, Xiao Huang, Guokai Wang, Lijuan Sun
    Food Bioscience.2025; 74: 107860.     CrossRef
  • Reconsidering Cardiovascular Risk Assessment in Patients With MASLD
    Ming Hou
    Liver International.2025;[Epub]     CrossRef
  • From steatosis to cirrhosis: the role of obesity in the progression of liver disease
    Klaudia Nowak, Maria Paluch, Maja Cudzik, Klaudia Syska, Wiktoria Gawlikowska, Jakub Janczura
    Journal of Diabetes & Metabolic Disorders.2025;[Epub]     CrossRef
  • Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study
    Li Fan, Yongkang Su, Yue Chen, Ling Xu, Hairong Huang, Chunsheng Lu, Jia Peng, Yingbin Sun, Min Jia
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism
    Rosellina M. Mancina, Luca Valenti, Stefano Romeo
    Nature Metabolism.2025; 7(11): 2199.     CrossRef
  • The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management
    Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano
    Exploration of Medicine.2025;[Epub]     CrossRef
  • The effects of salvia hispanica (chia seeds) on insulin sensitivity, hematological inflammatory indices and liver function in obese patients with non-alcoholic fatty liver disease (NAFLD)
    Sara Arefhosseini, Maryam Parimi, Helda Tutunchi, Mehrangiz Ebrahimi-Mameghani
    Nutrition & Metabolism.2025;[Epub]     CrossRef
  • Prevalence and Risk Factors of Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus at a Tertiary Center in Saudi Arabia: Cross-Sectional Questionnaire Study
    Abdulrahman M Elnasieh, Mohammed Almesned, Akram N Al Hazmi, Atheer Alturki, Faisal I Alhawaidi, Razan K Alhadlq, Maryam Alramadhan, Nasser Alobilan, Yasser Sheikh Qroosh
    JMIR Diabetes.2025; 10: e77772.     CrossRef
  • Differentiating MASL and MASH: Clinical Insights from Comparative Case Reports in MASLD
    Chang-Gue Son
    The Journal of Internal Korean Medicine.2025; 46(4): 954.     CrossRef
  • Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin
    Jiao-Xiang Wu, Yue-Lan Wu, Mei-Fang Li, Nian Liu, Ying Liu, Yan-Ping Huang, Yuan Gan, Xiao-Yu Wang, Hai-Sheng Chai, Jin Xu, Qian Xi, Xi-Rong Guo, Hui-Ming Sheng, Ting-Ting Shen, Qin Zhang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Implications of the Liver-Gut Axis in Liver Disease: From Mechanisms to Therapeutic Targets
    Mariana M. Ramírez-Mejía, Guadalupe Ponciano-Rodríguez, Nahum Méndez-Sánchez
    Archives of Medical Research.2025; 56(8): 103335.     CrossRef
  • Herbal Medicine for Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Effectiveness and Research Trends - A Systematic Review and Meta-Analysis
    Min-jo Seo, Su-na Park, Ji-won Lee, So-rim Kim, Jin-hyun Kim, Min-ji Sun, Geon-sik Kong, Yo-sup Choi
    The Journal of Internal Korean Medicine.2025; 46(4): 774.     CrossRef
  • Primary Human Tissue Models for Metabolic Dysfunction‐Associated Liver Disease ‐ toward Streamlining Drug Discovery with Patient‐Derived Assays
    Sonia Youhanna, Nayere Taebnia, Yingxin Liang, Ningtao Cheng, Yi Wang, Maurice Michel, Volker M. Lauschke
    Advanced Biology.2025;[Epub]     CrossRef
  • The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
    Jae Eun So, Jaehong Jeong, Jung Pyo Hong, Dong Yun Kim, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Hye Won Lee, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2025; 40(12): 2976.     CrossRef
  • Remnant cholesterol, low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a cohort study
    Di Zhou, Mengge Zhou, Shuohua Chen, Chenlu Yang, Yanhong Wang, Yang Zhou, Shutong Wu, Shouling Wu, Li Wang
    Lipids in Health and Disease.2025;[Epub]     CrossRef
  • Effects of long working hours on metabolic dysfunction-associated steatotic liver disease, with and without increased alcohol intake, in healthy workers: A 10-year cohort study
    Yesung Lee, Woncheol Lee, Anna Di Sessa
    PLOS One.2025; 20(11): e0336569.     CrossRef
  • Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
    Mazen Noureddin, Stephen A Harrison, Rohit Loomba, Naim Alkhouri, Naga Chalasani, Muhammad Y Sheikh, Shaheen Tomah, Julio A Gutierrez, Silvia Urbina, John J Suschak, Randy Brown, Ozioma Odili, Jay Yang, Stephine Keeton, Guy Neff, Edward Mena, M Scot Rober
    The Lancet.2025; 406(10520): 2644.     CrossRef
  • Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Fatigue and Pruritus in Primary Sclerosing Cholangitis: A U.S. Single-Center Study
    Natalia Rojas-Amaris, Ana Marenco-Flores, Carmen Lara-Romero, Romelia Barba, Denisse Rubio-Cruz, Ximena Parraga, Daniela Goyes, John Esli Medina-Morales, Leandro Sierra, Manuel Romero-Gomez, Michelle Lai, Behnam Saberi, Vilas Patwardhan, Alan Bonder
    Journal of Clinical Medicine.2025; 14(22): 8083.     CrossRef
  • Personalized management of metabolic dysfunction-associated steatotic liver disease
    Zhen Sun, Kui Ming Chan, Haojie Jin
    iLIVER.2025; 4(4): 100207.     CrossRef
  • Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
    Cong Xie, Yulian Yuan, Yunjing Wang, Cong Qi, Wei Wang, Chuan An, Aifeila Aikepaer, Yaofu Zhang, Ge Zhang, Xingzhong Feng, Huijuan Gao
    Current Obesity Reports.2025;[Epub]     CrossRef
  • Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses
    Tingfeng Huang, Jia-Hao Law, Ningqi Pang, Shichuan Tang
    iLIVER.2025; 4(4): 100208.     CrossRef
  • Plasma Extracellular Vesicles Contain Protein Biomarkers for Capturing Stages of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Preliminary Exploratory Study
    Yakun Li, Koen C. van Son, Sandra Serna-Salas, Justina C. Wolters, Nienke P. M. Wassenaar, Stan Driessen, Anne Linde Mak, Anne-Marieke van Dijk, Veera A. T. Houttu, Julia J. Witjes, Diona Zwirs, Michail Doukas, Joanne Verheij, Robin P. F. Dullaart, Hans B
    Biomolecules.2025; 15(11): 1596.     CrossRef
  • Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances
    Dalia M. Miller, Kiana F. McCauley, Kimberly J. Dunham‐Snary
    Endocrinology, Diabetes & Metabolism.2025;[Epub]     CrossRef
  • Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions
    Said A. Al-Busafi, Mohammed Eslam
    Transplantology.2025; 6(4): 35.     CrossRef
  • The albumin-to-creatinine ratio predicts and explores potential mediation of mortality in metabolic dysfunction-associated steatotic liver disease in U.S. adults: evidence from NHANES 1999–2018
    Huanjie Zhou, Hao Huang, Huiliu Zhao, Naiqi Pang, Meifang Huang, Chao Ou, Ming Lao
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice
    Yuxuan Chen, Chendong Liu, Qian Yang, Jingtao Yang, He Zhang, Yong Zhang, Yanruyu Feng, Jiaqi Liu, Lian Li, Dapeng Li
    Journal of Pharmaceutical Analysis.2025; 15(11): 101273.     CrossRef
  • К эпидемиологии жировой болезни печени, связанной с метаболической дисфункцией (систематический обзор литературы)
    Вера Людвиговна Грицинская, Валерия Павловна Новикова
    Children's medicine of the North-West.2025; 13(3): 108.     CrossRef
  • The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies

    Asian Biomedicine.2025; 19(5): 218.     CrossRef
  • An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease
    Gvzalnur Kurban, Xiangjun Chen, Xingyi Jin, Hui Xia, Shaokang Wang, Guiju Sun
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Linking bisphenol a exposure to MASLD: insights from network toxicology and machine learning based on NHANES 2005–2012 data
    Jiaquan Yuan, Haoyang Xu, Junhong Gan, Haiyan Zhao
    Toxicology Research.2025;[Epub]     CrossRef
  • Curcumin and Tetrahydrocurcumin as Multi-Organ Modulators of the Adipose Tissue–Gut–Liver Axis: Mechanistic Insights, Therapeutic Potential, and Translational Challenges
    Marina Konaktchieva, Radoslav Stojchevski, Nikola Hadzi-Petrushev, Hristo Gagov, Rositza Konakchieva, Vadim Mitrokhin, Gjoko Kungulovski, Mitko Mladenov, Dimiter Avtanski
    Pharmaceuticals.2025; 18(12): 1791.     CrossRef
  • Ten-Year Atherosclerotic Cardiovascular Disease Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Separate Analyses from Romanian and Italian Cohorts Integrating Metabolic, Hepatic, and Gut–Liver Axis Markers
    Naomi-Adina Ciurea, Cristina Monica Pantea, Paul Grama, Irina-Bianca Kosovski, Ilaria Farella, Simona Bataga, Agostino Di Ciaula, Piero Portincasa
    Journal of Clinical Medicine.2025; 14(23): 8361.     CrossRef
  • Ultra-processed food consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD): a five-year prospective cohort study in Iranian adults
    Omid Emami, Ali Nikparast, Matin Sepehrinia, Saeid Hadi, Jalaledin Mirzay Razzaz, Reza Homayounfar
    Journal of Health, Population and Nutrition.2025;[Epub]     CrossRef
  • MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury
    Sarmis Marian Săndulescu, Denisa Ștefania Ghiga, Diana Rodica Tudorașcu, Daniela Larisa Săndulescu, Adrian Mită, Marinela Cristiana Urhuț, Citto-Iulian Taisescu
    Life.2025; 15(12): 1805.     CrossRef
  • NAD + in fatty liver disease: mechanistic insights and associated targets
    Yaxin Guo, Yuting Wang, Shiran Wu, Yong Wang, Xinde Liu
    Cell Biology and Toxicology.2025;[Epub]     CrossRef
  • The impact of high fructose corn syrup on liver injury and glucose metabolism: a systematic review
    Zane Z. Yu, Sneha Varahala, Sean L. C. Lim, Maimuna C. Marenah, Julia Wattacheril
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Association Between Subclinical Hypothyroidism and MASLD: A Systematic Review and Meta‐Analysis
    Gedion Yilma Amdetsion, Chun-Wei Pan, Hiwot Tebeje, Abhin Sapkota, Shreyas Nandyal, Vikram Kotwal, Fortofoiu Mircea-Catalin
    International Journal of Hepatology.2025;[Epub]     CrossRef
  • Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis
    Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui, Ming Yang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Liver fibrosis index and mortality in metabolic dysfunction–associated steatotic liver disease: a Korean cohort study
    Yesung Lee, Woncheol Lee
    Scientific Reports.2025;[Epub]     CrossRef
  • Macrophage-tregs crosstalk: the “hub” of the immune network in MASLD
    Huihui Zhao, Weili Wang, Pengchao Zhu, Zhaohong Shi
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights
    Yibing Wang, Jiajing Peng
    Pharmacological Research.2025; 222: 108054.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease is associated with androgenetic alopecia in adults with stronger effects in women and unhealthy lifestyles
    Sina Bazmi, Mohammad Saeed Soleimani-Meigoli, Mohammadreza Fardaei, Zahra Mohammadi, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Mojtaba Farjam
    Scientific Reports.2025;[Epub]     CrossRef
  • Nutritional and Fasting Strategies for the Management of MASLD/MASH: An Integrative Review
    Diya Tawk, Ghalia Ghader, Yasmina Khatib, Philippe Attieh, Tya Youssef, Mahmoud Othman, Frederic Harb, Sami Azar, Hilda E. Ghadieh
    JGH Open.2025;[Epub]     CrossRef
  • Effects of glucagon-like peptide-1 receptor agonists on patients with metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and sequential meta-analysis
    Mei-jun Wang, Yu-nuo Jiang, Pei-pei Li, Yuan-jie Wu
    Systematic Reviews.2025;[Epub]     CrossRef
  • A network meta-analysis of the clinical efficacy of different dietary patterns in the treatment of adult metabolic dysfunction-associated steatotic liver diseases
    Diwen Yu, Peipei Yu, Wanting Huang, Pengwei Zhang, Li Li
    Clinical Nutrition Open Science.2025; 64: 357.     CrossRef
  • Synergistic Impact of Sarcopenia and T2DM on Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD)
    Qi Zhou, Peiyan Liu, Lixiang Li, Tengfei Yin, Hao Bai, Yanqing Li
    The FASEB Journal.2025;[Epub]     CrossRef
  • Early-Life Nutritional Determinants of Pediatric MASLD
    Johanna K. DiStefano
    Nutrients.2025; 17(24): 3871.     CrossRef
  • From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease
    Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
    Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329.     CrossRef
  • The association of multiple metabolic disorders with the severity of fasting blood glucose and hepatic steatosis in a Chinese population with MAFLD: a cross-sectional study of over 3000 participants
    Xue Qu, Shanshan Jin, Yuqing Shi, Weisong Zhang, Delong Cong, Yangyang Liu
    Scientific Reports.2025;[Epub]     CrossRef
  • Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide
    Husam Albarmawi, Firas Dabbous, Abdalla Aly, Alia Yousif, Samuel Huse, Maximilian Jara, Andres Quintero, Eric Lawitz
    Current Medical Research and Opinion.2025; 41(11): 2089.     CrossRef
  • Cross-sectional and longitudinal associations between fatty liver index and kidney function using updated MASLD and CKD–EPI 2021 definitions: a population-based study with region-specific cutoffs
    Sina Bazmi, Mohammadreza Fardaei, Reza Homayounfar, Maryam Kazemi, Babak Pezeshki, Reza Malekzadeh, Nasrollah Ghahramani, Mojtaba Farjam
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • The Impact of the Mediterranean Diet, Physical Activity, and Nutrition Education on Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Review
    Melvin Bernardino, Claudio Tiribelli, Natalia Rosso
    Nutrients.2025; 18(1): 28.     CrossRef
  • Machine learning-based model for predicting metabolic dysfunction-associated steatotic liver disease using non-invasive parameters in young adults
    Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Young Hoon Youn, Su Jung Baik, Hye Sun Lee, Hyun Wook Chae
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Soft drink consumption and liver fibrosis in type 2 diabetes
    Arianna Ferro, Martina Bollati, Gian Paolo Caviglia, Angelo Armandi, Stefania Bellini, Selene Limoncelli, Giulio Mengozzi, Federica Barutta, Fabio Broglio, Guglielmo Beccuti, Elisabetta Bugianesi, Marilena Durazzo, Gabriella Gruden
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Artificial intelligence applications for managing metabolic dysfunction-associated steatotic liver disease: Current status and future prospects
    Jian-Jun Lou, Jing Zeng
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Dual target, dual benefit: real-world effects of SGLT2 inhibitors and GLP-1 receptor agonists on the FIB-4 score in people with type 2 diabetes mellitus
    Virginia Markoutsaki, Georgios Dimakopoulos, Emmanouil Sinakos, Kalliopi Kotsa, Theocharis Koufakis
    Hormones.2025;[Epub]     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study
    Chan Kyeol Kim, Sangyong Jo, Kyupin Ha, Bongjo Kim, Hyeon Ji Kim, Sang Yi Moon, Byoung-Gwon Kim, Kyungil Park, Jong Sung Park, Young Rak Cho, Tae-Ho Park, Kyunghee Lim, Minkook Son
    Heart.2025; : heartjnl-2025-327102.     CrossRef
  • Association between vitamin D and metabolic-associated steatotic liver disease in type 2 diabetes mellitus patients: a systematic review and meta-analysis
    Bruno Basil, Winifred Adiri, Ejike Lawrence Ugwu, Ngozi Ijeoma Okoro
    Diabetology & Metabolic Syndrome.2025;[Epub]     CrossRef
  • Association between atherosclerosis-related indicators and fatty liver: a population-based observational study
    Xiaoping Liu, Ping Yuan, Ying Huang
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Associations Between Systemic Inflammatory Markers, Metabolic Dysfunction, and Liver Fibrosis Scores in Patients with MASLD
    Ragaey Ahmad Eid, Ahmed Moheyeldien Hamed, Sara O. Elgendy, Khalid M. Orayj, Ahmed R. N. Ibrahim, Ahmed M. Abdel Hamied, Engy A. Wahsh, Maha Youssif, Hoda Rabea, Yasmin M. Madney, Dina Attia, Shaymaa Nafady
    Metabolites.2025; 16(1): 25.     CrossRef
  • Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
    Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Javeed Mohammad, Mamatha Reddy Dundigalla, Pavan Kumar Madala, Sanyasirao KSSVV, Althaf Shaik
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Interplay between intestinal permeability and metabolic dysfunction-associated steatotic liver disease: Could there be a role for extra virgin olive oil consumption?
    Lydia Giannitrapani, Marinella Ferraro, Aurelio Seidita, Anna Licata, Maurizio Soresi
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Does Continuous Positive Airway Pressure Improve Liver Outcomes in MASLD with Obstructive Sleep Apnea? A Systematic Review
    Theja V. Channapragada, Clinton R. Brenner, Keven Guruswamy, Rewanth Katamreddy, Alwyn T. Pandian, Vyshnavi Pendala, Jaydon J. Sam, Jonathan G. Stine, Michael J. Brenner, Vinciya Pandian
    Journal of Clinical Medicine.2025; 15(1): 225.     CrossRef
  • Independent and Combined Effects of Resistance Training and Whey Protein on Skeletal Muscle Mass and Function in Individuals with MASLD Under Caloric Restriction
    Chae-Been Kim, Jinwoo Sung, Dohyun Ahn, Eun-Ah Jo, Kyung-Wan Baek, Hae-Ri Heo, Ju-Hwan Oh, Fengrui Zhang, Hyoung-Su Park, Hong-Soo Kim, Jung-Jun Park
    Nutrients.2025; 18(1): 83.     CrossRef
  • SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration
    Seung Wan Noh, Han Sol Ryu, Yong-Ho Kim, Byung-Chul Oh
    Endocrinology and Metabolism.2025; 40(6): 851.     CrossRef
  • Impact of liraglutide and dapagliflozin on steatosis, fibrosis, aminotransferases, and lipid profile in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus: results of a 6-month randomized study
    V.V. Cherniavskyi, A.I. Akimov, V.V. Tishchenko, L.M. Parunian
    GASTROENTEROLOGY.2025; 59(4): 269.     CrossRef
  • Circulating histones as potential biomarkers of MASLD-MASH-HCC progression
    Desislava K. Tsoneva, Diana Buzova, Salvatore Daniele Bianco, Maria Rita Braghini, Giulia Andolina, Antonio Liguori, Francesca D’ Ambrosio, Andrea Urbani, Antonio Gasbarrini, Maurizio Pompili, Anna Alisi, Jan Cerveny, Tommaso Mazza, Manlio Vinciguerra, Lu
    Epigenomics.2025; 17(18): 1435.     CrossRef
  • Modelos Animais de MASLD/NAFLD: uma revisão narrativa do estado atual e perspectivas futuras
    Gabriel dos Santos, Fabio de Castro Machado, Ana Beatriz Serrato Carmo, Alvaro Ivanski Sabedotti, Laura Moscardi Milléo, Lorenzo Cultz, Mateus Baptista Pizyblski, Leonardo Henrique de Figueiredo Lima, Mário Cláudio Soares Sturzeneker
    Cuadernos de Educación y Desarrollo.2025; 17(12): e10446.     CrossRef
  • THE EFFECT OF S-ADENOSYLMETHIONINE ON LIPID PROFILE PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA AND CONCOMITANT METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE DURING CHEMOTHERAPY
    Y. Stadnik, G. Maslova
    Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії.2025; 25(4): 76.     CrossRef
  • Serum Biomarkers for Hepatocellular Carcinoma: A Comparative Review of Traditional and Emerging Markers
    Min Kyung Park
    Journal of Digestive Cancer Research.2025; 13(3): 242.     CrossRef
  • Risk Factors for Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction–Associated Steatotic Liver Disease in Brazzaville
    Farel Elilie Mawa Ongoth, Rudel Godrèche Kondo, Philestine Clausina Mikolélé Ahoui Apendi, Nestor Ghislain Andzouana Mbamognoua, Raïssa Laure Mayanda Ohouana, Aymande Okoumou-Moko, Ornella Marline Yvonne Dinghat, Joël Rudy Ekoundzola, Sévérin Nkoua Eloi,
    Open Journal of Endocrine and Metabolic Diseases.2025; 15(08): 142.     CrossRef
  • Kidney function mediates the association of per- and poly-fluoroalkyl substances (PFAS) and heavy metals with hepatic fibrosis risk
    Zhengqi Wei, Jincheng Liu, Na Wang, Keke Wei
    Environmental Research.2024; 263: 120092.     CrossRef
  • Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis
    Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan
    Cureus.2024;[Epub]     CrossRef
  • Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
    Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
    Clinical and Molecular Hepatology.2024; 30(4): 982.     CrossRef
  • Understanding the epidemiology of metabolic dysfunction-associated steatotic liver disease is essential for its management: need for attention to accurate diagnostic coding and classification
    Han Ah Lee
    The Korean Journal of Internal Medicine.2024; 39(6): 869.     CrossRef
  • AI in Hepatology: Revolutionizing the Diagnosis and Management of Liver Disease
    Sheza Malik, Rishi Das, Thanita Thongtan, Kathryn Thompson, Nader Dbouk
    Journal of Clinical Medicine.2024; 13(24): 7833.     CrossRef
  • 65,535 View
  • 4,014 Download
  • 686 Web of Science
  • Crossref

Letters to the Editor

Steatotic liver disease

Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clin Mol Hepatol 2023;29(1):179-181.
Published online November 22, 2022
DOI: https://doi.org/10.3350/cmh.2022.0409

Citations

Citations to this article as recorded by  Crossref logo
  • Impact of smoking cessation on non-alcoholic fatty liver disease prevalence: a systematic review and meta-analysis
    Shengan Zhang, Zhidong Liu, Qinghua Yang, Zichun Hu, Wenjun Zhou, Guang Ji, Yanqi Dang
    BMJ Open.2023; 13(12): e074216.     CrossRef
  • 6,466 View
  • 57 Download
  • 1 Web of Science
  • Crossref

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 179.     CrossRef
  • 6,862 View
  • 62 Download
  • 1 Web of Science
  • Crossref

Correspondence

Steatotic liver disease

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clin Mol Hepatol 2023;29(1):185-187.
Published online November 10, 2022
DOI: https://doi.org/10.3350/cmh.2022.0375
  • 6,523 View
  • 57 Download

Editorial

Citations

Citations to this article as recorded by  Crossref logo
  • Association of four insulin resistance indices with liver‐related adverse outcomes: A prospective cohort study
    Xiao‐Meng Wang, Hao Yan, Wen‐Fang Zhong, Jia‐Hao Xie, Huan Chen, Jun‐Jie Wang, Wei‐Qi Song, Dong Shen, Pei‐Dong Zhang, Xi‐Ru Zhang, Jiao‐Jiao Ren, Dan Liu, Zhi‐Hao Li, Chen Mao
    Diabetes, Obesity and Metabolism.2026; 28(5): 3598.     CrossRef
  • Non-linear association of the metabolic score for insulin resistance with obstructive sleep apnea: a cross-sectional study from NHANES 2015–2018
    Zhimao Cai, Jiachen Li, Hui Peng, Ye Ye, Sixia Chen, Lingli Zeng, Jiashuang Lin, Weifeng Chen
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • Metabolic syndrome, social isolation, and sarcopenia in mild cognitive impairment: A multifaceted analysis of risk factors and mediating pathways
    Shuang Deng, Zhongqiang Guo, Min Liu, Marwan Salih Al-Nimer
    PLOS One.2025; 20(10): e0333266.     CrossRef
  • Association between METS-IR and heart failure: a cross-sectional study
    Xiaozhou Su, Chunli Zhao, Xianwei Zhang
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Understanding Insulin Resistance in NAFLD: A Systematic Review and Meta-Analysis Focused on HOMA-IR in South Asians
    Margeyi Mehta, Jigish Shah, Urvish Joshi
    Cureus.2024;[Epub]     CrossRef
  • Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”
    Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(1): 185.     CrossRef
  • Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Hye Won Lee
    Clinical and Molecular Hepatology.2023; 29(1): 169.     CrossRef
  • 7,924 View
  • 97 Download
  • 6 Web of Science
  • Crossref

Review

Hepatic neoplasm

Development and prognosis of hepatocellular carcinoma in patients with diabetes
Takuma Nakatsuka, Ryosuke Tateishi
Clin Mol Hepatol 2023;29(1):51-64.
Published online July 29, 2022
DOI: https://doi.org/10.3350/cmh.2022.0095
The incidence of diabetes mellitus and hepatocellular carcinoma (HCC) has been increasing worldwide during the last few decades, in the context of an increasing prevalence of obesity and non-alcoholic fatty liver disease (NAFLD). Epidemiologic studies have revealed that patients with diabetes have a 2- to 3-fold increased risk of developing HCC, independent of the severity and cause of the underlying liver disease. A bidirectional relationship exists between diabetes and liver disease: advanced liver disease promotes the onset of diabetes, and HCC is an important cause of death in patients with diabetes; conversely, diabetes is a risk factor for liver fibrosis progression and HCC development, and may worsen the long-term prognosis of patients with HCC. The existence of close interconnections among diabetes, obesity, and NAFLD causes insulin resistance-related hyperinsulinemia, increased oxidative stress, and chronic inflammation, which are assumed to be the underlying causes of hepatocarcinogenesis in patients with diabetes. No appropriate surveillance methods for HCC development in patients with diabetes have been established, and liver diseases, including HCC, are often overlooked as complications of diabetes. Although some antidiabetic drugs are expected to prevent HCC development, further research on the optimal use of antidiabetic drugs aimed at hepatoprotection is warranted. Given the increasing medical and socioeconomic impact of diabetes on HCC development, diabetologists and hepatologists need to work together to develop strategies to address this emerging health issue. This article reviews the current knowledge on the impact of diabetes on the development and progression of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad
    Alfredo Caturano, Enes Erul, Roberto Nilo, Davide Nilo, Vincenzo Russo, Luca Rinaldi, Carlo Acierno, Erman Akkus, Katerina Koudelkova, Federica Cerini, Alessandro Rizzo, Ferdinando Carlo Sasso, Leonilde Bonfrate, Antonio Giordano, Hatime Arzu Yaşar, Cater
    European Journal of Clinical Investigation.2026;[Epub]     CrossRef
  • Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Annals of Hepatology.2026; 31(1): 102175.     CrossRef
  • Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease
    Yu-Ping Chang, Yun-Chu Chen, Pin-Nan Cheng, Yu-Jen Fang, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng, Fu-Jen Lee, Ming-Chang Tsai, Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Chun-Jen Liu, Pei-Jer Chen, Jia-
    Gut.2026; : gutjnl-2025-337275.     CrossRef
  • Metabolic burden-based clinical-radiological model for predicting postoperative recurrence of hepatitis B-related hepatocellular carcinoma
    Beixuan Zheng, Heqing Wang, Yuyao Xiao, Fei Wu, Chun Yang, Ruofan Sheng, Mengsu Zeng
    Insights into Imaging.2026;[Epub]     CrossRef
  • Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id
    Heejoon Jang, Won Kim
    Clinical and Molecular Hepatology.2026; 32(1): 426.     CrossRef
  • Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor
    Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren
    Journal of Clinical Medicine.2026; 15(5): 1826.     CrossRef
  • Clinical Impact and Therapeutic Management of Diabetes Mellitus in Patients With Decompensated Cirrhosis
    Chiara Lisi, Maria Laura Robone, Mimma Bonomo, Daniela Campion, Elisabetta Bugianesi, Carlo Alessandria
    Liver International.2026;[Epub]     CrossRef
  • Mechanisms and Management Strategies of Hepatocarcinogenesis Driven by Chronic Hepatitis B Comorbid with Type 2 Diabetes
    Qin Lou, Jiarong Cai, Jianhua Yin
    Microorganisms.2026; 14(4): 853.     CrossRef
  • Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver‐Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy
    Chung‐Feng Huang, Yi‐Hung Lin, Pei‐Chien Tsai, Ming‐Lun Yeh, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yu‐Ju Wei, Nai‐Jen Hou, Ming‐Yen Hsieh, Chao‐Kuan Huang, Tzu‐Chun Lin, Jee‐Fu Huang, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu
    The Kaohsiung Journal of Medical Sciences.2026;[Epub]     CrossRef
  • Metformin counteracts lipid accumulation and cell proliferation in hepatocellular carcinoma via regulating METTL3-mediated m 6 A methylation
    Yannan Qi, Chuanrui Chen, Yuwei Dai, Zhouyuan Wang, Xinyi Liu, Chenxi Guo, Meina Wang, Zhigang Hu, Hongjie Di
    Cell Cycle.2026; 25(1): 1.     CrossRef
  • Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis
    Pedro Robson Costa Passos, Rodrigo Motta, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Roberto Cavalcante Venâncio, Guilherme Grossi Lopes Cançado, Amanda Adler, Jeremy F. Cobbold, Jeremy W. Tomlinson
    Diabetes Care.2026; 49(6): 1144.     CrossRef
  • Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
    Thanawin Pramotedham, Yong Chuan Tan
    Alimentary Pharmacology & Therapeutics.2026; 64(4): 536.     CrossRef
  • Seroprevalence of Hepatitis B and C Viral Infections Among Patients With Diabetes Mellitus in Africa: A Systematic Review and Meta-Analysis
    Ayanaw Dinku Abebe, Worku Chekol Tassew, Agerie Mengstie Zeleke, Yeshiwas Ayale Ferede, Jember Ayelgne Beyene
    Journal of the International Association of Providers of AIDS Care (JIAPAC).2026;[Epub]     CrossRef
  • Insulin Resistance and Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients Under Antiviral Therapy
    Dong Hyun Sinn, Kyung-Ah Kim, Jung Il Lee, Geum-Youn Gwak
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • Stereotactic body radiotherapy and other locoregional therapies for hepatocellular carcinoma in patients with cirrhosis: real-world treatment allocation, BCLC-stratified outcomes, and prognostic determinants
    Cyriac Abby Philips, Tharun Tom Oommen, Jose Paul, Rajesh Sasidharan, Arif Hussain Theruvath, Aryalakshmi Sreemohan, Ambily Baby, Rinu Mary Saji, Akshay Venugopal, Ajit Tharakan, Philip Augustine
    Discover Oncology.2026;[Epub]     CrossRef
  • New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study
    Yu-Wen Su, Yu-Hsuan Pai, Yao-Min Hung, Fuu-Jen Tsai, Renin Chang, Sung-Shuo Kao
    Hepatology International.2026;[Epub]     CrossRef
  • Prognostic nomogram model for overall survival in patients with hepatocellular carcinoma
    Jing-Yu Tan, Jing-Xian Yang, Qian-Jie Xu, Yu-Lan Zhao, Wei Zhang, Xiao-Sheng Li
    World Journal of Gastrointestinal Oncology.2026;[Epub]     CrossRef
  • High Cardiometabolic Risk Burden Predicts Adverse Outcomes in Patients with MASLD-Related Hepatocellular Carcinoma
    Yeonhong Do, Young Hyeon Ahn, Young Chang, Jeong-Ju Yoo, Sae Hwan Lee, Soung Won Jeong, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Hong Soo Kim, Keungmo Yang, Tom Ryu
    Gut and Liver.2026; 20(4): 655.     CrossRef
  • Metabolic Reprogramming of the Liver by IL-33: A Protective Response to Acute Injury
    Ying Wu, Weinan Gao, Mengrui He, Wenda Zhang
    Cells.2026; 15(15): 1346.     CrossRef
  • Triterpenes from Ganoderma lucidum inhibit hepatocellular carcinoma by regulating enhancer-associated lncRNA in vivo
    Ruolin Zhao, Caiyun Zhang, Chenchen Tang, Xinxin Wu, Sheng Hu, Qingqiong Luo, Ning Jia, Lingzhi Fan, Yixing Wang, Wencheng Jiang, Qilong Chen
    Journal of Ethnopharmacology.2025; 336: 118706.     CrossRef
  • A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B
    Moon Haeng Hur, Terry Cheuk-Fung Yip, Seung Up Kim, Hyun Woong Lee, Han Ah Lee, Hyung-Chul Lee, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Jun Yong Park, Sang Hoon Ahn, Beom Kyung Kim, Hwi Young Kim, Yeon Seok Seo, Hyunjae Shin, Jeayeon Park, Yunmi Ko, Yo
    Journal of Hepatology.2025; 82(2): 235.     CrossRef
  • Ashwagandharishta compounds possess affinity interactions against diabetes-linked liver cancer: Implications from network pharmacology, molecular docking and dynamics simulations
    Annadurai Vinothkanna, Ligang Chen, Ragothaman Prathiviraj, Srinivasan Prabhu, Rekha Thiruvengadam, Thasma Raman Sivakumar
    South African Journal of Botany.2025; 177: 26.     CrossRef
  • All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
    Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
    Journal of Hepatology.2025; 83(1): 43.     CrossRef
  • The prognosis of patients with co-morbid diabetes and hepatitis B and strategies for improving outcome
    Xiyu Liu, Xiaohong Wang
    The American Journal of the Medical Sciences.2025; 369(5): 638.     CrossRef
  • AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B
    Hyunjae Shin, Moon Haeng Hur, Byeong Geun Song, Soo Young Park, Gi-Ae Kim, Gwanghyeon Choi, Joon Yeul Nam, Minseok Albert Kim, Youngsu Park, Yunmi Ko, Jeayeon Park, Han Ah Lee, Sung Won Chung, Na Ryung Choi, Min Kyung Park, Yun Bin Lee, Dong Hyun Sinn, Se
    Journal of Hepatology.2025; 82(6): 1080.     CrossRef
  • Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis
    Zeli Tang, Caibiao Wei, Xueling Deng, Qiumei Lin, Qiping Hu, Shitao Li, Jilong Wang, Yuhong Wu, Dengyu Liu, Min Fang, Tingzheng Zhan
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Effect of metformin on hepatocellular carcinoma patients with type II diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study
    Lei Chen, Linxia Wu, Lijie Zhang, Bo Sun, Wenlong Wu, Yu Lei, Licheng Zhu, Tao Sun, Bin Liang, Huangxuan Zhao, Chuansheng Zheng
    International Journal of Surgery.2025; 111(1): 828.     CrossRef
  • A Machine Learning Model for Predicting Prognosis in HCC Patients With Diabetes After TACE
    Linxia Wu, Lei Chen, Lijie Zhang, Yiming Liu, Die Ouyang, Wenlong Wu, Yu Lei, Ping Han, Huangxuan Zhao, Chuansheng Zheng
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 77.     CrossRef
  • Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after vira
    Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
    Clinical and Molecular Hepatology.2025; 31(1): e64.     CrossRef
  • Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis
    Qingyan Kong, Diao Kong, Bei Li, Wei Peng, Zheyu Chen
    Academic Radiology.2025; 32(11): 6514.     CrossRef
  • Predicting the early therapeutic response to hepatic artery infusion chemotherapy in patients with unresectable HCC using a contrast-enhanced computed tomography-based habitat radiomics model: a multi-center retrospective study
    Mingsong Wu, Zenglong Que, Shujie Lai, Guanhui Li, Jie Long, Yuqin He, Shunan Wang, Hao Wu, Nan You, Xiang Lan, Liangzhi Wen
    Cellular Oncology.2025; 48(3): 709.     CrossRef
  • Non-liver comorbidity in patients with hepatocellular carcinoma and curative treatments – a Swedish national registry study
    Malin Sternby Eilard, Madeleine Helmersson, Magnus Rizell, Juan Vaz, Fredrik Åberg, Helena Taflin
    Scandinavian Journal of Gastroenterology.2025; 60(6): 572.     CrossRef
  • Non-receptor Type PTPases and their Role in Controlling Pathways Related to Diabetes and Liver Cancer Signalling
    Nidhee Chaudhary, Bellam Kiranmayee
    Current Pharmaceutical Biotechnology.2025; 26(5): 654.     CrossRef
  • Overview of the prevalence and features of oncological diseases in type 2 diabetes and possible immunological mechanisms
    Ya. V. Dvoryanchikov, S. M. Deunezhewa, I. A. Yatskov, V. A. Beloglazov
    Problems of Endocrinology.2025; 71(2): 75.     CrossRef
  • A review of the relationship between type 2 diabetes mellitus and different stages of hepatitis B infection (HCC, CHB, OBI)
    Radhwan Abdul Kareem, Hayder Naji Sameer, Zainab H. Athab, Mohaned Adil, Ahmed Yaseen, Omer Qutaiba B. Allela
    Microbial Pathogenesis.2025; 206: 107748.     CrossRef
  • Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population
    Takuma Nakatsuka, Yutaka Yamaji, Ryosuke Tateishi, Takako Ogasawara, Rena Mihara, Yoshiaki Kawashima, Tetsuharu Ono, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Takeshi Hayashi, Yuki Matsushita, Kazuyoshi Funato, Tatsuya Sato, Tomotaka Saito, Yotaro Kud
    Hepatology Research.2025; 55(8): 1101.     CrossRef
  • Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis
    Inderjeet Singh Bharaj, Ajit Singh Brar, Jasraj Kahlon, Anmol Singh, Priya Hotwani, Vikash Kumar, Aalam Sohal, Akash Batta
    World Journal of Cardiology.2025;[Epub]     CrossRef
  • Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
    Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats
    Clinical and Molecular Hepatology.2025; 31(3): 1003.     CrossRef
  • Impact of high fasting plasma glucose on liver cancer burden in China: a comprehensive analysis of trends from 1990 to 2021
    Zhouwei Zhan, Wei Lin, Xintong Yao, Shuqi Huang, Shuangting Lan, Lina Zheng, Zengqing Guo, Bijuan Chen
    Frontiers in Nutrition.2025;[Epub]     CrossRef
  • A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models
    Marialuisa de Ceglia, Rubén Tovar, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Elena Baixeras, Fernando Rodríguez de Fonseca, Juan Decara
    Biochemical Pharmacology.2025; 242: 117364.     CrossRef
  • Steatotic liver disease: what role does alcohol consumption play?
    Gianni TESTINO, Carmen FUCILE, Maurizia GNOCCHI, Gian M. ROSA, Fabio CAPUTO
    Minerva Medica.2025;[Epub]     CrossRef
  • Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma
    Muhammad Masroor Hussain, Bi Feng, Ju‐Mei Wang, Ao‐Qiang Zhai, Fu‐yu Li, Hai‐jie Hu
    Cancer Medicine.2025;[Epub]     CrossRef
  • Non-Viral Hepatocellular Carcinoma with Normal Alpha-Fetoprotein but Elevated CA19-9 in an Older Patient with Obesity: A Case Report
    Seung Hun Lee, Mi Soo Kim, Jeong Gyu Lee
    Korean Journal of Geriatrics & Gerontology.2025; 26(3): 147.     CrossRef
  • Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma
    Chi-Ping Tan, Teng-Yu Lee, I-Cheng Lee, Kuo-Cheng Wu, Chien-An Liu, Nai-Chi Chiu, Shao-Jung Hsu, Pei-Chang Lee, Chi-Jung Wu, Chen-Ta Chi, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang
    Liver Cancer.2025; : 1.     CrossRef
  • The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
    Shang‐Chin Huang, Jia‐Horng Kao
    The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6.     CrossRef
  • Exploring the links between types 2 diabetes and liver‐related complications: A comprehensive review
    Lukas Otero Sanchez, Yuping Chen, Guillaume Lassailly, Xiaolong Qi
    United European Gastroenterology Journal.2024; 12(2): 240.     CrossRef
  • The Role of Type 2 Diabetes Mellitus–Related Risk Factors and Drugs in Hepatocellular Carcinoma
    Yuhua Mai, Liheng Meng, Ganlu Deng, Yingfen Qin
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 159.     CrossRef
  • Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
    Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
    Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
    Diabetes Research and Clinical Practice.2024; 211: 111650.     CrossRef
  • SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
    Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
    Scientific Reports.2024;[Epub]     CrossRef
  • MLKL promotes hepatocarcinogenesis through inhibition of AMPK-mediated autophagy
    Xianjun Yu, Mengyuan Feng, Jian Guo, Haoyu Wang, Jun Yu, Anjie Zhang, Jingyi Wu, Yamei Han, Zequn Sun, Yingying Liao, Qun Zhao
    Cell Death & Differentiation.2024; 31(8): 1085.     CrossRef
  • Associations between “Cancer Risk”, “Inflammation” and “Metabolic Syndrome”: A Scoping Review
    Elsa Vitale, Alessandro Rizzo, Kazuki Santa, Emilio Jirillo
    Biology.2024; 13(5): 352.     CrossRef
  • The Association of Metformin, Other Antidiabetic Medications, and Statins with the Prognosis of Hepatocellular Carcinoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study
    Iida Tuunanen, Ari Hautakoski, Heikki Huhtamäki, Martti Arffman, Reijo Sund, Ulla Puistola, Peeter Karihtala, Arja Jukkola, Elina Urpilainen
    Biomedicines.2024; 12(8): 1654.     CrossRef
  • Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
    Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
    Clinical and Molecular Hepatology.2024; 30(3): 326.     CrossRef
  • Glycemic Burden and Clinical Outcomes of Early Stage Hepatocellular Carcinoma after Curative Treatment
    Hyun Joo Lee, Moon Seok Choi, Byeong Geun Song, Won Seok Kang, Geum Youn Gwak, Myung Ji Goh, Yong Han Paik, Joon Hyeok Lee, Dong Hyun Sinn
    Cancers.2024; 16(15): 2652.     CrossRef
  • Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
    Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
    Clinical and Molecular Hepatology.2024; 30(4): 1039.     CrossRef
  • A predicted epithelial-to-mesenchymal transition-associated mRNA/miRNA axis contributes to the progression of diabetic liver disease
    Alina-Veronica Ghionescu, Andrei Sorop, Ekaterini Linioudaki, Cristin Coman, Lorand Savu, Marton Fogarasi, Daniela Lixandru, Simona Olimpia Dima
    Scientific Reports.2024;[Epub]     CrossRef
  • Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal Ablation
    Kuo-Cheng Wu, I-Cheng Lee, Chien-An Liu, Nai-Chi Chiu, Shao-Jung Hsu, Pei-Chang Lee, Chi-Jung Wu, Chen‐Ta Chi, Jiing-Chyuan Luo, Ming-Chih Hou, Yi-Hsiang Huang
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 2257.     CrossRef
  • Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
    Han Ah Lee, Hye Ah Lee, Hwi Young Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • The Influence of Sex and Age on Survival in Patients with Hepatocellular Carcinoma
    Iuliana Pompilia Radu, Bernhard Scheiner, Jonas Schropp, Maria Gabriela Delgado, Birgit Schwacha-Eipper, Chaonan Jin, Jean-Francois Dufour, Matthias Pinter
    Cancers.2024; 16(23): 4023.     CrossRef
  • The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
  • The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study
    Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
    PLOS Medicine.2023; 20(6): e1004244.     CrossRef
  • Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
    Takao Watanabe, Yoshio Tokumoto, Kouji Joko, Kojiro Michitaka, Norio Horiike, Yoshinori Tanaka, Atsushi Hiraoka, Fujimasa Tada, Hironori Ochi, Yoshiyasu Kisaka, Seiji Nakanishi, Sen Yagi, Kazuhiko Yamauchi, Makoto Higashino, Kana Hirooka, Makoto Morita, Y
    Scientific Reports.2023;[Epub]     CrossRef
  • Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
    Mona Mohamed Ibrahim Abdalla
    World Journal of Gastroenterology.2023; 29(27): 4271.     CrossRef
  • Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography
    Madalina-Gabriela Taru, Monica Lupsor-Platon
    Cancers.2023; 15(16): 4097.     CrossRef
  • To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
    Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee
    Journal of the Chinese Medical Association.2022; 85(12): 1109.     CrossRef
  • 15,480 View
  • 318 Download
  • 63 Web of Science
  • Crossref

Original Articles

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults
Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn
Clin Mol Hepatol 2022;28(4):814-826.
Published online June 9, 2022
DOI: https://doi.org/10.3350/cmh.2022.0099
Background/Aims
The early detection and prevention of non-alcoholic fatty liver disease (NAFLD) has been emphasized considering the burden of this disease. Both hepatic and peripheral insulin resistances are strongly associated with NAFLD. We aimed to compare the predictive powers of a hepatic insulin resistance index, the homeostatic model assessment for insulin resistance (HOMA-IR), and a novel peripheral insulin resistance index, the metabolic score for insulin resistance (METS-IR), for the prediction of prevalent and incident NAFLD.
Methods
Data from 8,360 adults aged 40–69 years at baseline and 5,438 adults without NAFLD who were followed-up at least once after the baseline survey in the Korean Genome and Epidemiology Study were analyzed. The survey was performed biennially, up to the eighth follow-up.
Results
The predictive powers of the METS-IR and HOMA-IR for prevalent NAFLD were not significantly different (area under the receiver operating characteristic [ROC] curve [95% confidence interval]: METS-IR, 0.824 [0.814–0.834]; HOMAIR, 0.831 [0.821–0.842]; P=0.276). The area under the time-dependent ROC curve (Heagerty’s integrated area under the curve) of the METS-IR for incident NAFLD was 0.683 (0.671–0.695), significantly higher than that of the HOMA-IR (0.551 [0.539–0.563], P<0.001).
Conclusions
The METS-IR is superior to the HOMA-IR for the prediction of incident NAFLD and is not inferior to the HOMA-IR for the prediction of prevalent NAFLD. This suggests that the METS-IR can be a more useful insulin resistance index than the HOMA-IR for the early detection and prevention of NAFLD in Korean population.

Citations

Citations to this article as recorded by  Crossref logo
  • Serum soluble ASGR1 concentration is elevated in patients with metabolic dysfunction-associated steatotic liver disease and is associated with adiponectin
    Jing-Ming Wang, Li-Yan Jiang, Yu-Ting Deng, Jiao-Yang Li, Heng Sun, Li Ran, Xinhua Xiao
    BMJ Open Diabetes Research & Care.2026; 14(1): e005638.     CrossRef
  • Insulin Resistance Metabolic Score as a predictor of gestational diabetes mellitus: evidence from NHANES 1999-2016
    Youlian Dong, Shijun Zhang
    Nutrición Hospitalaria.2026;[Epub]     CrossRef
  • Incorporating Insulin Resistance Biomarkers into Machine Learning Models Enhances Diagnostic Accuracy for Metabolic Dysfunction–Associated Steatotic Liver Disease
    Jingyuan Nie, Jing Zhou, Yuanjia Hu, Changhong Zhang, Pingping Yu, Xun Lei
    Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
  • Development and validation of a predictive model for the severity of hyperlipidemic acute pancreatitis based on the bedside index for severity in acute pancreatitis and metabolic score for insulin resistance: A retrospective cohort study
    Longhui Kou, Huan Li, Wei Li, Xin Cheng, Yi Li, Bolun Zhang, Weitian Xu, Hui Long, Qingming Wu
    Journal of International Medical Research.2026;[Epub]     CrossRef
  • Associations of metabolic score for insulin resistance with type 2 diabetes, cancer, and all-cause mortality: a meta-analysis of cohort studies
    Feng Guo, Hui Liu, Junyi Sun, Jiajing Zhang, Jiawei Wang, Wei Liu, Jiangxue Feng
    Frontiers in Endocrinology.2026;[Epub]     CrossRef
  • Comparison of SPISE and METS-IR and Other Markers to Predict Insulin Resistance and Elevated Liver Transaminases in Children and Adolescents
    Kyungchul Song, Eunju Lee, Hye Sun Lee, Hana Lee, Ji-Won Lee, Hyun Wook Chae, Yu-Jin Kwon
    Diabetes & Metabolism Journal.2025; 49(2): 264.     CrossRef
  • The association between novel metabolic parameters and all-cause/cardiovascular mortality in patients with metabolic syndrome is modified by age
    Jiajun Liu, Yihui Fu, Pengpeng Liang, Zhangxiao Song, Yue Li, Hongyan Wu
    Cardiovascular Diabetology.2025;[Epub]     CrossRef
  • Identification of pediatric MASLD using insulin resistance indices
    Kyungchul Song, Eunju Lee, Hye Sun Lee, Young Hoon Youn, Su Jung Baik, Hyun Joo Shin, Hyun Wook Chae, Ji-Won Lee, Yu-Jin Kwon
    JHEP Reports.2025; 7(7): 101419.     CrossRef
  • Comparison of the predictive value of TyG index and METS-IR for OSA combined with NAFLD: a retrospective observational study based on a physical examination population
    Min Li, Yujing Wan, Ziyue Wei, Weihong Lin
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases
    Ludovico Abenavoli, Giuseppe Guido Maria Scarlata, Massimo Borelli, Evelina Suraci, Raffaella Marasco, Maria Imeneo, Rocco Spagnuolo, Francesco Luzza
    Journal of Clinical Medicine.2025; 14(9): 2973.     CrossRef
  • Associations between non-insulin-based insulin resistance surrogate markers and liver-related outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in South Korea
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Commentary on “Preoperative carbohydrate loading reduces perioperative insulin resistance and hastens functional recovery of remnant liver after living donor hepatectomy: an open-label randomized controlled trial”
    Meng-Yuan Shen, Rong Zhou, Jian-Nong Wu
    Hepatology International.2025; 19(5): 1264.     CrossRef
  • Lessons Learned from Liver-on-Chip Platform
    Zahra Sadat Razavi, Fateme Sadat Razavi, Madjid Soltani, Hamidreza Pazoki-Toroudi, Simin Farokhi, Iraj Azimi, Nahid Ahmadi
    Annals of Biomedical Engineering.2025; 53(9): 1993.     CrossRef
  • Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences
    Haiyuan Zhao, Yongxin Fang, Jun Zhao, Nianzhao Yang, Yang Li, Fubao Liu, Xiaopeng Chen
    Scientific Reports.2025;[Epub]     CrossRef
  • Non-linear association between metabolic score for insulin resistance and nonalcoholic fatty liver disease: analysis of US National health and nutrition examination survey data, 2017–2020
    Shanshan Wang, Ping Li, Zhenhong Guo, Xiaojuan Rao
    BMC Endocrine Disorders.2025;[Epub]     CrossRef
  • The association of the metabolic score for insulin resistance and metabolic dysfunction-related steatosis liver disease: a population-based observational study
    Haoxuan Zou, Xiaopu Ma, Wen Pan, Yan Xie
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • ISImatsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
    Jing Liu, Yueqiu Wang, Xinghang Zhou, Zaixin Wen, Yu Chen, Yiqiong Sun, Shuaiying Su, Weiwei Lin, Ruiting Shen, Xiaoyu Sun, Hongru Li, Xia Yu, Mingchen Zhang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Insulin resistance as potential mediator linking ApoB/ApoA1 to MAFLD, but not inflammation
    Mengying Yang, Xiaoman Liu, Qianqian Li, Jun Liu, Baogui Wang
    Therapeutic Advances in Endocrinology and Metabolism.2025;[Epub]     CrossRef
  • Associations between metabolic score for visceral fat and nonalcoholic fatty liver disease (NAFLD) in US adults: A cross-sectional study based on NHANES 2017–2020
    Juan Li, Shenglan Dai
    Medicine.2025; 104(46): e45082.     CrossRef
  • Association between the metabolic score for insulin resistance and osteoarthritis prevalence: A cross-sectional population-based study
    Yanghua Weng, Hongdong Yang, Langming Li, Shuchi Lv, Guibin Chen
    Medicine.2025; 104(44): e44850.     CrossRef
  • Relationship of the metabolic score for insulin resistance and the new-onset hypertension: Evidence from CHARLS
    Chun-Fang Ma, Xiang-Xiang Li, Shan Liu, Xiao-Fei Wu, Ozra Tabatabaei-Malazy,
    PLOS One.2025; 20(11): e0336388.     CrossRef
  • Effect of Goserelin acetate on non-invasive indices of hepatic steatosis in women with endometriosis
    Dimitrios A. Anastasilakis, Athanasios D. Anastasilakis, Athina Gkiomisi, Anastasios Semertzidis, Panagiotis Nikolakopoulos, Stergios Papachatzopoulos, Angelos Daniilidis, Dimitrios G. Goulis, Antonis Goulas, Stergios A. Polyzos
    Endocrine.2025;[Epub]     CrossRef
  • Sex-specific differences in the prognostic value of METS-IR for long-term outcomes in patients with MASLD and advanced liver fibrosis: a nationwide study
    Binbin Song, Yuan Zhou, Rui Su, Yan Wang, Song Chen, Wenjin Chen
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • TyG-GGT is a Reliable Non-Invasive Predictor of Advanced Liver Fibrosis in Overweight or Obese Individuals
    Lei Jin, Jing Gu, Zhe Zhang, Cheng-Fei Du, Fei-Qi Xu, Xiao-Kun Huang, Zhen-Yu Gao, Ying Li, Li-Li Yu, Xin Zhang, Guo-Qing Ru, Jun-Wei Liu, Lei Liang, Xiao-Dong Sun, Zun-Qiang Xiao
    Obesity Surgery.2024; 34(4): 1333.     CrossRef
  • Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
    Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
    Gut and Liver.2024; 18(2): 283.     CrossRef
  • Negative correlation between metabolic score for insulin resistance index and testosterone in male adults
    ChunMei Li, Jing Xu
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • METS-IR/HOMA-IR and MAFLD in U.S. adults: dose–response correlation and the effect mediated by physical activity
    Hongye Peng, Jingjing Xiang, Liang Pan, Mo Zhao, Bin Chen, Shuxia Huang, Ziang Yao, Jing Liu, Wenliang Lv
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Sex differences in the association between metabolic score for insulin resistance and the reversion to normoglycemia in adults with prediabetes: a cohort study
    Xiaomin Liang, Zemao Xing, Kai Lai, Xiaohong Li, Shuiqing Gui, Ying Li
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • Automated machine learning models for nonalcoholic fatty liver disease assessed by controlled attenuation parameter from the NHANES 2017–2020
    Lihe Liu, Jiaxi Lin, Lu Liu, Jingwen Gao, Guoting Xu, Minyue Yin, Xiaolin Liu, Airong Wu, Jinzhou Zhu
    DIGITAL HEALTH.2024;[Epub]     CrossRef
  • Advancing non-alcoholic fatty liver disease prediction: a comprehensive machine learning approach integrating SHAP interpretability and multi-cohort validation
    Bo Yang, Huaguan Lu, Yinghui Ran
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Association between the triglyceride–glucose index and spine fracture: A cross-sectional study of American adults
    Maosen Geng, Cheng Lv, Ke Zhang
    Medicine.2024; 103(41): e40119.     CrossRef
  • METS-IR, a Novel Simple Insulin Resistance Index, is Associated with NAFLD in Patients with Type 2 Diabetes Mellitus
    Xuan Ma, Baolan Ji, Wenhua Du, Shuwei Shi, Hongyan Zhao, Jie Sheng, Xinghe Jiang, Bo Ban, Guanqi Gao
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 3481.     CrossRef
  • Association Between Percent Body Fat Reduction and Changes of the Metabolic Score for Insulin Resistance in Overweight/Obese People with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Yan Han, Jinhan Liu, Wenjian Li, Fan Zhang, Yonghua Mao
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 4735.     CrossRef
  • Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
    Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim
    Liver International.2023; 43(3): 608.     CrossRef
  • Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”
    Hye Won Lee
    Clinical and Molecular Hepatology.2023; 29(1): 169.     CrossRef
  • Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Sang Bong Ahn
    Clinical and Molecular Hepatology.2023; 29(Suppl): S150.     CrossRef
  • Association between MetS-IR and prediabetes risk and sex differences: a cohort study based on the Chinese population
    Qiyang Xie, Maobin Kuang, Song Lu, Xin Huang, Chao Wang, Shuhua Zhang, Guotai Sheng, Yang Zou
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Relationship Between Six Insulin Resistance Surrogates and Nonalcoholic Fatty Liver Disease Among Older Adults: A Cross-Sectional Study
    Haojie Li, Zhan Shi, Xuejiao Chen, Junjie Wang, Jiacheng Ding, Shuoji Geng, Xinyuan Sheng, Songhe Shi
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1685.     CrossRef
  • Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease
    Haoxuan Zou, Xiaopu Ma, Fan Zhang, Yan Xie
    Lipids in Health and Disease.2023;[Epub]     CrossRef
  • Insulin resistance in non-diabetic hypothyroid patients: a critical examination of METS-IR as a diagnostic marker
    Sibel Tunç Karaman
    Current Medical Research and Opinion.2023; 39(11): 1431.     CrossRef
  • Homeostatic Model Assessment of Insulin Resistance as a Potential Screening Test for Non-Alcoholic Fatty Liver Disease in Korean Adults without Diabetes
    Hyejung Lee, Jae-Ho Lee
    Korean Journal of Family Practice.2023; 13(4): 233.     CrossRef
  • The Metabolic Score for Insulin Resistance Index is Superior to the Triglyceride and Glucose Index in Identifying Nonalcoholic Fatty Liver Disease in Hyperuricemia Subjects
    Yimeng Shu, Guoqing Huang, Yushan Mao
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4235.     CrossRef
  • Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations
    Soon Sun Kim, Jae Youn Cheong
    Clinical and Molecular Hepatology.2022; 28(4): 802.     CrossRef
  • Relationship of the metabolic score for insulin resistance and the risk of stroke in patients with hypertension: A cohort study
    Xintian Cai, Junli Hu, Qing Zhu, Mengru Wang, Shasha Liu, Yujie Dang, Jing Hong, Nanfang Li
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice
    Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren
    International Journal of Molecular Sciences.2022; 23(24): 15931.     CrossRef
  • 10,400 View
  • 238 Download
  • 42 Web of Science
  • Crossref

Viral hepatitis

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
Hee Jae Jung, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Soung Won Jeong, Jae Young Jang, Sae Hwan Lee, Hong Soo Kim, Boo Sung Kim
Clin Mol Hepatol 2014;20(1):38-46.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.38
Background/Aims

Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was to determine the association between CHC treatment response and lipid profile and IR change during treatment.

Methods

In total, 203 CHC patients were reviewed retrospectively between January 2005 and December 2011 at Soon Chun Hyang University Hospital. The lipid profile, homeostasis model for assessment (HOMA) of IR (HOMA-IR), and HOMA of β cells (HOMA-β) were evaluated before interferon plus ribavirin therapy (BTx), at the end of treatment (DTx), and 24 weeks after the end of treatment (ATx).

Results

A sustained virologic response (SVR) was achieved by 81% of all patients (49/60), 60% (n=36) of whom possessed genotype 1, with the remainder being non-genotype-1 (40%, n=24). Apart from age, which was significantly higher in the non-SVR group (SVR, 48.0±11.2 years, mean±SD; non-SVR, 56.6±9.9 years; P<0.01), there were no significant differences in the baseline characteristics between the SVR and non-SVR groups. In the SVR group, low density lipoprotein-cholesterol (LDL-C) had significantly changed at DTx and ATx compared to BTx. In addition, HOMA-IR and HOMA-β were significantly changed at DTx in the SVR group. Among those with a high baseline insulin resistance (HOMA-IR >2.5), HOMA-IR was significantly changed at DTx in the SVR group.

Conclusions

LDL-C appears to be associated with HCV treatment in SVR patients. Furthermore, eradication of HCV may improve whole-body IR and insulin hypersecretion, as well as high baseline insulin resistance (HOMA-IR >2.5).

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals
    Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed, Nagwa A. Sabri
    F1000Research.2022; 11: 649.     CrossRef
  • Lipid profile changes after direct acting antiviral treatment in different genotypes of chronic hepatitis C virus‐infected patients
    Cheng‐Heng Lin, Jyh‐Jou Chen, Pei‐Lun Lee, Hung‐Da Tung, Chun‐Ta Cheng, Hsu‐Ju Kao, Yu‐Hsun Wu, Mai‐Gio Pang, Tang‐Wei Chuang
    Advances in Digestive Medicine.2021; 8(3): 139.     CrossRef
  • Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir
    Mahmoud Abdo, Ahmed Rabiee, Zeinab Abdellatif, Shereen Abdel Alem, Ahmed Moustafa
    European Journal of Gastroenterology & Hepatology.2021; 33(12): 1588.     CrossRef
  • The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments
    Phumelele Yvonne Siphepho, Yi-Ting Liu, Ciniso Sylvester Shabangu, Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Ming-Lung Yu, Shu-Chi Wang
    Biomedicines.2021; 9(10): 1491.     CrossRef
  • Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment
    Mostafa Elhelbawy, Wael Abdel-Razek, Ayman Alsebaey, Mohamed Hashim, Hassan Elshenawy, Imam Waked
    European Journal of Gastroenterology & Hepatology.2019; 31(1): 16.     CrossRef
  • Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C
    Yi-Hao Yen, Kwong-Ming Kee, Chien-Hung Chen, Tsung-Hui Hu, Sheng-Nan Lu, Jing-Houng Wang, Chao-Hung Hung, Tatsuo Kanda
    PLOS ONE.2019; 14(1): e0208858.     CrossRef
  • Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients
    Ayush Jain, Bhupinder Singh Kalra, Siddharth Srivastava, Shalini Chawla
    Indian Journal of Gastroenterology.2019; 38(1): 39.     CrossRef
  • Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
    Mary-Anne Doyle, Chrissi Galanakis, Erin Mulvihill, Angela Crawley, Curtis L. Cooper
    Cells.2019; 8(3): 252.     CrossRef
  • Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
    Mary-Anne Doyle, Terry Lee, Joel Singer, Angela Crawley, Marina Klein, Curtis Cooper
    Open Forum Infectious Diseases.2019;[Epub]     CrossRef
  • HCV treatment with direct acting antivirals improves the insulin sensitivity
    Ayman Alsebaey, Mostafa Elhelbawy, Wael Abdel-Razek, Mohammed Hashim, Hassan Elshenawy, Imam Waked
    Expert Review of Anti-infective Therapy.2019; 17(9): 749.     CrossRef
  • Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis
    Jing‑Hong Hu, Ming‑Ling Chang, Nai‑Jen Liu, Chu‑Ting Yeh, Tung‑Jung Huang
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study
    Goki Suda, Jun Ito, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Munenori Okamoto, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Junichi Yoshida, Takashi Meguro, Masatsugu Ohara, Naoki Kawagishi, Megumi Kimura, Machiko Umemura, Takaaki Izumi, Y
    Hepatology Research.2018;[Epub]     CrossRef
  • Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
    Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi
    Gut and Liver.2018; 12(2): 201.     CrossRef
  • Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment
    Gilmar de Souza Lacerda, Thalia Medeiros, Natalia Fonseca do Rosário, Regina Helena Saramago Peralta, Mauro Jorge Cabral-Castro, Eliane Bordalo Cathalá Esberard, Thaís Guaraná de Andrade, Analúcia Rampazzo Xavier, Andrea Alice Silva
    Clinical Biochemistry.2018; 60: 17.     CrossRef
  • Hepatitis C Virus Eradication with New Interferon‐Free Treatment Improves Metabolic Profile in Hepatitis C Virus‐Related Liver Transplant Recipients
    Junaid Beig, David Orr, Barry Harrison, Edward Gane
    Liver Transplantation.2018; 24(8): 1031.     CrossRef
  • Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
    Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Muts
    PLOS ONE.2018; 13(12): e0209615.     CrossRef
  • The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
    Batbold Batsaikhan, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Nei-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Jin-Ching Lee, Chia-Yen Dai
    Oncotarget.2018; 9(30): 21313.     CrossRef
  • Hepatitis C virus and atherosclerosis: A legacy after virologic cure?
    M.F. Bassendine, S.U. Nielsen, S.H. Bridge, D.J. Felmlee, D.A. Sheridan, C.J. Packard, R.D. Neely
    Clinics and Research in Hepatology and Gastroenterology.2017; 41(1): 25.     CrossRef
  • Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review
    Anne-Claire Desbois, Patrice Cacoub
    World Journal of Gastroenterology.2017; 23(9): 1697.     CrossRef
  • Endemic hepatitis B and C virus areas are associated with lower prevalence of hyperlipidemia: Ecological and cross‐sectional studies
    Chao‐Tung Chen, Wei‐Cheng Huang, Jing‐Houng Wang, Chuan‐Mo Lee, Chao‐Hung Hung, Lin‐San Tsai, Shu‐Chuan Chen, Sheng‐Che Lin, Sheng‐Nan Lu, Kwong‐Ming Kee
    Advances in Digestive Medicine.2017; 4(2): 54.     CrossRef
  • Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin
    Beti Todorovska, Nenad Joksimovic, Viktorija Caloska-Ivanova, Magdalena Dimitrova-Genadieva, Meri Trajkovska, Elena Curakova, Sanja Kiprijanovska, Beti Zafirova-Ivanovska, Vladimir Serafimoski
    PRILOZI.2017; 38(1): 25.     CrossRef
  • Diabetes and Glucose Metabolism in Thalassemia Major: An Update
    Vincenzo De Sanctis, Ashraf T Soliman, Heba Elsedfy, Alessia Pepe, Christos Kattamis, Mohamed El Kholy, Mohamed Yassin
    Expert Review of Hematology.2016; 9(4): 401.     CrossRef
  • Change in insulin resistance according to virological response during antiviral treatment for hepatitis C virus infection
    Cheng‐Hao Tseng, Yao‐Chun Hsu, Chi‐Yang Chang, Chih‐Wen Lin, Jaw‐Town Lin, Lein‐Ray Mo
    Advances in Digestive Medicine.2016; 3(2): 43.     CrossRef
  • Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir
    Sebastian Bernuth, Eray Yagmur, Detlef Schuppan, Martin F. Sprinzl, Anca Zimmermann, Arno Schad, Jens M. Kittner, Veronika Weyer, Johanna Knapstein, Jörn M. Schattenberg, Marcus A. Wörns, Peter R. Galle, Tim Zimmermann
    Digestive and Liver Disease.2016; 48(3): 291.     CrossRef
  • Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes
    Lucivalda Pereira Magalhães Oliveira, Rosangela Passos de Jesus, Ramona Souza Silva Baqueiro Boulhosa, Thiago Onofre, Carlos Mauricio Cardeal Mendes, Leonardo Vinhas, Dan Linetzky Waitzberg, Denise Carneiro Lemaire, Lourianne N. Cavalcante, Andre Castro L
    Journal of the American College of Nutrition.2016; 35(5): 436.     CrossRef
  • Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
    Magnus Hedenstierna, Ali Nangarhari, Ola Weiland, Soo Aleman
    Clinical Infectious Diseases.2016; 63(6): 723.     CrossRef
  • Genotype specific peripheral lipid profile changes with hepatitis C therapy
    Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam
    World Journal of Gastroenterology.2016; 22(46): 10226.     CrossRef
  • Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES
    Adeel A. Butt, Peng Yan, Tracey G. Simon, Raymond T. Chung, Abdul-Badi Abou-Samra
    BMC Infectious Diseases.2015;[Epub]     CrossRef
  • A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients
    Sadia Qamar Arain, Farah Naz Talpur, Naseem Aslam Channa
    Lipids in Health and Disease.2015;[Epub]     CrossRef
  • Improvement of glucose and lipid metabolism with pegylated interferon-α plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus
    Shao Qing, Dong Ji, Bing Li, Fan Li, Yudong Wang, Xioaxia Niu, Binfang Ling, Yuhua Meng, George Lau, Guofeng Chen
    Annals of Saudi Medicine.2015; 35(4): 293.     CrossRef
  • Liver steatosis in hepatitis C patients
    Emilio González-Reimers
    World Journal of Hepatology.2015; 7(10): 1337.     CrossRef
  • 13,623 View
  • 86 Download
  • 33 Web of Science
  • Crossref

Steatotic liver disease

The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults
Deok Yun Ju, Young Gil Choe, Yong Kyun Cho, Dong Suk Shin, Su Hyeon Yoo, Seo Hyoung Yim, Ji Yong Lee, Jung Ho Park, Hong Joo Kim, Dong Il Park, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim
Clin Mol Hepatol 2013;19(2):140-147.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.140
Background/Aims

Waist circumference (WC) is a risk factor for metabolic syndrome and is related to insulin resistance (IR) and nonalcoholic fatty liver disease (NAFLD). The purpose of this study was to determine the association between WC and IR and NAFLD in apparently healthy Korean adults.

Methods

The volunteers included in this cross-sectional study comprised 9,159 adults (5,052 men, 4,107 women) who participated in a comprehensive health checkup program. IR was evaluated by the homeostasis model assessment of IR (HOMA-IR) and was considered to be present when the HOMA-IR score was >2. NAFLD was evaluated by ultrasound examination. Elevated alanine aminotransferase (ALT) was defined as >40 IU/L in men and >35 IU/L in women. Logistic regression was performed to determine the odds ratios (ORs) and 95% confidence intervals (95% CIs) for NAFLD, IR, and ALT according to categorized levels of WC.

Results

NAFLD was found in 2,553 (27.9%) of the participants (82.6% men, 17.4% women), while IR and elevated ALT were found in 17.2% (68.1% men, 31.9% women) and 10% (83% men, 17% women), respectively. After adjusting for confounding factors, the prevalence of NAFLD, IR, and elevated ALT was significantly associated with increases in WC quartile: highest quartile for NAFLD in men, OR=15.539, 95% CI=12.687-19.033; highest quartile for NAFLD in women, OR=48.732, 95% CI=23.918-99.288 (P<0.001); and highest quartile for IR in men, OR=17.576, 95% CI=13.283-23.255; highest quartile for IR in women, OR=11.078, 95% CI=7.813-15.708 (P<0.001); highest quartile for elevated ALT in men, OR=7.952, 95% CI=6.046-10.459; and highest quartile for elevated ALT in women, OR=8.487, 95% CI=4.679-15.395 (P<0.001).

Conclusions

WC contributes to IR and NAFLD in apparently healthy Korean adults, and thus may be an important factor in the development of IR and NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between TyG-related parameters and NAFLD risk in Japanese non-obese population
    Xiuli Wang, Jie Liu, Ke Yu, Zhenhua Huang, Hanxiong Liu, Xiang Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease
    Hanaa Badran, Maha Elsabaawy, Mai Magdy, Hazem Omar, Olfat Hendy, Eman Awaad, Maymona Abd El-Wahed Al-Khalifa, Mai Abozeid
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Study of association and diagnostic utility of novel anthropometric and lipid indices for nonalcoholic fatty liver disease: A hospital-based study
    Anand K. Pyati, Sakthivadivel Varatharajan, Abhishek Arora, Vaman Kulkarni, Aparna Varma Bhongir, Sangeetha Sampath, Gomathi Ramaswamy, Madhu Latha Karra, Priyanka Das, Pawan Pagaku
    Journal of Family Medicine and Primary Care.2025; 14(6): 2365.     CrossRef
  • Global prevalence of insulin resistance in the adult population: a systematic review and meta-analysis
    Jhosmer Ballena-Caicedo, Fiorella E. Zuzunaga-Montoya, Joan A. Loayza-Castro, Juan Carlos Bustamante-Rodríguez, Luisa Erika Milagros Vásquez Romero, Rafael Tapia-Limonchi, Carmen Inés Gutierrez De Carrillo, Víctor Juan Vera-Ponce
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • Exploring The Impact of Dietary and Metabolic Risk Factors on Non-Alcoholic Fatty Liver Disease (NAFLD) : A Cross-Sectional Study
    İzel Aycan Orakçı, İlyas Tuncer, Fatma Esra Güneş
    Turkish Journal of Health Science and Life.2025; 8(2): 29.     CrossRef
  • Garlic ( Allium sativum L. ) in diabetes and its complications: Recent advances in mechanisms of action
    Yayi Jiang, Rensong Yue, Guojie Liu, Jun Liu, Bo Peng, Maoyi Yang, Lianxue Zhao, Zihan Li
    Critical Reviews in Food Science and Nutrition.2024; 64(16): 5290.     CrossRef
  • Validity of fatty liver prediction scores for diagnosis of fatty liver by Fibroscan
    Seogsong Jeong, Sun Jae Park, Seong Kyun Na, Sang Min Park, Byung-Cheol Song, Yun Hwan Oh
    Hepatobiliary & Pancreatic Diseases International.2024; 23(4): 353.     CrossRef
  • Effectiveness of the ALT/AST ratio for predicting insulin resistance in a Korean population: A large-scale, cross-sectional cohort study
    Seul Ki Han, Myung Jae Seo, Taesic Lee, Moon Young Kim, Anna Di Sessa
    PLOS ONE.2024; 19(5): e0303333.     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Waist to height ratio in nonalcoholic fatty liver disease – Systematic review and meta-analysis
    Abdulrahman Ismaiel, Blal El Hosiny, Mohamed Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Cristina Sorina Catana, Dan L. Dumitrascu
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(7): 102160.     CrossRef
  • Is There any Need for the Early Detection of Non-alcoholic Fatty Liver Disease in Children with Type 1 Diabetes Mellitus?
    Soodeh Salehi, Sanaz Mehrpour, Shahin Koohmanaee, Shohreh Maleknejad, Mohammad Ali Esfandiari, Saman Maroufizadeh, Setila Dalili, Afagh Hassanzadeh Rad
    Hepatitis Monthly.2023;[Epub]     CrossRef
  • Metabolic and Risk Profiles of Lean and Non-Lean Hepatic Steatosis among US Adults
    Meiling Li, Weiping Zhang, Xiude Li, Shaoxian Liang, Yaozong Zhang, Yufeng Mo, Songxian Rao, Honghua Zhang, Yong Huang, Yu Zhu, Zhuang Zhang, Wanshui Yang
    Nutrients.2023; 15(13): 2856.     CrossRef
  • Neck Circumference as a Predictor of Insulin Resistance in People with Non-alcoholic Fatty Liver Disease
    Da-Hye Son, Jee Hye Han, Jun-Hyuk Lee
    Journal of Obesity & Metabolic Syndrome.2023; 32(3): 214.     CrossRef
  • Association between waist circumference trajectories and incident non-alcoholic fatty liver disease
    Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon
    Obesity Research & Clinical Practice.2023; 17(5): 398.     CrossRef
  • Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis
    Katherine J.P. Schwenger, Alexander Kiu, Maryam AlAli, Amnah Alhanaee, Sandra E. Fischer, Johane P. Allard
    Nutrition.2022; 93: 111491.     CrossRef
  • The value of combining the simple anthropometric obesity parameters, Body Mass Index (BMI) and a Body Shape Index (ABSI), to assess the risk of non-alcoholic fatty liver disease
    Maobin Kuang, Guotai Sheng, Chong Hu, Song Lu, Nan Peng, Yang Zou
    Lipids in Health and Disease.2022;[Epub]     CrossRef
  • IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IDENTIFICATION?
    Bárbara Ferreira de Mello BARRETO, Giovana Rita PUNARO, Maria Cristina ELIAS, Edison Roberto PARISE
    Arquivos de Gastroenterologia.2022; 59(3): 402.     CrossRef
  • Identify Functional lncRNAs in Nonalcoholic Fatty Liver Disease by Constructing a ceRNA Network
    Wei Xue, Jia Zhang, Yali Zhu, Wenxiang Huang
    ACS Omega.2022; 7(26): 22522.     CrossRef
  • Anthropometric clinical indicators of visceral adiposity as predictors of nonalcoholic fatty liver disease
    Naiade Silveira Almeida, Raquel Rocha, Carla Daltro, Claudineia Almeida de Souza, Rafael Leiróz Pereira Duarte Silva, Manoel Alfredo Curvelo Sarno, Helma Pinchemel Cotrim
    Revista da Associação Médica Brasileira.2021; 67(11): 1544.     CrossRef
  • Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population
    Jinwei Cai, Cuiting Lin, Shuiqing Lai, Yingshan Liu, Min Liang, Yingfen Qin, Xinghuan Liang, Aihua Tan, Yong Gao, Zheng Lu, Chunlei Wu, Shengzhu Huang, Xiaobo Yang, Haiying Zhang, Jian Kuang, Zengnan Mo
    Lipids in Health and Disease.2021;[Epub]     CrossRef
  • Comparison of Body Mass Index and Fat Indices in Predicting the Severity of Nonalcoholic Fatty Liver Disease Among Children Who Are Overweight and Obese
    Hsun-Chin Chao, Hsin-Yeh Lin
    Frontiers in Pediatrics.2021;[Epub]     CrossRef
  • Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
    Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
    Pegah Golabi, James M. Paik, Tamoore Arshad, Youssef Younossi, Alita Mishra, Zobair M. Younossi
    Hepatology Communications.2020; 4(8): 1136.     CrossRef
  • Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review
    Shagufta Akhtar, Azhar Khan
    Advanced Journal of Graduate Research.2020; 9(1): 46.     CrossRef
  • Clinical, Anthropometric, Biochemical and Histological Character of Nonalcoholic Fatty Liver Disease Without Insulin Resistance
    Shahinul Alam, Kamrul Anam, Saiful Islam, Golam Mustafa, Ayub Al Mamun, Nooruddin Ahmad
    Journal of Clinical and Experimental Hepatology.2019; 9(2): 176.     CrossRef
  • Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity
    Antônio Sérgio Barcala Jorge, João Marcus Oliveira Andrade, Alanna Fernandes Paraíso, Gislaine Candida Batista Jorge, Christine Mendes Silveira, Ludmilla Regina de Souza, Erivelton Pereira Santos, André Luiz Sena Guimaraes, Sérgio Henrique Sousa Santos, A
    Obesity Research & Clinical Practice.2018; 12(1): 1.     CrossRef
  • Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review
    Naiade Silveira Almeida, Raquel Rocha, Helma Pinchemel Cotrim, Carla Daltro
    World Journal of Hepatology.2018; 10(10): 695.     CrossRef
  • Circunferência da cintura como marcador para triagem de doença hepática gordurosa não alcoólica em adolescentes obesos
    Ana Paula Grotti Clemente, Bárbara Dal Molin Netto, Joana Pereira de Carvalho‐Ferreira, Raquel Munhoz da Silveira Campos, Aline de Piano Ganen, Lian Tock, Marco Túlio de Mello, Ana Raimunda Dâmaso
    Revista Paulista de Pediatria.2016; 34(1): 47.     CrossRef
  • Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents
    Ana Paula Grotti Clemente, Bárbara Dal Molin Netto, Joana Pereira de Carvalho-Ferreira, Raquel Munhoz da Silveira Campos, Aline de Piano Ganen, Lian Tock, Marco Túlio de Mello, Ana Raimunda Dâmaso
    Revista Paulista de Pediatria (English Edition).2016; 34(1): 47.     CrossRef
  • Relationship of Colorectal Polyps and Fatty Liver Disease Diagnosed by Ultrasonography
    Hye-Nam Lee, Cheong-Hwan Lim, Hong-Ryang Jung
    Journal of Digital Convergence.2014; 12(3): 345.     CrossRef
  • Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
    Xing-Chun Wang
    World Journal of Gastroenterology.2014; 20(40): 14821.     CrossRef
  • 12,403 View
  • 79 Download
  • Crossref

Review

Nonalcoholic steatohepatitis: Pathogenesis and treatment
Sang Hoon Park
Korean J Hepatol 2008;14(1):12-27.
Published online March 20, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.1.12
Nonalcoholic fatty liver disease (NAFLD) is characterized by a wide spectrum of liver damage spanning steatosis, nonalcoholic steatohepatitis (NASH), cryptogenic liver cirrhosis, and even to hepatocellular carcinoma. Investigations in the last few years have focused on NASH, a relatively aggressive form of liver disease, due largely to the explosion of information provided by clinical and basic science studies related to the widespread presence of risk factors, such as obesity, type II diabetes mellitus, and dyslipidemia. This is especially important given that obesity and type II diabetes mellitus have recently reached epidemic proportions in Korea. The pathogenesis of NASH is multifactorial, with insulin resistance and increased fatty acid possibly being important factors in the accumulation of hepatocellular fat, and oxidant stress, lipid peroxidation, mitochondrial dysfunction, and dysregulation of variable cytokines possibly being important causes of hepatocellular injury in steatotic liver. Because not all steatotic livers progress to NASH, some other environmental factors or a combination of genetic factors are thought to be required for progression to NASH and fibrosis. Lifestyle modifications continue to be the cornerstone therapy in NAFLD, but some insulin-sensitizing drugs might be more effective in treating NASH. Many pilot trials for antioxidants and lipid-lowering and hepatic protective agents have yielded promising initial results in improving liver enzymes or features of liver histology. However, the efficacy of these agents remains questionable. Despite recent gains in understanding NASH, several issues related to its natural history, pathogenesis, and treatment remain unresolved. (Korean J Hepatol 2008;14:12- 27)

Citations

Citations to this article as recorded by  Crossref logo
  • Elevated red cell distribution width is associated with advanced fibrosis in NAFLD
    Hwa Mok Kim, Bum Soo Kim, Yong Kyun Cho, Byung Ik Kim, Chong Il Sohn, Woo Kyu Jeon, Hong Joo Kim, Dong Il Park, Jung Ho Park, Kwan Joong Joo, Chang Joon Kim, Yong Sung Kim, Woon Je Heo, Won Seok Choi
    Clinical and Molecular Hepatology.2013; 19(3): 258.     CrossRef
  • Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors
    Kyung-Hun Lee, Sang Hoon Park, Yu Jin Kim, Kyung Rim Huh, Kwang Seon Min, Sun-Young Jun, Kyoung Oh Kim, Cheol Hee Park, Taeho Hahn, Kyo-Sang Yoo, Jong Hyeok Kim, Myung-Seok Lee, Choong Kee Park
    The Korean Journal of Hepatology.2010; 16(1): 29.     CrossRef

  • Ko NOMURA
    Environmental Education.2010; 20(1): 6.     CrossRef
  • Pathology of nonalcoholic steatohepatitis
    Yoon-Mi Jeen, So-Young Jin
    The Korean Journal of Hepatology.2009; 15(2): 122.     CrossRef
  • The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology
    Stephen Caldwell, Sang H. Park
    Journal of Gastroenterology.2009; 44(S19): 96.     CrossRef
  • 8,825 View
  • 108 Download
  • Crossref

Editorial

Nonalcoholic fatty Liver disease as a risk factor of cardiovascular disease
Moon Young Kim , Soon Koo Baik
Korean J Hepatol 2008;14(1):1-3.
Published online March 20, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.1.1

Citations

Citations to this article as recorded by  Crossref logo
  • Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?
    Emily N. W. Yeung, Philipp Treskes, Sarah F. Martin, Jonathan R. Manning, Donald R. Dunbar, Sophie M. Rogers, Thierry Le Bihan, K. Ann Lockman, Steven D. Morley, Peter C. Hayes, Leonard J. Nelson, John N. Plevris
    Lipids in Health and Disease.2015;[Epub]     CrossRef
  • Prevalence of Metabolic Syndrome and Related Risk Factors of Elderly Residents in Andong Rural Area 2. Based on the Biochemical Measurements and Nutrient Intakes
    Hye-Sang Lee, Chong-Suk Kwon
    Journal of the Korean Society of Food Science and Nutrition.2010; 39(10): 1459.     CrossRef
  • 6,622 View
  • 68 Download
  • Crossref

Reviews

Insulin Resistance in Non-Alcoholic Fatty Liver Disease
Jeong Hyun Park
Korean J Hepatol 2006;12(1):16-30.
Insulin resistance is the pathophysiological hallmark of various kinds of clinical diseases, including non- alcoholic fatty liver disease. Insulin resistance is the common characteristic of metabolic syndrome and its related features. Insulin resistance is a systemic disease that affects the nervous system, muscles, pancreas, kidney, heart and immune system, in addition to the liver. A complex interaction between genes and environment factors enhances insulin resistance and the phenotypic expression of NAFLD (non- alcoholic fatty liver disease) in individual patients. Advanced fibrotic liver disease is associated with many features of metabolic syndrome, and the risk of progressive liver disease should not be underestimated for the individuals suffering with metabolic disorders. Abnormalities of insulin signaling can cause the state of insulin resistance, but there is no clear cut scientific evidence that distorted insulin signaling is the primary pathophysiological defect. Increased adipose tissue mass can cause peripheral tissue insulin resistance via the changes of the adipocytokine secretory patterns. We discuss in this article the sequences of the insulin signaling cascades and the possible molecular targets of insulin resistance, the humoral “cross talk” between the distorted secretory patterns of the adipocytokines, and the peripheral tissue insulin resistance along with the pathophysiology of NAFLD. (Korean J Hepatol 2006;12:16-30)
  • 4,026 View
  • 28 Download
Special Liver Cirrhosis and Diabetes Mellitus
Yong Soo Park,Tae Wha Kim
Korean J Hepatol 2002;8(1):22-34.
  • 3,373 View
  • 18 Download
Original Article
Background
/Aim: The liver plays important roles in the homeostasis of glucose metabolism since it acts as a major target organ for insulin and a site for gluconeogenesis and glycogen storage. Diabetes mellitus (DM) commonly develops in patients with liver cirrhosis as the result of hepatocyte dysfunction and/or inadequate mass. To assess differences between DM due to liver cirrhosis (hepatogenous DM) and the other type 2 DM, we compared the patterns of hyperglycemia and hyperinsulinemia in hepatogenous DM with those observed in type 2 DM. Methods: 18 diabetic patients with liver cirrhosis (caused by alcohol, n=8; HBV, n=5; HCV, n=2; others, n=3) were matched with 18 type 2 diabetic patients without liver cirrhosis for age and gender. None of the patients or controls had been treated with insulin or β-blockers. The level of glycosylated hemoglobin (HbA1C), fasting plasma glucose (FPG), postprandial plasma glucose (PP2h), fasting plasma C-peptide and insulin were measured. Results: The ratio of PP2h/FPG (2.27 vs. 1.69), fasting insulin (23.2: 11.6 ?IU/mL) and HOMA-IR index (8.38 vs. 3.52) were significantly higher in hepatogenous DM than the other type 2 DM (P<0.05). PP2h, fasting C-peptide and ratio of fasting insulin/C-peptide tend to be higher in hepatogenous DM than those of controls, but which were not statistically significant. Conclusions: The ratio of PP2h/FPG and fasting plasma insulin differentiated hepatogenous DM from the other type 2 DM. Insulin resistance in liver cirrhosis was higher than the other type 2 DM, and impaired hepatic insulin degradation might be an important mechanism of hyperinsulinemia in liver cirrhosis. (Korean J Hepatol 2006;12:524-529)
  • 5,351 View
  • 130 Download